


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 8

August 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 8
August 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

BOCA PHARMACAL INC
(BOCA PHARMA)

BOCA PHARMACAL LLC
(BOCA PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt,

ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445	15408		
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)	2440 (15.8%)		
MULTISOURCE	12825 (83.6%)	12900 (83.5%)	12890 (83.7%)		
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)	12750 (82.7%)		
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)	140 (0.9%)		
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	17	9	5		
NUMBER OF APPLICANTS	835	844	841		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

TABLET; ORAL

ABACAVIR SULFATE

>A>	AB	HETERO LABS LTD III	EQ 300MG BASE	A091560	001	Sep 13, 2013	Aug NEWA
-----	----	---------------------	---------------	---------	-----	--------------	----------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

AB		GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	Jul NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

CAMPRAL

AB	+	FOREST LABS	333MG	N021431	001	Jul 29, 2004	Jul CFTG
----	---	-------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ WEST WARD 500MG; 50MG; 40MG

A040261	001	Oct 28, 1998	Jul DISC
---------	-----	--------------	----------

ESGIC-PLUS

+ MIKART 500MG; 50MG; 40MG

A040085	001	Mar 28, 1996	Jul CTEC
---------	-----	--------------	----------

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIRROR PHARMS LLC 500MG; 50MG; 40MG

A040883	001	Dec 23, 2008	Feb DISC
---------	-----	--------------	----------

>D>	AA	WEST WARD	500MG; 50MG; 40MG	A040336	001	Aug 18, 1999	Aug DISC
-----	----	-----------	-------------------	---------	-----	--------------	----------

>A>		@	500MG; 50MG; 40MG	A040336	001	Aug 18, 1999	Aug DISC
-----	--	---	-------------------	---------	-----	--------------	----------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 356.4MG; 30MG; 16MG

A040109	001	Aug 26, 1997	Feb DISC
---------	-----	--------------	----------

@ WRASER PHARMS LLC 356.4MG; 30MG; 16MG

A040688	001	Apr 03, 2007	Jun DISC
---------	-----	--------------	----------

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ BOCA PHARMA 712.8MG; 60MG; 32MG

A040701	001	Apr 03, 2007	Jun DISC
---------	-----	--------------	----------

@ MIKART 712.8MG; 60MG; 32MG

A040316	001	Apr 28, 1999	Feb DISC
---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AUROLIFE PHARMA LLC	300MG; 15MG	A202800	001	Apr 15, 2013	Apr NEWA
----	--	---------------------	-------------	---------	-----	--------------	----------

AA			300MG; 30MG	A202800	002	Apr 15, 2013	Apr NEWA
----	--	--	-------------	---------	-----	--------------	----------

AA			300MG; 60MG	A202800	003	Apr 15, 2013	Apr NEWA
----	--	--	-------------	---------	-----	--------------	----------

	@	MIKART	300MG; 30MG	A089238	001	Feb 25, 1986	Jun DISC
--	---	--------	-------------	---------	-----	--------------	----------

	@		650MG; 30MG	A089231	001	Mar 03, 1986	Feb DISC
--	---	--	-------------	---------	-----	--------------	----------

	@		650MG; 60MG	A089363	001	Sep 09, 1991	Feb DISC
--	---	--	-------------	---------	-----	--------------	----------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MIKART 500MG; 5MG

A081067	001	Nov 30, 1989	Feb DISC
---------	-----	--------------	----------

@ 500MG; 5MG

A089008	001	Feb 21, 1986	Jun DISC
---------	-----	--------------	----------

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		PAI	325MG/15ML; 7.5MG/15ML	A040838	001	May 10, 2013	Apr NEWA
----	--	-----	------------------------	---------	-----	--------------	----------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		CARACO	325MG; 5MG	A090118	001	Dec 23, 2008	May CAHN
----	--	--------	------------	---------	-----	--------------	----------

AA			325MG; 7.5MG	A090118	002	Dec 23, 2008	May CAHN
----	--	--	--------------	---------	-----	--------------	----------

AA			325MG; 10MG	A090118	003	Dec 23, 2008	May CAHN
----	--	--	-------------	---------	-----	--------------	----------

AA			500MG; 5MG	A090265	001	Dec 23, 2008	May CAHN
----	--	--	------------	---------	-----	--------------	----------

AA			500MG; 7.5MG	A090265	002	Dec 23, 2008	May CAHN
----	--	--	--------------	---------	-----	--------------	----------

AA			500MG; 10MG	A090265	003	Dec 23, 2008	May CAHN
----	--	--	-------------	---------	-----	--------------	----------

AA			650MG; 7.5MG	A090380	001	Dec 23, 2008	Jun CAHN
----	--	--	--------------	---------	-----	--------------	----------

AA			650MG; 10MG	A090380	002	Dec 23, 2008	Jun CAHN
----	--	--	-------------	---------	-----	--------------	----------

AA			660MG; 10MG	A090380	003	Dec 23, 2008	Jun CAHN
----	--	--	-------------	---------	-----	--------------	----------

AA			750MG; 7.5MG	A090380	004	Dec 23, 2008	Jun CAHN
----	--	--	--------------	---------	-----	--------------	----------

	+	MIKART	325MG; 2.5MG	A040846	001	Jun 09, 2010	Jul CRLD
--	---	--------	--------------	---------	-----	--------------	----------

	@		500MG; 2.5MG	A089698	001	Aug 25, 1989	Feb DISC
--	---	--	--------------	---------	-----	--------------	----------

	@		650MG; 5MG	A040849	001	Jun 09, 2010	Feb DISC
--	---	--	------------	---------	-----	--------------	----------

AA		TRIS PHARMA INC	325MG; 5MG	A202214	001	Mar 27, 2013	Mar NEWA
----	--	-----------------	------------	---------	-----	--------------	----------

AA			325MG; 7.5MG	A202214	002	Mar 27, 2013	Mar NEWA
----	--	--	--------------	---------	-----	--------------	----------

AA			325MG; 10MG	A202214	003	Mar 27, 2013	Mar NEWA
----	--	--	-------------	---------	-----	--------------	----------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS ELIZABETH	325MG; 2.5MG	A201447	001	Apr 12, 2013	Apr	NEWA
AA		325MG; 5MG	A201447	002	Apr 12, 2013	Apr	NEWA
AA		325MG; 7.5MG	A201447	003	Apr 12, 2013	Apr	NEWA
AA		325MG; 10MG	A201447	004	Apr 12, 2013	Apr	NEWA
AA	AUROLIFE PHARMA LLC	325MG; 2.5MG	A201972	001	Jul 15, 2013	Jul	NEWA
AA		325MG; 5MG	A201972	002	Jul 15, 2013	Jul	NEWA
AA		325MG; 7.5MG	A201972	003	Jul 15, 2013	Jul	NEWA
AA		325MG; 10MG	A201972	004	Jul 15, 2013	Jul	NEWA
	@ MIKART	400MG; 2.5MG	A040679	001	May 16, 2006	Jul	DISC
AA	VINTAGE PHARMS	325MG; 2.5MG	A090733	001	Jul 11, 2013	Jul	NEWA
AA		325MG; 7.5MG	A090734	001	Jul 11, 2013	Jul	NEWA
AA		325MG; 10MG	A090734	002	Jul 11, 2013	Jul	NEWA
>D>	ROXICET 5/500						
>D>	+ ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989	Aug	DISC
>A>	@	500MG; 5MG	A089775	001	Jan 12, 1989	Aug	DISC

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

@ WATSON LABS

250MG

A088882 001 Oct 22, 1985 Jan DISC

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP SAGENT AGILA

EQ 500MG BASE/VIAL

A200880 001 May 09, 2012 Jan CAHN

ACITRETIN

CAPSULE; ORAL

ACITRETIN

AB BARR LABS INC

10MG

A091455 001 Apr 04, 2013 Mar NEWA

AB

25MG

A091455 002 Apr 04, 2013 Mar NEWA

AB TEVA PHARMS USA

17.5MG

A202897 001 Apr 04, 2013 Mar NEWA

AB

22.5MG

A202897 002 Apr 04, 2013 Mar NEWA

SORIATANE

AB STIEFEL LABS INC

10MG

N019821 001 Oct 28, 1996 Mar CFTG

AB

17.5MG

N019821 003 Aug 06, 2009 Mar CFTG

AB

22.5MG

N019821 004 Aug 06, 2009 Mar CFTG

AB +

25MG

N019821 002 Oct 28, 1996 Mar CFTG

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ ACTIENT PHARMS

8MG; 60MG

N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D> AB MYLAN

200MG

A074977 001 Apr 13, 1998 Aug DISC

>A> @

200MG

A074977 001 Apr 13, 1998 Aug DISC

CREAM; TOPICAL

ZOVIRAX

+ VALEANT BERMUDA

5%

N021478 001 Dec 30, 2002 Jul CAHN

OINTMENT; TOPICAL

ACYCLOVIR

AB MYLAN PHARMS INC

5%

A202459 001 Apr 03, 2013 Mar NEWA

ZOVIRAX

AB + VALEANT BERMUDA

5%

N018604 001 Mar 29, 1982 May CAHN

AB + VALEANT INTL

5%

N018604 001 Mar 29, 1982 Mar CFTG

SUSPENSION; ORAL

ZOVIRAX

AB + DELCOR ASSET

200MG/5ML

N019909 001 Dec 22, 1989 Jun CAHN

TABLET; BUCCAL

SITAVIG

+ BIOALLIANCE PHARMA

50MG

N203791 001 Apr 12, 2013 Apr NEWA

TABLET; ORAL

ACYCLOVIR

>D> AB MYLAN

400MG

A074976 001 Apr 13, 1998 Aug DISC

>A> @

400MG

A074976 001 Apr 13, 1998 Aug DISC

		TABLET;ORAL							
		ACYCLOVIR							
>D>	AB		800MG		A074976	002	Apr 13, 1998	Aug	DISC
>A>		@	800MG		A074976	002	Apr 13, 1998	Aug	DISC
		<u>ACYCLOVIR; HYDROCORTISONE</u>							
		CREAM;TOPICAL							
		XERESE							
		+ VALEANT BERMUDA	5%;1%		N022436	001	Jul 31, 2009	Apr	CAHN
		<u>ADEFOVIR DIPIVOXIL</u>							
		TABLET;ORAL							
>A>		ADEFOVIR DIPIVOXIL							
>A>	AB	SIGMAPHARM LABS LLC	10MG		A202051	001	Aug 29, 2013	Aug	NEWA
		HEPSERA							
>D>		+ GILEAD	10MG		N021449	001	Sep 20, 2002	Aug	CFTG
>A>	AB	+	10MG		N021449	001	Sep 20, 2002	Aug	CFTG
		<u>ADENOSINE</u>							
		INJECTABLE;INJECTION							
		ADENOSCAN							
>D>		+ ASTELLAS	3MG/ML		N020059	001	May 18, 1995	Aug	CTEC
>A>	AP	+	3MG/ML		N020059	001	May 18, 1995	Aug	CTEC
		ADENOSINE							
		@ TEVA PHARMS USA	3MG/ML		A076564	001	Jun 16, 2004	Apr	CAHN
>A>	AP		3MG/ML		A077425	001	Aug 29, 2013	Aug	NEWA
		@	3MG/ML		A078676	001	Jul 31, 2008	Apr	CAHN
		<u>AFATINIB DIMALEATE</u>							
		TABLET;ORAL							
		GILOTRIF							
		BOEHRINGER INGELHEIM	EQ 20MG BASE		N201292	001	Jul 12, 2013	Jul	NEWA
			EQ 30MG BASE		N201292	002	Jul 12, 2013	Jul	NEWA
		+	EQ 40MG BASE		N201292	003	Jul 12, 2013	Jul	NEWA
		<u>ALBENDAZOLE</u>							
		TABLET;ORAL							
		ALBENZA							
		+ AMEDRA PHARMS	200MG		N020666	001	Jun 11, 1996	Feb	CAHN
		<u>ALBUTEROL SULFATE</u>							
		AEROSOL, METERED;INHALATION							
		PROAIR HFA							
BX		+ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH		N021457	001	Oct 29, 2004	Apr	CAHN
		VENTOLIN HFA							
BX		+ GLAXO GRP LTD	EQ 0.09MG BASE/INH		N020983	001	Apr 19, 2001	May	CAHN
		SOLUTION;INHALATION							
		ALBUTEROL SULFATE							
		@ APOTEX INC	EQ 0.021% BASE		A078623	001	Apr 05, 2010	Apr	DISC
		@	EQ 0.042% BASE		A078623	002	Apr 05, 2010	Apr	DISC
		@	EQ 0.083% BASE		A075717	001	Feb 02, 2007	Apr	DISC
		@	EQ 0.5% BASE		A076391	001	Apr 01, 2003	Apr	DISC
AN		+ MYLAN SPECLT	EQ 0.083% BASE		A072652	001	Feb 21, 1992	Jan	CAHN
		@ WOCKHARDT EU OPERATN	EQ 0.083% BASE		A075394	001	Nov 22, 1999	Mar	DISC
		<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
		SOLUTION;INHALATION							
		ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
		@ APOTEX INC	EQ 0.083% BASE;0.017%		A077117	001	Dec 31, 2007	Apr	DISC
>A>	AN	CIPLA LTD	EQ 0.083% BASE;0.017%		A077559	001	Dec 31, 2007	Aug	CAHN
>D>	AN	WATSON LABS	EQ 0.083% BASE;0.017%		A077559	001	Dec 31, 2007	Aug	CAHN
		<u>ALENDRONATE SODIUM</u>							
		SOLUTION;ORAL							
		ALENDRONATE SODIUM							
AA		ROXANE	EQ 70MG BASE/75ML		A090520	001	Feb 25, 2013	Feb	NEWA
		FOSAMAX							
AA		+ MERCK	EQ 70MG BASE/75ML		N021575	001	Sep 17, 2003	Feb	CFTG
		TABLET;ORAL							
		ALENDRONATE SODIUM							
AB		CIPLA LTD	EQ 5MG BASE		A076768	001	Aug 04, 2008	Jul	CAHN

TABLET; ORAL

ALENDRONATE SODIUM

AB		EQ 10MG BASE	A076768	002	Aug 04, 2008	Jul CAHN	
AB		EQ 35MG BASE	A076768	003	Aug 04, 2008	Jul CAHN	
AB		EQ 40MG BASE	A076768	004	Aug 04, 2008	Jul CAHN	
AB		EQ 70MG BASE	A076768	005	Aug 04, 2008	Jul CAHN	
>D>	AB	MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Aug DISC
>A>	@		EQ 35MG BASE	A078638	001	Aug 04, 2008	Aug DISC
>D>	AB		EQ 70MG BASE	A078638	002	Aug 04, 2008	Aug DISC
>A>	@		EQ 70MG BASE	A078638	002	Aug 04, 2008	Aug DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

AB	+	COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003	Apr CAHN
----	---	-------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB		ACCORD HLTHCARE	100MG	A203154	001	May 06, 2013	Apr NEWA
AB			300MG	A203154	002	May 06, 2013	Apr NEWA

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

		TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013	Jan NEWA
			EQ 12.5MG BASE	N022271	002	Jan 25, 2013	Jan NEWA
	+		EQ 25MG BASE	N022271	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

	+	TAKEDA PHARMS USA	EQ 12.5MG BASE; 1GM	N203414	002	Jan 25, 2013	Jan NEWA
			EQ 12.5MG BASE; 500MG	N203414	001	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSEN

		TAKEDA PHARMS USA	EQ 12.5MG BASE; 15MG	N022426	004	Jan 25, 2013	Jan NEWA
			EQ 12.5MG BASE; 30MG	N022426	005	Jan 25, 2013	Jan NEWA
			EQ 12.5MG BASE; 45MG	N022426	006	Jan 25, 2013	Jan NEWA
			EQ 25MG BASE; 15MG	N022426	001	Jan 25, 2013	Jan NEWA
			EQ 25MG BASE; 30MG	N022426	002	Jan 25, 2013	Jan NEWA
	+		EQ 25MG BASE; 45MG	N022426	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

		TAKEDA PHARMS USA	EQ 12.5MG BASE; EQ 15MG BASE	N022426	004	Jan 25, 2013	Feb CAIN
			EQ 12.5MG BASE; EQ 30MG BASE	N022426	005	Jan 25, 2013	Feb CAIN
			EQ 12.5MG BASE; EQ 45MG BASE	N022426	006	Jan 25, 2013	Feb CAIN
			EQ 25MG BASE; EQ 15MG BASE	N022426	001	Jan 25, 2013	Feb CAIN
			EQ 25MG BASE; EQ 30MG BASE	N022426	002	Jan 25, 2013	Feb CAIN
	+		EQ 25MG BASE; EQ 45MG BASE	N022426	003	Jan 25, 2013	Feb CAIN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

	@	TEVA PHARMS USA	0.5MG	A077979	001	Feb 28, 2007	Jun DISC
	@		1MG	A077979	002	Feb 28, 2007	Jun DISC
	@		2MG	A077979	003	Feb 28, 2007	Jun DISC
	@		3MG	A077979	004	Feb 28, 2007	Jun DISC

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP		TEVA PHARMS USA	0.5MG/ML	A075196	001	Apr 30, 1999	Apr CAHN
----	--	-----------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

	@	HOSPIRA	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994	Mar DISC
--	---	---------	------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

AMIKACIN SULFATE

	@ TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Jun CAHN
AP		EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Jun CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

	@ INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982	Jun DISC
	@ PHARMA SERVE NY	25MG/ML	A087392	001	Dec 15, 1983	Jun DISC

TABLET; ORAL

AMINOPHYLLINE

	@ WEST WARD	100MG	A084540	001		Jul DISC
	@	200MG	A085003	001		Jul DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>A>	@ AGILA SPECLTS	50MG/ML	A076394	001	Apr 25, 2003	Aug CAHN
>D>	@ APOTEX INC	50MG/ML	A076394	001	Apr 25, 2003	Aug CAHN
	@	50MG/ML	A076394	001	Apr 25, 2003	Apr DISC
AP	+ MYLAN INSTITUTIONAL	50MG/ML	A076217	001	Oct 15, 2002	Apr CAHN
	@ TEVA PHARMS USA	50MG/ML	A076163	001	Sep 05, 2003	Apr CAHN

AMLEXANOX

PASTE; DENTAL

APHTHASOL

	@ ULURU	5%	N020511	001	Dec 17, 1996	Jun DISC
--	---------	----	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013	Apr NEWA
AB		EQ 5MG BASE	A202553	002	Apr 29, 2013	Apr NEWA
AB		EQ 10MG BASE	A202553	003	Apr 29, 2013	Apr NEWA
>A> AB	CIPLA LTD	EQ 2.5MG BASE	A077073	001	Sep 26, 2007	Aug CAHN
>A> AB		EQ 5MG BASE	A077073	002	Sep 26, 2007	Aug CAHN
>A> AB		EQ 10MG BASE	A077073	003	Sep 26, 2007	Aug CAHN
>D> AB	WATSON LABS	EQ 2.5MG BASE	A077073	001	Sep 26, 2007	Aug CAHN
>D> AB		EQ 5MG BASE	A077073	002	Sep 26, 2007	Aug CAHN
>D> AB		EQ 10MG BASE	A077073	003	Sep 26, 2007	Aug CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE; 160MG	A090011	001	Mar 28, 2013	Mar NEWA
AB		EQ 5MG BASE; 320MG	A090144	001	Mar 28, 2013	Mar NEWA
AB		EQ 10MG BASE; 160MG	A090011	002	Mar 28, 2013	Mar NEWA
AB		EQ 10MG BASE; 320MG	A090011	004	Mar 28, 2013	Mar NEWA
	EXFORGE					
AB	NOVARTIS	EQ 5MG BASE; 160MG	N021990	002	Jun 20, 2007	Mar CFTG
AB		EQ 5MG BASE; 320MG	N021990	004	Jun 20, 2007	Mar CFTG
AB	+	EQ 10MG BASE; 160MG	N021990	003	Jun 20, 2007	Mar CFTG
AB	+	EQ 10MG BASE; 320MG	N021990	005	Jun 20, 2007	Mar CFTG

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700	001	Feb 25, 2013	Feb NEWA
AP	+ FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007	Feb CFTG
AP	MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321	001	Feb 25, 2013	Feb NEWA
AP	UCLA BIOMEDICAL	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203812	001	Jun 27, 2013	Jun NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

	@ RANBAXY	200MG/5ML	A065113	001	Nov 29, 2002	Feb DISC
	@	400MG/5ML	A065113	002	Nov 29, 2002	Feb DISC

TABLET; ORAL

AMOXICILLIN

	@ DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009	Jun DISC
--	-------------------	-------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

TABLET, CHEWABLE;ORAL

AMOXICILLIN

@ DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996	Mar DISC
@	250MG	A064139	002	Jan 29, 1996	Mar DISC
@ RANBAXY	200MG	A065060	001	Nov 29, 2000	Feb DISC
@	400MG	A065060	002	Nov 29, 2000	Feb DISC
AMOXIL					
@ DR REDDYS LABS INC	200MG	N050761	001	Apr 15, 1999	Feb DISC
@	400MG	N050761	002	Apr 15, 1999	Feb DISC

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN

@ AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007	Jan DISC
@	400MG	A065324	002	Jan 17, 2007	Jan DISC

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

>A>									
>A>	AB	TEVA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A200218	001	Aug 30, 2013	Aug	NEWA	
		PREVPAC							
>D>	+	TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997	Aug	CFTG	
>A>	AB	+	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997	Aug	CFTG	

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@	APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009	Apr	DISC	
	@		500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009	Apr	DISC	
	@		875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008	Apr	DISC	
	@	RANBAXY LABS	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	DISC	
AB		TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096	001	Oct 29, 2002	Apr	CRLD	
		AUGMENTIN '250'							
AB	+	DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Apr	CRLD	
		AUGMENTIN '500'							
AB	+	DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Apr	CRLD	
		AUGMENTIN '875'							
AB	+	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Apr	CRLD	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB		TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Apr	NEWA	
AB			2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Apr	NEWA	
AB			3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Apr	NEWA	
AB			5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Apr	NEWA	
AB			6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Apr	NEWA	
AB			7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Apr	NEWA	
		DEXTROAMP SACCHARATE,AMP	ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE						
AB		BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb 12, 2013	Jan	NEWA	
AB			2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb 12, 2013	Jan	NEWA	
AB			3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb 12, 2013	Jan	NEWA	
AB			5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013	Jan	NEWA	
AB			6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013	Jan	NEWA	
AB			7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013	Jan	NEWA	

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003	Jan	DISC	
@		2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003	Jan	DISC	
@		5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003	Jan	DISC	
@		7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003	Jan	DISC	

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP		ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013	Mar	NEWA	
AP			EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013	Mar	NEWA	
AP			EQ 10GM BASE/VIAL	A090889	001	Apr 03, 2013	Mar	NEWA	
AP			EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013	Mar	NEWA	
	@	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Jun	DISC	
	@		EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Jun	DISC	
	@		EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Jun	DISC	

INJECTABLE; INJECTION
AMPICILLIN SODIUM

@ EQ 500MG BASE/VIAL A090354 002 Dec 28, 2009 Jun DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
UNASYN

AP + PFIZER EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL A062901 002 Feb 27, 1992 Jul NEWA
AP + EQ 1GM BASE/VIAL; EQ 500MG A062901 001 Nov 23, 1988 Jul CRDL
BASE/VIAL

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB ACCORD HLTHCARE 1MG A090568 001 Jun 28, 2010 Apr CAHN
@ KUDCO IRELAND 1MG A091331 001 Jan 05, 2011 Feb DISC

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ABILIFY MAINTENA KIT

OTSUKA PHARM CO LTD 300MG/VIAL N202971 001 Feb 28, 2013 Feb NEWA
+ 400MG/VIAL N202971 002 Feb 28, 2013 Feb NEWA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL
MOVIPREP

>D> AA NOVEL LABS INC 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM A090145 001 Jan 25, 2012 Aug DISC
>A> @ 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM A090145 001 Jan 25, 2012 Aug DISC
>D> AA + SALIX PHARMS 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM N021881 001 Aug 02, 2006 Aug CTEC
>A> + 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM N021881 001 Aug 02, 2006 Aug CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ PRINSTON INC 385MG; 30MG; 25MG A075141 001 May 29, 1998 Apr CAHN

ORPHENGESIC FORTE

@ PRINSTON INC 770MG; 60MG; 50MG A075141 002 May 29, 1998 Apr CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

>D> AB MYLAN 25MG A074126 003 Aug 26, 1998 Aug DISC
>A> @ 25MG A074126 003 Aug 26, 1998 Aug DISC
>D> AB 50MG A074126 001 Mar 23, 1994 Aug DISC
>A> @ 50MG A074126 001 Mar 23, 1994 Aug DISC
>D> AB 100MG A074126 002 Mar 23, 1994 Aug DISC
>A> @ 100MG A074126 002 Mar 23, 1994 Aug DISC
@ WATSON LABS 50MG A073352 001 Dec 27, 1991 Mar DISC
@ 100MG A073353 001 Dec 27, 1991 Mar DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB KUDCO IRELAND EQ 10MG BASE A091624 001 Apr 05, 2013 Mar NEWA
AB EQ 20MG BASE A091624 002 Apr 05, 2013 Mar NEWA
AB EQ 40MG BASE A091624 003 Apr 05, 2013 Mar NEWA
AB EQ 80MG BASE A091624 004 Apr 05, 2013 Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

MERCK SHARP DOHME EQ 10MG BASE; 10MG N200153 001 May 03, 2013 May NEWA
EQ 20MG BASE; 10MG N200153 002 May 03, 2013 May NEWA
EQ 40MG BASE; 10MG N200153 003 May 03, 2013 May NEWA
+ EQ 80MG BASE; 10MG N200153 004 May 03, 2013 May NEWA

AZACITIDINE

INJECTABLE; IV-SC

		INJECTABLE;IV-SC					
>A>		AZACITIDINE					
>A> AP		DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Aug NEWA
		VIDAZA					
>D>		+ CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Aug CFTG
>A> AP		+	100MG/VIAL	N050794	001	May 19, 2004	Aug CFTG
<u>AZELAIC ACID</u>							
		GEL;TOPICAL					
		FINACEA					
		+ BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun CAHN
<u>AZITHROMYCIN</u>							
		FOR SUSPENSION, EXTENDED RELEASE;ORAL					
		ZMAX					
>A>		+ PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Aug CAHN
>D>		+ PFIZER GLOBAL	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Aug CAHN
		INJECTABLE;INJECTION					
		AZITHROMYCIN					
AP		SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	Mar NEWA
<u>BACITRACIN</u>							
		OINTMENT;OPHTHALMIC					
		BACITRACIN					
		+ PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Jun CAHN
		POWDER;FOR RX COMPOUNDING					
		BACI-RX					
		@ X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001		Mar DISC
<u>BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
		OINTMENT;OPHTHALMIC					
		NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC					
AT		PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM	A060764	002		Jun CAHN
<u>BACITRACIN ZINC; POLYMYXIN B SULFATE</u>							
		OINTMENT;OPHTHALMIC					
		BACITRACIN ZINC AND POLYMYXIN B SULFATE					
AT		PERRIGO CO TENNESSEE	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jun CAHN
<u>BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
		OINTMENT;OPHTHALMIC					
		BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE					
		+ PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE;10,000 UNITS/GM	A062166	002		Jun CAHN
<u>BACLOFEN</u>							
		INJECTABLE;INTRATHECAL					
		GABLOFEN					
AP		MALLINCKRODT INC	0.05MG/ML	N022462	001	Nov 19, 2010	May CAHN
AP			0.5MG/ML	N022462	002	Nov 19, 2010	May CAHN
			1MG/ML	N022462	004	Jun 22, 2012	May CAHN
AP			2MG/ML	N022462	003	Nov 19, 2010	May CAHN
<u>BENZONATATE</u>							
		CAPSULE;ORAL					
		BENZONATATE					
AA		CARACO	100MG	A040587	001	Mar 19, 2008	May CAHN
AA			200MG	A040587	002	Mar 19, 2008	May CAHN
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>							
		GEL;TOPICAL					
		ACANYA					
		+ DOW PHARM	2.5%;1.2%	N050819	001	Oct 23, 2008	Apr CAHN
		BENZACLIN					
AB		VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr CAHN
BT		+	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr CAHN
<u>BENZOYL PEROXIDE; ERYTHROMYCIN</u>							
		GEL;TOPICAL					
		BENZAMYCIN PAK					
		+ VALEANT LUXEMBOURG	5%;3%	N050769	001	Nov 27, 2000	Jun CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ COREPHARMA	50MG	A040714	001	Oct 29, 2007	Feb DISC
--------------	------	---------	-----	--------------	----------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	NAVINTA LLC	1MG/ML	A091525	001	Feb 05, 2013	Jan NEWA
----	-------------	--------	---------	-----	--------------	----------

TABLET; ORAL

BENZTROPINE MESYLATE

@ PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Mar DISC
---------------	-------	---------	-----	--------------	----------

@	1MG	A040705	001	Feb 14, 2008	Mar DISC
---	-----	---------	-----	--------------	----------

@	2MG	A040706	001	Feb 14, 2008	Mar DISC
---	-----	---------	-----	--------------	----------

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ MERCK SHARP DOHME	0.6MG/5ML	N014215	002		Apr CAHN
---------------------	-----------	---------	-----	--	----------

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

CELESTONE SOLUSPAN

AB	+ MERCK SHARP DOHME	3MG/ML; EQ 3MG BASE/ML	N014602	001		Apr CAHN
----	---------------------	------------------------	---------	-----	--	----------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	PERRIGO	0.12%	A078337	001	Nov 26, 2012	Apr CPOT
----	---------	-------	---------	-----	--------------	----------

LUXIQ

AB	+ STIEFEL	0.12%	N020934	001	Feb 28, 1999	Apr CPOT
----	-----------	-------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000	Apr DISC
--------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	CARACO	5MG	A040897	001	Apr 22, 2009	Jun CAHN
----	--------	-----	---------	-----	--------------	----------

AA		10MG	A040897	002	Apr 22, 2009	Jun CAHN
----	--	------	---------	-----	--------------	----------

AA		25MG	A040897	003	Apr 22, 2009	Jun CAHN
----	--	------	---------	-----	--------------	----------

AA		50MG	A040897	004	Apr 22, 2009	Jun CAHN
----	--	------	---------	-----	--------------	----------

@ LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Jun DISC
------------------------	-----	---------	-----	--------------	----------

@	50MG	A040677	001	Mar 27, 2008	Jun DISC
---	------	---------	-----	--------------	----------

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CAHN
---	--------------------	------	---------	-----	--------------	----------

GEL; TOPICAL

TARGRETIN

+	VALEANT LUXEMBOURG	1%	N021056	001	Jun 28, 2000	Jun CAHN
---	--------------------	----	---------	-----	--------------	----------

+	VALEANT PHARMS INC	1%	N021056	001	Jun 28, 2000	Feb CAHN
---	--------------------	----	---------	-----	--------------	----------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ACCORD HLTHCARE	50MG	A078917	001	Jul 06, 2009	Apr CAHN
----	-----------------	------	---------	-----	--------------	----------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@ PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007	Feb DISC
-------------------	-----------------------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE

>A> GEL; TOPICAL

>A> MIRVASO

>A>	+	GALDERMA R AND D	0.33%	N204708	001	Aug 23, 2013	Aug NEWA
-----	---	------------------	-------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE; BRINZOLAMIDESUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA

	+	ALCON RES LTD	0.2%;1%	N204251	001	Apr 19, 2013	Apr NEWA
--	---	---------------	---------	---------	-----	--------------	----------

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMDAY

	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr CPOT
		BROMFENAC SODIUM					
AT		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Apr CPOT
AT		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Apr CPOT
AT			0.09%	A202030	001	Jan 09, 2013	Feb CAHN
		PROLENSA					
	+	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013	Apr NEWA
		XIBROM					
	@	ISTA PHARMS INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr CPOT

BUDESONIDESUSPENSION;INHALATION
BUDESONIDE

	@	APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Apr DISC
	@		0.5MG/2ML	A078202	002	Mar 30, 2009	Apr DISC

TABLET, EXTENDED RELEASE;ORAL
UCERIS

	+	SANTARUS	9MG	N203634	001	Jan 14, 2013	Jan NEWA
--	---	----------	-----	---------	-----	--------------	----------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

	@	INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002	Jun DISC
	@		0.5%	A076012	002	Jan 09, 2002	Jun DISC
	@		0.75%	A076012	003	Jan 09, 2002	Jun DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

>A>		PURDUE PHARMA LP	15MCG/HR	N021306	004	Jul 25, 2013	Aug NEWA
-----	--	------------------	----------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Jul CRLD
	+		EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Jul CRLD

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE;EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Jul CTNA
AB	+		EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Jul CTNA
>A> AB		AMNEAL PHARMS	EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	Aug CTNA
		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
>A> AB		AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Aug CTNA
		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE					
AB		ACTAVIS ELIZABETH	EQ 2MG BASE;EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Feb NEWA
AB	+		EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Apr CRLD
AB			EQ 8MG BASE;EQ 2MG BASE	A091422	002	Feb 22, 2013	Feb NEWA
>D> AB		AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Aug CTNA
AB			EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Feb NEWA
>D> AB			EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	Aug CTNA
AB			EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	Feb NEWA

SUBOXONE

	@	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Mar DISC
AB			EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Feb CFTG
	@		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Mar DISC
AB	+		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Feb CFTG

ZUBSOLV

		OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul NEWA
	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

TABLET, EXTENDED RELEASE;ORAL									
APLENZIN									
	VALEANT BERMUDA	174MG		N022108	001	Apr 23, 2008	Apr	CAHN	
+		348MG		N022108	002	Apr 23, 2008	Apr	CAHN	
		522MG		N022108	003	Apr 23, 2008	Apr	CAHN	
<u>BUPROPION HYDROCHLORIDE</u>									
TABLET;ORAL									
BUPROPION HYDROCHLORIDE									
	@ TEVA	75MG		A075310	001	Nov 29, 1999	Feb	CDFR	
	@	100MG		A075310	002	Nov 29, 1999	Feb	DISC	
TABLET, EXTENDED RELEASE;ORAL									
BUPROPION HYDROCHLORIDE									
	@ IMPAX LABS	300MG		A077415	002	Dec 15, 2006	Apr	DISC	
AB1	WATSON LABS INC	100MG		A077455	001	Jul 19, 2010	Apr	CAHN	
AB3		150MG		A077285	001	Nov 26, 2008	Apr	CAHN	
AB1		150MG		A077455	002	Mar 12, 2008	Apr	CAHN	
AB1		200MG		A077455	003	Jul 19, 2010	Apr	CAHN	
AB3		300MG		A077285	002	Aug 15, 2008	Apr	CAHN	
<u>BUTOCONAZOLE NITRATE</u>									
CREAM;VAGINAL									
BUTOCONAZOLE NITRATE									
+	PERRIGO ISRAEL	2%		A200923	001	May 18, 2012	Mar	CRLD	
	GYNAZOLE-1								
	@ KV PHARM	2%		N019881	001	Feb 07, 1997	Mar	DISC	
<u>BUTORPHANOL TARTRATE</u>									
INJECTABLE;INJECTION									
BUTORPHANOL TARTRATE									
	@ APOTEX INC	2MG/ML		A075697	001	Oct 23, 2001	Apr	DISC	
BUTORPHANOL TARTRATE PRESERVATIVE FREE									
	@ APOTEX INC	1MG/ML		A075695	001	Oct 23, 2001	Apr	DISC	
	@	2MG/ML		A075695	002	Oct 23, 2001	Apr	DISC	
STADOL									
	@ APOTHECON	2MG/ML		N017857	004		Jun	DISC	
STADOL PRESERVATIVE FREE									
	@ APOTHECON	1MG/ML		N017857	001		Jun	DISC	
	@	2MG/ML		N017857	002		Jun	DISC	
<u>CABERGOLINE</u>									
TABLET;ORAL									
CABERGOLINE									
AB	APOTEX CORP	0.5MG		A201503	001	Mar 08, 2013	Feb	NEWA	
<u>CAFFEINE; ERGOTAMINE TARTRATE</u>									
TABLET;ORAL									
ERGOTAMINE TARTRATE AND CAFFEINE									
AA	MIKART	100MG;1MG		A040590	001	Sep 16, 2005	Mar	CMFD	
	@	100MG;1MG		A040590	001	Sep 16, 2005	Jan	DISC	
<u>CALCITRIOL</u>									
CAPSULE;ORAL									
CALCITRIOL									
AB	BANNER PHARMACAPS	0.25MCG		A091174	001	May 24, 2013	May	NEWA	
AB		0.5MCG		A091174	002	May 24, 2013	May	NEWA	
<u>CALCIUM ACETATE</u>									
CAPSULE;ORAL									
CALCIUM ACETATE									
AB	INVAGEN PHARMS	EQ 169MG CALCIUM		A203135	001	Feb 07, 2013	Jan	NEWA	
TABLET;ORAL									
CALCIUM ACETATE									
AB	INVAGEN PHARMS	EQ 169MG CALCIUM		A202420	001	Feb 05, 2013	Jan	NEWA	
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE</u>									
INJECTABLE;INJECTION									
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER									
	@ B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74	N019867	001	Dec 20, 1993	Mar	DISC		
		MG/100ML;640MG/100ML;500MG/100ML;7							
		4MG/100ML							

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	001	Jun 13, 1994	Feb DISC
-------------	---	---------	-----	--------------	----------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	002	Jun 13, 1994	Feb DISC
-------------	---	---------	-----	--------------	----------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	003	Jun 13, 1994	Feb DISC
-------------	---	---------	-----	--------------	----------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESenius	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020374	004	Jun 13, 1994	Feb DISC
-------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

+ LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996	Jun CAHN
----------------------	--	---------	-----	--------------	----------

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr CAHN
+	300MG	N204042	002	Mar 29, 2013	Apr CAHN
JANSSEN RES AND DEV	100MG	N204042	001	Mar 29, 2013	Mar NEWA
+	300MG	N204042	002	Mar 29, 2013	Mar NEWA

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

AB	ASTRAZENECA	4MG	N020838	001	Jun 04, 1998	Apr CFTG
AB		8MG	N020838	002	Jun 04, 1998	Apr CFTG
AB		16MG	N020838	003	Jun 04, 1998	Apr CFTG
AB	+	32MG	N020838	004	Jun 04, 1998	Apr CFTG
	CANDESARTAN CILEXETIL					
AB	SANDOZ	4MG	A078702	001	May 03, 2013	Apr NEWA
AB		8MG	A078702	002	May 03, 2013	Apr NEWA
AB		16MG	A078702	003	May 03, 2013	Apr NEWA
AB		32MG	A078702	004	May 03, 2013	Apr NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	32MG;25MG	A202884	003	Jun 03, 2013	May NEWA
AB	DR REDDYS LABS LTD	16MG;12.5MG	A202965	001	Jun 03, 2013	May NEWA
AB		32MG;12.5MG	A202965	002	Jun 03, 2013	May NEWA
AB		32MG;25MG	A202965	003	Jun 03, 2013	May NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

>A>	TEVA PHARMS USA	150MG	A091649	001	Sep 16, 2013	Aug NEWA
>A>		500MG	A091649	002	Sep 16, 2013	Aug NEWA
	XELODA					
>D>	HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998	Aug CFTG
>A>		150MG	N020896	001	Apr 30, 1998	Aug CFTG
>D>	+	500MG	N020896	002	Apr 30, 1998	Aug CFTG
>A>	+	500MG	N020896	002	Apr 30, 1998	Aug CFTG

CAPSAICIN

PATCH;TOPICAL

QUTENZA

+	ACORDA	8%	N022395	001	Nov 16, 2009	Jul CAHN
---	--------	----	---------	-----	--------------	----------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jun DISC
@	25MG	A074477	002	Feb 13, 1996	Jun DISC

TABLET; ORAL
CAPTOPRIL

@	50MG	A074477	003	Feb 13, 1996	Jun	DISC
@	100MG	A074477	004	Feb 13, 1996	Jun	DISC
@ TEVA	12.5MG	A074483	001	Feb 13, 1996	Jun	DISC
@	25MG	A074483	002	Feb 13, 1996	Jun	DISC
@	50MG	A074483	003	Feb 13, 1996	Jun	DISC
@	100MG	A074483	004	Feb 13, 1996	Jun	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

AB	TARO	100MG	A201106	001	Jun 21, 2013	Jun	NEWA
AB		200MG	A201106	002	Jun 21, 2013	Jun	NEWA
AB		300MG	A201106	003	Jun 21, 2013	Jun	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB	ACCORD HLTHCARE	25MG; 100MG	A202323	001	Feb 08, 2013	Jan	NEWA
AB		50MG; 200MG	A202323	002	Feb 08, 2013	Jan	NEWA

CARBINOXAMINE MALEATE

SUSPENSION, EXTENDED RELEASE; ORAL
KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013	Mar	NEWA
---	-----------------	---------	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

@ PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004	Feb	DISC
@	150MG/VIAL	A076602	002	Nov 16, 2004	Feb	DISC
@	450MG/VIAL	A076602	003	Nov 16, 2004	Feb	DISC

INJECTABLE; IV (INFUSION)
CARBOPLATIN

@ FRESenius KABI USA	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	DISC
@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	DISC
@ PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Apr	DISC
@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Apr	DISC
@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Apr	DISC
PARAPLATIN						
@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CAHN
@	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CAHN
@	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CAHN
@	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	ACCEL RX LABS	350MG	A040576	001	Jun 07, 2005	May	CAHN
	@ COREPHARMA	350MG	A040397	001	Sep 21, 2000	Feb	DISC
	@ PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Jun	DISC

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996	Mar	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION
BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422	001		Jan	CAHN
---	-------------------	------------	---------	-----	--	-----	------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

@ APOTEX INC	1%	A076097	001	Feb 06, 2002	Apr	DISC
--------------	----	---------	-----	--------------	-----	------

CARVEDILOL

TABLET; ORAL
CARVEDILOL

>A> AB	CIPLA LTD	3.125MG	A077474	001	Sep 05, 2007	Aug	CAHN
>A> AB		6.25MG	A077474	002	Sep 05, 2007	Aug	CAHN
>A> AB		12.5MG	A077474	003	Sep 05, 2007	Aug	CAHN

TABLET; ORAL
CARVEDILOL

>A>	AB	25MG	A077474	004	Sep 05, 2007	Aug CAHN
>D>	AB	3.125MG	A077474	001	Sep 05, 2007	Aug CAHN
>D>	AB	6.25MG	A077474	002	Sep 05, 2007	Aug CAHN
>D>	AB	12.5MG	A077474	003	Sep 05, 2007	Aug CAHN
>D>	AB	25MG	A077474	004	Sep 05, 2007	Aug CAHN
	@ WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009	Feb DISC
	@	6.25MG	A078786	002	Dec 22, 2009	Feb DISC
	@	12.5MG	A078786	003	Dec 22, 2009	Feb DISC
	@	25MG	A078786	004	Dec 22, 2009	Feb DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349	001	Apr 25, 2013	Apr NEWA
AB		EQ 500MG BASE/5ML	A065349	002	Apr 25, 2013	Apr NEWA
	@ TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Mar DISC
	@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Mar DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

>D>	AP	AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008	Aug DISC
>A>		@	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008	Aug DISC
>D>	AP		EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008	Aug DISC
>A>		@	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008	Aug DISC
AP	+	HOSPIRA INC	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Feb CRLD
AP	+		EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Feb CRLD
AP	+		EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Feb CRLD
AP	+		EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Feb CRLD
AP	+	STERI PHARMA	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jul CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

	@ SANDOZ	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Mar DISC
	@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Mar DISC
	@	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL
SUPRAX

+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Feb CDFR
	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Feb CDFR
		200MG/5ML	A065355	001	Apr 10, 2007	Feb CDFR

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

>D>	AP	AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009	Aug DISC
>A>		@	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009	Aug DISC
>D>	AP		EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009	Aug DISC
>A>		@	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009	Aug DISC
>D>	AP		EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009	Aug DISC
>A>		@	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009	Aug DISC
		@ AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009	Jun DISC

CEFTAZIDIME

INJECTABLE; INJECTION
CEFTAZIDIME

	@ AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010	Jun DISC
	@	2GM/VIAL	A065481	003	May 28, 2010	Jun DISC
	@	6GM/VIAL	A065482	001	May 28, 2010	Jun DISC
	@	500MG/VIAL	A065481	001	May 28, 2010	Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

	@ AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008	May DISC
	@	EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008	May DISC
	@	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008	May DISC

INJECTABLE;IM-IV
CEFTRIAXONE

	@	EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008	May DISC
	@ TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006	Jul DISC
	@	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006	Jul DISC
AP	TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007	May CAHN
AP		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007	May CAHN
AP		EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007	May CAHN
AP		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007	May CAHN

INJECTABLE;INJECTION
CEFTRIAXONE

@ AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008	May DISC
------------------------	-------------------	---------	-----	--------------	----------

CEFUROXIME SODIUM

INJECTABLE;IM-IV
CEFUROXIME SODIUM

@ TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998	Jul DISC
@	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998	Jul DISC

INJECTABLE;INJECTION

>D>	CEFUROXIME SODIUM IN PLASTIC CONTAINER					
>D>	+ SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009	Aug DISC
>A>	@	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009	Aug DISC
>D>	+	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009	Aug DISC
>A>	@	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009	Aug DISC
	ZINACEF IN PLASTIC CONTAINER					
	@ COVIS PHARMA SARL	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun DISC

CEPHALEXIN

CAPSULE;ORAL
CEPHALEXIN

AB	ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013	Mar NEWA
		EQ 750MG BASE	A090836	004	Mar 29, 2013	Mar NEWA
	KEFLEX					
AB	+ SHIONOGI INC	EQ 750MG BASE	N050405	005	May 12, 2006	Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL
CETIRIZINE HYDROCHLORIDE

	@ APOTEX INC	5MG/5ML	A078412	001	Jun 18, 2008	Apr DISC
	@ AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb DISC
AA	BIO PHARM INC	5MG/5ML	A078870	001	Apr 27, 2009	May CAHN
AA	CARACO	5MG/5ML	A090191	001	Nov 12, 2009	Jun CAHN

CETRORELIX

INJECTABLE;INJECTION
CETROTIDE

@ EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Jun DISC
------------------	----------------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

AB	ROXANE	30MG	A091591	001	Jul 08, 2013	Jun NEWA
----	--------	------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL
CHLORHEXIDINE GLUCONATE

	@ APOTEX INC	0.12%	A075561	001	Nov 14, 2000	Apr DISC
	PAROEX					
AT	SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005	Apr CTNA

CHLOROTHIAZIDE

TABLET;ORAL
CHLOROTHIAZIDE

+ MYLAN	250MG	A084388	001		Jul CTEC
	500MG	A084217	001		Jul CTEC
@ WEST WARD	250MG	A086028	001	Jul 14, 1982	Jul DISC
@	500MG	A087736	001	Jul 14, 1982	Jul DISC
	DIURIL				
@ OAK PHARMS AKORN	250MG	N011145	004		Jan CAHN
@	500MG	N011145	002		Jan CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
CHLOROTHIAZIDE SODIUM

AP	LUITPOLD	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013	Jun CAHN
AP	PHARMAFORCE	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013	Apr NEWA
DIURIL						
AP	+ OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145	005		Jan CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL
VITUZ

	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Feb NEWA
--	-----------------	------------------	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

	@ WATSON LABS INC	100MG	A088852	001	Sep 26, 1984	Jan DISC
	@	250MG	A088826	001	Sep 26, 1984	Jan DISC

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL
FENOFIBRIC ACID

AB	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Jul NEWA
AB		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Jul NEWA
AB	MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	Mar NEWA
AB		EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	Mar NEWA
TRILIPIX						
AB	ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008	Mar CFTG
AB	+	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Mar CFTG

CICLOPIROX

SOLUTION; TOPICAL
CICLOPIROX

>A>	AT	@ APOTEX INC	8%	A078172	001	Sep 18, 2007	Apr DISC
		CIPLA LTD	8%	A078124	001	Sep 18, 2007	Aug CAHN
		@ TEVA PHARMS	8%	A078079	001	Sep 18, 2007	Jan DISC
>D>	AT	WATSON LABS	8%	A078124	001	Sep 18, 2007	Aug CAHN
PENLAC							
AT	+	VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	May CAHN
AT	+	VALEANT INTL	8%	N021022	001	Dec 17, 1999	Feb CAHN

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	@ WATSON LABS INC	200MG	A074349	001	Aug 30, 1996	May DISC
	@	300MG	A074349	002	Aug 30, 1996	May DISC
	@	400MG	A074349	003	Aug 30, 1996	May DISC
	@	800MG	A074316	001	Feb 28, 1996	Jun DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE

	@ APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000	Apr DISC
--	--------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACIN

INJECTABLE; INJECTION
CIPROFLOXACIN

	@ TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Apr CAHN
	@	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

	@ APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Apr DISC
--	--------------	--------------	---------	-----	--------------	----------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CIPRO XR

	@ BAYER HLTHCARE	212.6MG; EQ 287.5MG BASE	N021473	001	Dec 13, 2002	May DISC
	@	425.2MG; EQ 574.9MG BASE	N021473	002	Aug 28, 2003	May DISC
CIPROFLOXACIN EXTENDED RELEASE						

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

	@ DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007	Jun	DISC
AB	+ MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May	CRLD
AB	+	425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May	CRLD

CISPLATIN

INJECTABLE;INJECTION

PLATINOL

	@ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Jan	CAHN
	@	50MG/VIAL	N018057	002		Jan	CAHN
	PLATINOL-AQ						
	@ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Jan	CAHN
	@	1MG/ML	N018057	004	Nov 08, 1988	Jan	CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

	@ APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005	Apr	DISC
--	--------------	------------------	---------	-----	--------------	-----	------

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

>A>	AB	CIPLA LTD	EQ 10MG BASE	A077044	001	Nov 05, 2004	Aug	CAHN
>A>	AB		EQ 20MG BASE	A077044	002	Nov 05, 2004	Aug	CAHN
>A>	AB		EQ 40MG BASE	A077044	003	Nov 05, 2004	Aug	CAHN
	@ COREPHARMA	EQ 10MG BASE	A077036	001	Oct 28, 2004	Feb	DISC	
	@	EQ 20MG BASE	A077036	002	Oct 28, 2004	Feb	DISC	
	@	EQ 40MG BASE	A077036	003	Oct 28, 2004	Feb	DISC	
	@ NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008	Jun	DISC	
	@	EQ 40MG BASE	A077141	001	Apr 10, 2008	Jun	DISC	
>D>	AB	WATSON LABS	EQ 10MG BASE	A077044	001	Nov 05, 2004	Aug	CAHN
>D>	AB		EQ 20MG BASE	A077044	002	Nov 05, 2004	Aug	CAHN
>D>	AB		EQ 40MG BASE	A077044	003	Nov 05, 2004	Aug	CAHN

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

AB	ALLIED PHARMA INC	250MG	A202710	001	Jun 10, 2013	May	NEWA
AB		500MG	A202710	002	Jun 10, 2013	May	NEWA

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

	@ APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000	Apr	DISC
	@ SILARX	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Mar	DISC

CLEVIDIPINE

EMULSION;INTRAVENOUS

CLEVIPREX

+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Feb	CAIN
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Feb	CAIN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409	001	Apr 30, 2013	Apr	NEWA
----	----------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	AKORN INC	EQ 6MG BASE/ML	A203048	001	Apr 04, 2013	Mar	NEWA
AP		EQ 12MG BASE/ML	A203048	002	Apr 04, 2013	Mar	NEWA
AP		EQ 18MG BASE/ML	A203048	003	Apr 04, 2013	Mar	NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

	@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN
>D>	@ PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Aug	CMFD
>A>	AT	EQ 1% BASE	A064050	001	Nov 30, 1995	Aug	CMFD
	@	EQ 1% BASE	A064050	001	Nov 30, 1995	Feb	DISC

CLOBAZAM

TABLET;ORAL

ONFI

ABX	Product	Strength	Manufacturer	Approval Number	Approval Date	Approval Status
	<u>TABLET; ORAL</u>					
	ONFI					
	@ LUNDBECK LLC	5MG		N202067	001 Oct 21, 2011	Jul DISC
	<u>CLOBETASOL PROPIONATE</u>					
	AEROSOL, FOAM; TOPICAL					
	OLUX E					
AB2	+ DELCOR ASSET	0.05%		N022013	001 Jan 12, 2007	Jun CAHN
	CREAM; TOPICAL					
	CLOBETASOL PROPIONATE					
	@ TEVA PHARMS USA	0.05%		A074087	001 Feb 16, 1994	Jun DISC
	SOLUTION; TOPICAL					
	EMBELINE					
AT	+ HI TECH PHARMA	0.05%		A074222	001 Dec 06, 1995	Jul CRLD
	TEMOVATE					
	@ FOUGERA PHARMS	0.05%		N019966	001 Feb 22, 1990	Jul DISC
	<u>CLONAZEPAM</u>					
	TABLET; ORAL					
	CLONAZEPAM					
AB	ACCORD HLTHCARE	0.5MG		A077147	001 May 02, 2005	Apr CAHN
AB		1MG		A077147	002 May 02, 2005	Apr CAHN
AB		2MG		A077147	003 May 02, 2005	Apr CAHN
	@ APOTEX INC	0.5MG		A075468	001 Oct 06, 2000	Feb DISC
	@	1MG		A075468	002 Oct 06, 2000	Feb DISC
	@	2MG		A075468	003 Oct 06, 2000	Feb DISC
	<u>CLONIDINE HYDROCHLORIDE</u>					
	TABLET; ORAL					
	CLONIDINE HYDROCHLORIDE					
AB	CARLSBAD	0.1MG		A202297	001 Jun 13, 2013	May NEWA
AB		0.2MG		A202297	002 Jun 13, 2013	May NEWA
AB		0.3MG		A202297	003 Jun 13, 2013	May NEWA
	TABLET, EXTENDED RELEASE; ORAL					
	JENLOGA					
	@ CONCORDIA PHARMS INC	0.1MG		N022331	001 Sep 30, 2009	May CAHN
	@	0.2MG		N022331	002 May 25, 2010	May CAHN
	KAPVAY					
	+ CONCORDIA PHARMS INC	0.1MG		N022331	003 Sep 28, 2010	May CAHN
		0.2MG		N022331	004 Sep 28, 2010	May CAHN
	<u>CLOPIDOGREL BISULFATE</u>					
	TABLET; ORAL					
	CLOPIDOGREL BISULFATE					
AB	ACCORD HLTHCARE	EQ 75MG BASE		A202925	001 Mar 27, 2013	Mar NEWA
AB		EQ 300MG BASE		A202925	002 Mar 27, 2013	Mar NEWA
AB	ACTAVIS TOTOWA	EQ 75MG BASE		A090307	001 May 28, 2013	May NEWA
AB	MUTUAL PHARM	EQ 75MG BASE		A078133	001 Jun 10, 2013	May NEWA
	<u>CLORAZEPATE DIPOTASSIUM</u>					
	CAPSULE; ORAL					
	TRANXENE					
	@ RECORDATI RARE	3.75MG		N017105	001	May CAHN
	@	7.5MG		N017105	002	May CAHN
	@	15MG		N017105	003	May CAHN
	TABLET; ORAL					
	TRANXENE					
AB	RECORDATI RARE	3.75MG		N017105	006	May CAHN
AB		7.5MG		N017105	007	May CAHN
AB	+	15MG		N017105	008	May CAHN
	TRANXENE SD					
	@ RECORDATI RARE	11.25MG		N017105	005	May CAHN
	@	22.5MG		N017105	004	May CAHN
	<u>CLOZAPINE</u>					
	SUSPENSION; ORAL					
	VERSACLOZ					
	+ DOUGLAS PHARMS	50MG/ML		N203479	001 Feb 06, 2013	Feb NEWA
	+ JAZZ PHARMS III	50MG/ML		N203479	001 Feb 06, 2013	Mar CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	AMNEAL PHARMS	10MG/5ML;6.25MG/5ML	A200894	001	Apr 24, 2013	Apr NEWA
AA	CARACO	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	May CAHN
>D> AA	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988	Aug DISC
>A>	@	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988	Aug DISC

COSYNTROPIN

INJECTABLE;INJECTION

COSYNTROPIN

AP	MYLAN LLC	0.25MG/VIAL	A090574	001	Dec 17, 2009	Feb CAHN
----	-----------	-------------	---------	-----	--------------	----------

CROMOLYN SODIUM

CONCENTRATE;ORAL

CROMOLYN SODIUM

AA	MICRO LABS LTD INDIA	100MG/5ML	A202745	001	Apr 04, 2013	Mar NEWA
----	----------------------	-----------	---------	-----	--------------	----------

SOLUTION;INHALATION

CROMOLYN SODIUM

@ APOTEX INC 10MG/ML

A075333 001 Apr 30, 2002 Apr DISC

SOLUTION/DROPS;OPHTHALMIC

CROMOLYN SODIUM

@ APOTEX INC 4%

A075615 001 Jan 26, 2001 Apr DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMRIX

AB	IVAX INTL	15MG	N021777	001	Feb 01, 2007	Jan CAHN
----	-----------	------	---------	-----	--------------	----------

AB	+	30MG	N021777	002	Feb 01, 2007	Jan CAHN
----	---	------	---------	-----	--------------	----------

CYCLOBENZAPRINE HYDROCHLORIDE

AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Jan NEWA
----	----------------	------	---------	-----	--------------	----------

AB		30MG	A091281	002	Jan 31, 2013	Jan NEWA
----	--	------	---------	-----	--------------	----------

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	7.5MG	A073144	003	Mar 25, 2013	Mar NEWA
----	------------------	-------	---------	-----	--------------	----------

@ PROSAM LABS 5MG

A077291 001 Feb 03, 2006 Mar DISC

@ SANDOZ 5MG

A072854 002 Feb 03, 2006 Apr DISC

@ 10MG

A072854 001 Nov 19, 1991 Apr DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPENTOLATE

@ AKORN 2%

A040165 001 Jan 13, 1997 Mar DISC

CYCLOGYL

+ ALCON LABS INC 2%

A084108 001 Mar CTEC

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION

CYTOXAN (LYOPHILIZED)

AP	+	BAXTER HLTHCARE	1GM/VIAL	N012142	004	Aug 30, 1982	Mar CTNA
----	---	-----------------	----------	---------	-----	--------------	----------

@ 1GM/VIAL

N012142 010 Sep 24, 1985 Jan CTNA

AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Mar CTNA
----	---	--	----------	---------	-----	--------------	----------

@ 2GM/VIAL

N012142 009 Dec 10, 1985 Jan CTNA

AP	+		500MG/VIAL	N012142	003		Mar CTNA
----	---	--	------------	---------	-----	--	----------

@ 500MG/VIAL

N012142 008 Jan 04, 1984 Jan CTNA

CYCLOSPORINE

SOLUTION;ORAL

CYCLOSPORINE

@ APOTEX INC 100MG/ML

A065167 001 Jan 05, 2005 Apr DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Mar NEWA
----	-------------	---------	---------	-----	--------------	----------

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

RAPTOR PHARMS EQ 25MG BASE

N203389 001 Apr 30, 2013 Apr NEWA

+ EQ 75MG BASE

N203389 002 Apr 30, 2013 Apr NEWA

CYTARABINEINJECTABLE; INJECTION
CYTOSAR-U

AP	+	TEVA PHARMS USA	1GM/VIAL	A075206	004	Dec 30, 1998	Jun CAHN
AP	+		2GM/VIAL	A075206	003	Dec 30, 1998	Jun CAHN
AP			100MG/VIAL	A075206	001	Dec 30, 1998	Jun CAHN
AP	+		500MG/VIAL	A075206	002	Dec 30, 1998	Jun CAHN

DABRAFENIB MESYLATECAPSULE; ORAL
TAFINLARGLAXOSMITHKLINE EQ 50MG BASE
+ EQ 75MG BASE

N202806	001	May 29, 2013	May NEWA
N202806	002	May 29, 2013	May NEWA

DACARBAZINEINJECTABLE; INJECTION
DACARBAZINE

AP		TEVA PHARMS USA	200MG/VIAL	A075259	002	Aug 27, 1998	Apr CAHN
AP	+		500MG/VIAL	A075259	001	Sep 22, 2000	Apr CAHN

DACTINOMYCININJECTABLE; INJECTION
COSMEGEN

AP	+	RECORDATI RARE	0.5MG/VIAL	N050682	001		May CAHN
>A> AP		DACTINOMYCIN PHARMAFORCE	0.5MG/VIAL	A202562	001	Aug 23, 2013	Aug NEWA

DALTEPARIN SODIUMINJECTABLE; SUBCUTANEOUS
FRAGMIN@ EISAI INC 10,000IU/0.4ML (25,000IU/ML)
@ 95,000IU/9.5ML (10,000IU/ML)

N020287	002	May 01, 2007	Jun DISC
N020287	007	Apr 04, 2002	Jun DISC

DANTROLENE SODIUMCAPSULE; ORAL
DANTROLENE SODIUM

AB		MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul CMFD
AB			50MG	A076686	002	Oct 24, 2005	Jul CMFD
AB			100MG	A076686	003	Oct 24, 2005	Jul CMFD

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DAUNORUBICIN HYDROCHLORIDE

AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Apr CAHN
----	--	-----------------	----------------	---------	-----	--------------	----------

DECITABINEINJECTABLE; INTRAVENOUS
DACOGEN

AP	+	EISAI INC	50MG/VIAL	N021790	001	May 02, 2006	Jul CFTG
AP		DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013	Jul NEWA

DESMOPRESSIN ACETATEINJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP		SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Jan NEWA
AP		TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Apr CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

>A> AB		FAMY CARE LTD	0.15MG,N/A;0.02MG,0.01MG	A202296	001	Aug 30, 2013	Aug NEWA
AB		NOVAST LABS LTD	0.15MG;0.03MG	A091234	001	Jul 12, 2013	Jul NEWA
		ENSKYCE					
AB		LUPIN LTD	0.15MG;0.03MG	A201887	001	Mar 07, 2013	Feb NEWA
		PIMTREA					
AB		NOVAST LABS LTD	0.15MG,N/A;0.02MG,0.01MG	A091247	001	Aug 01, 2013	Jul NEWA

DESONIDE

GEL; TOPICAL

GEL; TOPICAL
DESONATE

+ BAYER HLTHCARE 0.05% N021844 001 Oct 20, 2006 Jun CAHN

DESOXIMETASONE

SPRAY; TOPICAL
TOPICORT

+ TARO 0.25% N204141 001 Apr 11, 2013 Apr NEWA

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE

BC	+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Jul CTEC
	+		50MG	N204150	001	Mar 04, 2013	Apr CRLD
			50MG	N204150	001	Mar 04, 2013	Mar NEWA
BC	+		100MG	N204150	002	Mar 04, 2013	Jul CTEC
	+		100MG	N204150	002	Mar 04, 2013	Mar NEWA
		KHEDEZLA					
BC		OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	Jul NEWA
BC			100MG	N204683	002	Jul 10, 2013	Jul NEWA

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

AA WOCKHARDT EU OPERATN 0.5MG/5ML A088254 001 Jul 27, 1983 May CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT PERRIGO CO TENNESSEE 0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM A062938 001 Jul 31, 1989 Jun CAHN

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

@ ALCON PHARMS LTD 0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML A062721 001 Nov 17, 1986 Jan DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
PRECEDEX

+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar NEWA
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>							
>A>	AB	MYLAN PHARMS INC	30MG	A202580	001	Aug 28, 2013	Aug NEWA
		FOCALIN XR					
>D>		NOVARTIS	30MG	N021802	005	Oct 23, 2009	Aug CFTG
>A>	AB		30MG	N021802	005	Oct 23, 2009	Aug CFTG

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
TOTECT

+ BIOCODEX INC EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 May CAHN

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL
DEXTROAMPHETAMINE SULFATE

AA	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008	May CFTG
AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013	May NEWA

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

AA		AUROLIFE PHARMA LLC	5MG	A202893	001	Jul 31, 2013	Jul NEWA
AA			10MG	A202893	002	Jul 31, 2013	Jul NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN 5GM/100ML; 220MG/100ML N018744 003 Nov 09, 1982 Jan DISC

DIAZEPAMINJECTABLE; INJECTION
DIAZEPAM

@ WATSON LABS 5MG/ML

A070296 001 Feb 12, 1986 Jun DISC

DIAZOXIDESUSPENSION; ORAL
PROGLYCEM

+ TEVA BRANDED PHARM 50MG/ML

N017453 001 Apr CAHN

DICLOFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

@ APOTEX INC 0.1%

A077600 001 Nov 13, 2008 Apr DISC

DICLOFENAC SODIUM; MISOPROSTOLTABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM AND MISOPROSTOL

AB SANDOZ 50MG; 0.2MG

A200158 001 May 09, 2013 Apr NEWA

AB 75MG; 0.2MG

A200158 002 May 09, 2013 Apr NEWA

DICYCLOMINE HYDROCHLORIDECAPSULE; ORAL
DICYCLOMINE HYDROCHLORIDE

@ WEST WARD 10MG

A040204 001 Feb 28, 1997 Jul DISC

DIDANOSINETABLET, FOR SUSPENSION; ORAL
DIDANOSINE

AUROBINDO 100MG

A077275 001 Aug 14, 2012 Apr CDFR

150MG

A077275 002 Aug 14, 2012 Apr CDFR

+ 200MG

A077275 003 Aug 14, 2012 Apr CDFR

DIFLORASONE DIACETATECREAM; TOPICAL
DIFLORASONE DIACETATE

@ FOUGERA PHARMS 0.05%

A075187 001 Mar 30, 1998 May DISC

BX + TARO 0.05%

A075508 001 Apr 24, 2000 May CRLD

PSORCON

@ TARO PHARMS NORTH 0.05%

N020205 001 Nov 20, 1992 Jun CAHN

DIGOXINTABLET; ORAL
DIGOXIN

@ CARACO 0.125MG

A076363 001 Jan 31, 2003 Jun DISC

@ 0.25MG

A076363 002 Jan 31, 2003 Jun DISC

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB3 PAR PHARM 120MG

A074984 001 Dec 20, 1999 Jan CAHN

AB3 180MG

A074984 002 Dec 20, 1999 Jan CAHN

AB3 240MG

A074984 003 Dec 20, 1999 Jan CAHN

AB3 300MG

A074984 004 Dec 20, 1999 Jan CAHN

AB4 SANDOZ 120MG

A091022 001 Sep 28, 2012 Feb CAHN

AB4 180MG

A091022 002 Sep 28, 2012 Feb CAHN

AB4 240MG

A091022 003 Sep 28, 2012 Feb CAHN

AB4 300MG

A091022 004 Sep 28, 2012 Feb CAHN

AB4 360MG

A091022 005 Sep 28, 2012 Feb CAHN

AB4 420MG

A091022 006 Sep 28, 2012 Feb CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP AKORN INC 5MG/ML

A075086 001 Apr 09, 1998 Jul CAHN

@ APOTEX INC 5MG/ML

A075375 001 Sep 30, 1999 Apr DISC

@ TEVA PHARMS USA 5MG/ML

A074894 001 Aug 26, 1997 Apr CAHN

+ 10MG/ML

A074894 002 Apr 19, 2002 Apr CAHN

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@ DAVA PHARMS INC 30MG

A074093 001 Nov 05, 1992 Jan DISC

@ 60MG

A074093 002 Nov 05, 1992 Jan DISC

@ 90MG

A074093 003 Nov 05, 1992 Jan DISC

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

@ 120MG

A074093 004 Nov 05, 1992 Jan DISC

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

+ FRESenius KABI USA 50MG/ML

A040519 001 Jun 23, 2004 Apr CRLD

@ WATSON LABS 50MG/ML

A080615 001 Apr DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

TECFIDERA

BIOGEN IDEC INC 120MG

N204063 001 Mar 27, 2013 Mar NEWA

+ 240MG

N204063 002 Mar 27, 2013 Mar NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ WATSON LABS INC 10MG/ML

A080873 001 Mar DISC

@ 50MG/ML

A080873 002 Mar DISC

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP BD RX 50MG/ML

A091526 001 Mar 26, 2013 Mar NEWA

@ WATSON LABS INC 50MG/ML

A080873 003 Mar DISC

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

>A> @ AGILA SPECLTS 5MG/ML

A075769 001 Nov 27, 2002 Aug CAHN

>D> @ APOTEX INC 5MG/ML

A075769 001 Nov 27, 2002 Aug CAHN

@ 5MG/ML

A075769 001 Nov 27, 2002 Apr DISC

@ TEVA PHARMS USA 5MG/ML

A074952 001 Nov 26, 1997 May CAHN

TABLET;ORAL

DIPYRIDAMOLE

@ PROSAM LABS 25MG

A040542 001 Apr 21, 2006 Jun DISC

@ 50MG

A040542 002 Apr 21, 2006 Jun DISC

@ 75MG

A040542 003 Apr 21, 2006 Jun DISC

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB ALVOGEN PINE BROOK 250MG

A091681 001 Aug 08, 2013 Jul NEWA

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

>D> AB MYLAN EQ 125MG VALPROIC ACID

A077254 001 Jul 29, 2008 Aug DISC

>A> @ EQ 125MG VALPROIC ACID

A077254 001 Jul 29, 2008 Aug DISC

>D> AB EQ 250MG VALPROIC ACID

A077254 002 Jul 29, 2008 Aug DISC

>A> @ EQ 250MG VALPROIC ACID

A077254 002 Jul 29, 2008 Aug DISC

>D> AB EQ 500MG VALPROIC ACID

A077254 003 Jul 29, 2008 Aug DISC

>A> @ EQ 500MG VALPROIC ACID

A077254 003 Jul 29, 2008 Aug DISC

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@ TEVA PHARMS USA EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009 Mar DISC

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

>D> ACCORD HLTHCARE 160MG/8ML (20MG/ML)

N201195 005 Apr 20, 2012 Aug CTEC

>A> AP 160MG/8ML (20MG/ML)

N201195 005 Apr 20, 2012 Aug CTEC

AP ACTAVIS INC 20MG/ML (20MG/ML)

N203551 001 Apr 12, 2013 Apr NEWA

AP 80MG/4ML (20MG/ML)

N203551 002 Apr 12, 2013 Apr NEWA

140MG/7ML (20MG/ML)

N203551 003 Apr 12, 2013 Apr NEWA

@ APOTEX INC 20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012 May DISC

@ 80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012 May DISC

TAXOTERE

>A> AP + SANOFI AVENTIS US 160MG/8ML (20MG/ML)

N020449 005 Apr 13, 2012 Aug NEWA

>A> DOLUTEGRAVIR SODIUM

>A> TABLET;ORAL

>A> TIVICAY

>A>	TABLET;ORAL						
>A>	TIVICAY						
>A>	+ VIIV HLTHCARE	EQ 50MG BASE	N204790	001	Aug 12, 2013	Aug	NEWA
<u>DONEPEZIL HYDROCHLORIDE</u>							
	TABLET;ORAL						
	ARICEPT						
AB	+ EISAI INC	23MG	N022568	001	Jul 23, 2010	Jul	CTEC
	DONEPEZIL HYDROCHLORIDE						
	@ ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011	Jan	DISC
	@	10MG	A201335	002	Aug 29, 2011	Jan	DISC
AB	ACTAVIS GRP PTC	5MG	A090551	001	May 31, 2011	Apr	CAHN
AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
AB	ALEMBIC PHARMS LTD	5MG	A201724	001	Feb 25, 2013	Feb	NEWA
AB		10MG	A201724	002	Feb 25, 2013	Feb	NEWA
AB	ALVOGEN PINE BROOK	5MG	A202114	001	Jul 05, 2013	Jun	NEWA
AB		10MG	A202114	002	Jul 05, 2013	Jun	NEWA
AB	DR REDDYS LABS LTD	23MG	A202723	001	Jul 24, 2013	Jul	NEWA
AB	PAR PHARM	23MG	A202542	001	Jul 24, 2013	Jul	NEWA
<u>DORZOLAMIDE HYDROCHLORIDE</u>							
	SOLUTION/DROPS;OPHTHALMIC						
	DORZOLAMIDE HYDROCHLORIDE						
	@ APOTEX INC	EQ 2% BASE	A078395	001	Oct 28, 2008	Apr	DISC
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE</u>							
	SOLUTION/DROPS;OPHTHALMIC						
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE						
	@ APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Apr	DISC
<u>DOXAPRAM HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION						
	DOPRAM						
AP	+ HIKMA MAPLE	20MG/ML	N014879	001		Jul	CAHN
<u>DOXAZOSIN MESYLATE</u>							
	TABLET;ORAL						
	DOXAZOSIN MESYLATE						
	@ WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000	Jan	DISC
	@	EQ 2MG BASE	A075426	002	Oct 18, 2000	Jan	DISC
	@	EQ 4MG BASE	A075426	003	Oct 18, 2000	Jan	DISC
	@	EQ 8MG BASE	A075426	004	Oct 18, 2000	Jan	DISC
<u>DOXEPIN HYDROCHLORIDE</u>							
	CAPSULE;ORAL						
	DOXEPIN HYDROCHLORIDE						
AB	MYLAN PHARMS INC	EQ 10MG BASE	A070791	002	May 13, 1986	Jun	CRLD
AB		EQ 10MG BASE	A070791	002	May 13, 1986	May	CRLD
AB	+	EQ 25MG BASE	A070791	003	May 13, 1986	Jun	CRLD
	@ PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987	May	DISC
	@	EQ 25MG BASE	A071437	001	Nov 09, 1987	May	DISC
	@	EQ 50MG BASE	A071595	001	Nov 09, 1987	May	DISC
	@	EQ 75MG BASE	A071608	001	Nov 09, 1987	May	DISC
	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	May	DISC
	@ WATSON LABS	EQ 10MG BASE	A071485	001	Apr 30, 1987	May	DISC
	@	EQ 25MG BASE	A071486	001	Apr 30, 1987	May	DISC
	@	EQ 50MG BASE	A071238	001	Apr 30, 1987	May	DISC
	@	EQ 75MG BASE	A071326	001	Apr 30, 1987	May	DISC
	@	EQ 100MG BASE	A071239	001	Apr 30, 1987	May	DISC
	CONCENTRATE;ORAL						
	DOXEPIN HYDROCHLORIDE						
	@ PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004	Mar	DISC
	TABLET;ORAL						
	DOXEPIN HYDROCHLORIDE						
AB	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jul	NEWA
AB		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jul	NEWA
	SILENOR						
AB	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jul	CFTG
		EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
AB	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jul	CFTG
	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

>A>		DOXERCALCIFEROL					
>A>	AP	INNOPHARMA INC	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Aug NEWA
		HECTOROL					
>D>	+	GENZYME CORP	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug CFTG
>A>	AP	+	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		SAGENT PHARMS	2MG/ML	A091495	001	Mar 18, 2013	Mar NEWA
AP		TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995	Jun CAHN
AP			200MG/100ML	A064140	002	Jul 28, 1995	Jun CAHN

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL

AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan CFTG
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan CFTG

DOXIL (LIPOSOMAL)

AB		JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jun CRLD
AB	+		20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Apr CTNA
AB			50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jun CRLD
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Apr CTNA

DOXORUBICIN HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jan NEWA
AB			50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jan NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	+	SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jun CRLD
AB	+		20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Apr CTNA
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jun CRLD
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Apr CTNA

DOXYCYCLINE

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Mar NEWA
----	--	-----------	------------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		HIKMA PHARMS	EQ 50MG BASE	A062396	002	Nov 07, 1984	May CAHN
AB			EQ 100MG BASE	A062396	001	May 07, 1984	May CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

	@	BLU CARIBE INC	EQ 50MG BASE	A062269	003		Mar CAHN
	@		EQ 100MG BASE	A062269	002	Nov 08, 1982	Mar CAHN
AB		CHARTWELL LIFE SCI	EQ 100MG BASE	A062505	001	Sep 11, 1984	Jul CAHN
AB	+	HIKMA PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	May CAHN

TABLET, DELAYED RELEASE;ORAL

DORYX

		MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr NEWA
			EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr NEWA

DOXYCYCLINE HYCLATE

AB		HERITAGE PHARMS INC	EQ 75MG BASE	A200856	001	Apr 30, 2013	Apr NEWA
AB			EQ 100MG BASE	A200856	002	Apr 30, 2013	Apr NEWA
AB			EQ 150MG BASE	A200856	003	Apr 30, 2013	Apr NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

+		DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Apr NEWA
---	--	-----------	-----------	---------	-----	--------------	----------

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB		BANNER PHARMACAPS	0.5MG	A200899	001	May 30, 2013	May NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		IGI LABS INC	1%	A076574	001	Dec 17, 2004	Mar CAHN
----	--	--------------	----	---------	-----	--------------	----------

EDROPHONIUM CHLORIDEINJECTABLE;INJECTION
TENSILON

AP	+	VALEANT PHARMS	10MG/ML	N007959	001		Jul	CAHN
AP	+	VALEANT PHARMS	10MG/ML	N007959	002		Jul	CAHN

ENALAPRIL MALEATE>A> FOR SOLUTION;ORAL
>A> EPANED KIT

>A>	+	SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Aug	NEWA
-----	---	-------------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

ENALAPRIL MALEATE

>D>	AB	MYLAN	2.5MG	A075472	001	Aug 22, 2000	Aug	DISC
>A>		@	2.5MG	A075472	001	Aug 22, 2000	Aug	DISC
>D>	AB		5MG	A075472	002	Aug 22, 2000	Aug	DISC
>A>		@	5MG	A075472	002	Aug 22, 2000	Aug	DISC
>D>	AB		10MG	A075472	003	Aug 22, 2000	Aug	DISC
>A>		@	10MG	A075472	003	Aug 22, 2000	Aug	DISC
>D>	AB		20MG	A075472	004	Aug 22, 2000	Aug	DISC
>A>		@	20MG	A075472	004	Aug 22, 2000	Aug	DISC

ENALAPRILATINJECTABLE;INJECTION
ENALAPRILAT

AP		TEVA PHARMS USA	1.25MG/ML	A075578	001	Aug 22, 2000	May	CAHN
----	--	-----------------	-----------	---------	-----	--------------	-----	------

ENTACAPONETABLET;ORAL
ENTACAPONE

AB		MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	Apr	NEWA
----	--	------------------	-------	---------	-----	--------------	-----	------

EPINEPHRINEINJECTABLE;IM-SC
EPIPEN

BX	+	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul	CDFR
BX	+	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul	CDFR

EPIRUBICIN HYDROCHLORIDEINJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

		@ MYLAN LLC	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Feb	DISC
		@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Feb	DISC
AP		TEVA PHARMS USA	50MG/25ML (2MG/ML)	A065331	001	Aug 09, 2007	Apr	CAHN
AP			200MG/100ML (2MG/ML)	A065331	002	Aug 09, 2007	Apr	CAHN

EPOPROSTENOL SODIUMINJECTABLE;INJECTION
EPOPROSTENOL SODIUM

AP		TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Apr	CAHN
AP			EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Apr	CAHN

ERTAPENEM SODIUMINJECTABLE;INTRAMUSCULAR, IV (INFUSION)
INVANZ

	+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun	CAHN
--	---	-------------------	------------------	---------	-----	--------------	-----	------

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS;ORAL
ERYC

AB	+	MAYNE PHARMA	250MG	N050536	001		Mar	CAHN
		@ WARNER CHILCOTT LLC	250MG	A062338	001		Apr	DISC

GEL;TOPICAL

ERYGEL

AT	+	DELCOR ASSET CORP	2%	N050617	001	Oct 21, 1987	Jul	CAHN
----	---	-------------------	----	---------	-----	--------------	-----	------

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT	+	PERRIGO CO TENNESSEE	0.5%	A062447	001	Sep 26, 1983	Jun	CAHN
----	---	----------------------	------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

SOLUTION; TOPICAL
SANSAC

@ DOW PHARM	2%	A062522	001	Jan 24, 1985	Apr CAHN
-------------	----	---------	-----	--------------	----------

ESCITALOPRAM OXALATESOLUTION; ORAL
ESCITALOPRAM OXALATE

AA	SILARX PHARMS INC	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	May NEWA
----	-------------------	-----------------	---------	-----	--------------	----------

ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Mar NEWA
AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Mar NEWA
NEXIUM IV						
AP	+ ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Mar CFTG
AP	+	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Mar CFTG

>A> ESOMEPRAZOLE STRONTIUM

>A> CAPSULE, DELAYED RELEASE; ORAL

>A> ESOMEPRAZOLE STRONTIUM

>A>	HANMI USA	EQ 20MG BASE	N202342	001	Aug 06, 2013	Aug NEWA
>A>	+	EQ 40MG BASE	N202342	002	Aug 06, 2013	Aug NEWA

ESTRADIOL VALERATEINJECTABLE; INJECTION
ESTRADIOL VALERATE

@ WATSON LABS	40MG/ML	A083714	001		Jun DISC
@ WATSON LABS INC	20MG/ML	A083547	001		Jun DISC

ESTRONEINJECTABLE; INJECTION
ESTRONE

@ WATSON LABS	5MG/ML	A085239	001		Jun DISC
---------------	--------	---------	-----	--	----------

ESTROPIPATETABLET; ORAL
ORTHO-EST

@ CARACO	0.75MG	A089567	001	Feb 27, 1991	Apr DISC
@	1.5MG	A089582	001	Jul 17, 1991	Apr DISC

ESZOPICLONETABLET; ORAL
ESZOPICLONE

AB	MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013	Mar NEWA
AB		2MG	A091151	002	Mar 26, 2013	Mar NEWA
AB		3MG	A091151	003	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013	Mar NEWA
AB		2MG	A091103	002	Apr 03, 2013	Mar NEWA
AB		3MG	A091103	003	Apr 03, 2013	Mar NEWA
LUNESTA						
AB	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Mar CTEC
AB		2MG	N021476	002	Dec 15, 2004	Mar CTEC
AB	+	3MG	N021476	003	Dec 15, 2004	Mar CTEC

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL
ETHAMBUTOL HYDROCHLORIDE

@ WEST WARD	100MG	A075095	001	Nov 30, 1999	Jul DISC	
@	400MG	A075095	002	Nov 30, 1999	Jul DISC	
MYAMBUTOL						
AB	+ STI PHARMA LLC	400MG	N016320	003		Jul CRLD

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
DAYSEE

AB	LUPIN LTD	0.03MG, 0.01MG; 0.15MG, N/A	A091467	001	Apr 10, 2013	Mar NEWA
QUARTETTE						
+	TEVA BRANDED PHARM	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	N204061	001	Mar 28, 2013	Mar NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

TABLET;ORAL-28

	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

	NORETHINDRONE AND ETHINYL ESTRADIOL					
AB	FAMY CARE LTD	0.05MG;1MG	A203006	001	Aug 05, 2013	Jul NEWA
	OVCON-50					
AB	+ WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Jul CFTG
	PIRMELLA 1/35					
AB	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Apr NEWA
	PIRMELLA 7/7/7					
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75 MG,1MG	A201510	001	Apr 24, 2013	Apr NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

MINASTRIN 24 FE

+	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
@	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	May DISC

TABLET;ORAL

FEMHRT

@	WARNER CHILCOTT LLC	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Jan CRLD

TABLET;ORAL-28

>A>	LARIN FE 1.5/30					
>A> AB	NOVAST LABS LTD	0.03MG;1.5MG	A091453	001	Aug 23, 2013	Aug NEWA
>A>	LARIN FE 1/20					
>A> AB	NOVAST LABS LTD	0.02MG;1MG	A091454	001	Aug 26, 2013	Aug NEWA

TABLET, CHEWABLE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2003	May NEWA
---	---------------------	------------	---------	-----	--------------	----------

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

+	WARNER CHILCOTT	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jul NEWA
---	-----------------	-------------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

ESTARYLLA

AB	SANDOZ	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Jan NEWA
	TRI LO SPRINTEC					
@	BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A076784	001	Jun 29, 2009	Apr DISC
	TRI-ESTARYLLA					
AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.2 15MG,0.25MG	A090793	001	Jan 30, 2013	Jan NEWA

ETHOTOIN

TABLET;ORAL

PEGANONE

+	RECORDATI RARE	250MG	N010841	001		May CAHN
---	----------------	-------	---------	-----	--	----------

ETODOLAC

TABLET;ORAL

ETODOLAC

@	PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Mar DISC
@		500MG	A074819	002	Apr 28, 1998	Mar DISC

ETOPOSIDE

INJECTABLE;INJECTION

ETOPOSIDE

AP	ACCORD HLTHCARE	20MG/ML	A074513	001	Mar 14, 1996	Apr CAHN
@	PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996	Apr DISC
AP	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May CAHN
AP		20MG/ML	A074529	001	Jul 24, 1996	Apr CAHN

FAMCICLOVIR

TABLET;ORAL

TABLET;ORAL
FAMCICLOVIR

AB	CIPLA LTD	125MG	A078278	001	Mar 21, 2011	Jul CAHN
AB		250MG	A078278	002	Mar 21, 2011	Jul CAHN
AB		500MG	A078278	003	Mar 21, 2011	Jul CAHN

FAMOTIDINE

INJECTABLE;INJECTION
FAMOTIDINE

	@ APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002	Apr DISC
	FAMOTIDINE PRESERVATIVE FREE					
AP	AKORN INC	10MG/ML	A076324	001	Nov 27, 2002	Mar CAHN
	@ APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Apr DISC
	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)					
AP	AKORN INC	10MG/ML	A076322	001	Nov 27, 2002	Mar CAHN
	@ APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Apr DISC
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
	@ MERCK SHARP DOHME	0.4MG/ML	N020249	001	Feb 18, 1994	Apr CAHN

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

AB	APOTEX INC	43MG	A202252	001	Jul 26, 2013	Jul NEWA
AB		130MG	A202252	002	Jul 26, 2013	Jul NEWA

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

	MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Feb CAHN
+		105MG	N022418	002	Aug 14, 2009	Feb CAHN

FENOPROFEN CALCIUM

TABLET;ORAL
FENOPROFEN CALCIUM

	@ IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988	Mar DISC
+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988	Mar CTEC

FENTANYL

SPRAY;SUBLINGUAL
SUBSYS

>A>	INSYS THERAP	1.2MG	N202788	006	Aug 30, 2012	Aug NEWA
>A>		1.6MG	N202788	007	Aug 30, 2012	Aug NEWA

FENTANYL CITRATE

FILM;BUCCAL
ONSOLIS

	@ MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	May DISC
	@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	May DISC
	@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	May DISC
	@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	May DISC
	@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	May DISC

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+ HIKMA MAPLE	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jul CAHN
----	---------------	-------------------	---------	-----	--------------	----------

TABLET;BUCCAL, SUBLINGUAL
FENTORA

AB	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Feb CDFR
AB		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Feb CDFR
	@	EQ 0.3MG BASE	N021947	006	Mar 02, 2007	Feb CDFR
AB	+	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Feb CDFR
AB		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Feb CDFR
AB		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Feb CDFR

TABLET;SUBLINGUAL
ABSTRAL

	GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	May CAHN
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	May CAHN
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	May CAHN
+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	May CAHN
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	May CAHN
		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	May CAHN

FERRIC CARBOXYMALTOSEINJECTABLE; IV
INJECTAFER

+ LUITPOLD 750MG IRON/15ML (50MG IRON/ML) N203565 001 Jul 25, 2013 Jul NEWA

FERUMOXSISUSPENSION; ORAL
GASTROMARK

@ AMAG PHARMS INC EQ 0.175MG IRON/ML N020410 001 Dec 06, 1996 Feb DISC

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010	Apr CAHN
AB	HETERO LABS LTD III	1MG	A090060	001	Jul 01, 2013	Jun NEWA
AB		5MG	A090061	001	Jun 07, 2010	Apr CAHN
AB	SUN PHARMA GLOBAL	1MG	A090508	001	Jul 01, 2013	Jun NEWA

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

	@ APOTEX INC	50MG	A079164	001	Jul 09, 2009	Apr DISC
	@	100MG	A079164	002	Jul 09, 2009	Apr DISC
	@	150MG	A079164	003	Jul 09, 2009	Apr DISC
AB	+ ROXANE	150MG	A076278	003	Jan 14, 2003	May CRLD
	TAMBOCOR					
	@ MEDICIS	50MG	N018830	004	Aug 23, 1988	May DISC
	@	100MG	N018830	001	Oct 31, 1985	May DISC
	@	150MG	N018830	003	Jun 03, 1988	May DISC

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

	@ TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006	Mar DISC
	@	200MG/5ML	A076918	002	Dec 18, 2006	Mar DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	@ AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug CAHN
>A>	@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug CAHN
>D>	@ APOTEX INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug CAHN
	@	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr DISC
>D>	@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug CAHN
	@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr DISC

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	May CAHN
AP		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	@ AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug CAHN
>A>	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug CAHN
>D>	@ APOTEX INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug CAHN
	@	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr DISC
>D>	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug CAHN
	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP	+ FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CRLD
AP	TEVA PARENTERAL	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan CRLD
AP	TEVA PHARMS USA	50MG/VIAL	A076349	001	Aug 28, 2003	Apr CAHN
AP		50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Apr CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+	HOUSTON CYCLOTRON	20-500mCi/ML	A203665	001	Feb 14, 2013	Jun CRLD
+		20-500mCi/ML	A203665	001	Feb 14, 2013	Jan NEWA
	MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013	Jul NEWA
+	UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Jun NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr DISC
@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr DISC
@ TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Apr CAHN
@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT	PERRIGO ISRAEL	0.01%	A202847	001	Aug 09, 2013	Jul NEWA
AT		0.01%	A202848	001	Aug 09, 2013	Jul NEWA

FLUOCINONIDE

CREAM; TOPICAL

LIDEX

@ CNTY LINE PHARMS	0.05%	N016908	002		Jan CAHN
--------------------	-------	---------	-----	--	----------

LIDEX-E

@ CNTY LINE PHARMS	0.05%	N016908	003		Jan CAHN
--------------------	-------	---------	-----	--	----------

GEL; TOPICAL

FLUOCINONIDE

AB	+ TARO	0.05%	A074935	001	Jul 29, 1997	Jan CRLD
----	--------	-------	---------	-----	--------------	----------

LIDEX

@ CNTY LINE PHARMS	0.05%	N017373	001		Jan CAHN
--------------------	-------	---------	-----	--	----------

OINTMENT; TOPICAL

FLUOCINONIDE

AB	+ TARO	0.05%	A075008	001	Jun 30, 1999	Jan CRLD
----	--------	-------	---------	-----	--------------	----------

LIDEX

@ CNTY LINE PHARMS	0.05%	N016909	002		Jan CAHN
--------------------	-------	---------	-----	--	----------

SOLUTION; TOPICAL

FLUOCINONIDE

AT	ACTAVIS MID ATLANTIC	0.05%	A071535	001	Dec 02, 1988	May CAHN
----	----------------------	-------	---------	-----	--------------	----------

AT	+ TARO	0.05%	A074799	001	Dec 31, 1996	Jan CRLD
----	--------	-------	---------	-----	--------------	----------

LIDEX

@ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	May CAHN
--------------------	-------	---------	-----	--------------	----------

@ MEDICIS	0.05%	N018849	001	Apr 06, 1984	Jan DISC
-----------	-------	---------	-----	--------------	----------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	+ MYLAN LLC	1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Feb CAHN
AP	+	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Feb CAHN
AP	+ TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000	May CAHN
AP	+	5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000	May CAHN
AP	+	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@ CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002	Mar DISC	
@	EQ 20MG BASE	A076022	002	Jan 30, 2002	Mar DISC	
@ CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002	Apr DISC	
AB1	EQ 10MG BASE	A076165	001	Feb 01, 2002	Mar CAHN	
@	EQ 20MG BASE	A076165	002	Feb 01, 2002	Apr DISC	
AB1	EQ 20MG BASE	A076165	002	Feb 01, 2002	Mar CAHN	
AB1	TEVA PHARMS USA	EQ 10MG BASE	A076001	001	Jan 29, 2002	Jul CAHN
AB1	EQ 20MG BASE	A076001	002	Jan 29, 2002	Jul CAHN	
@ WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008	Feb DISC	
@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Feb DISC	
@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Feb DISC	

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

@ APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr DISC
--------------	------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	TEVA PHARMS	EQ 25MG BASE; EQ 3MG BASE	A202074	001	Mar 25, 2013	Mar NEWA
----	-------------	---------------------------	---------	-----	--------------	----------

FLUPHENAZINE DECANOATEINJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

>A>	@ AGILA SPECLTS	25MG/ML	A075918	001	Aug 17, 2001	Aug CAHN
>D>	@ APOTEX INC	25MG/ML	A075918	001	Aug 17, 2001	Aug CAHN
	@	25MG/ML	A075918	001	Aug 17, 2001	Apr DISC

FLURAZEPAM HYDROCHLORIDECAPSULE; ORAL
FLURAZEPAM HYDROCHLORIDE

@ WEST WARD	15MG	A071107	001	Dec 08, 1986	Jul DISC
@	30MG	A071108	001	Dec 08, 1986	Jul DISC

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREGO ELLIPTA

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013	May NEWA
---	---------------	-------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

CREAM; TOPICAL

>D>	CUTIVATE					
>D> AB	+	FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990
>A>	@		0.05%	N019958	001	Dec 18, 1990

LOTION; TOPICAL

		FLUTICASONE PROPIONATE				
AB		PERRIGO ISRAEL	0.05%	A091553	001	Jul 30, 2013
		POWDER; INHALATION				
		FLOVENT DISKUS 100				
	+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000
		FLOVENT DISKUS 250				
	+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000
		FLOVENT DISKUS 50				
	+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEAEROSOL, METERED; INHALATION
ADV AIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May CAHN
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May CAHN
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May CAHN

POWDER; INHALATION

		ADV AIR DISKUS 100/50				
	+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000
		ADV AIR DISKUS 250/50				
	+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000
		ADV AIR DISKUS 500/50				
	+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000

FLUVOXAMINE MALEATECAPSULE, EXTENDED RELEASE; ORAL
FLUVOXAMINE MALEATE

AB		ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013
AB		ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013
AB			150MG	A091476	002	Mar 13, 2013

LUVOX CR

AB		JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008
AB	+		150MG	N022033	002	Feb 28, 2008

TABLET; ORAL

FLUVOXAMINE MALEATE

@ CARACO	25MG	A075900	001	Feb 23, 2006	Jun DISC
@	50MG	A075900	002	Feb 23, 2006	Jun DISC
@	100MG	A075900	003	Feb 23, 2006	Jun DISC

FOLIC ACIDTABLET; ORAL
FOLIC ACID

AA		BICON PHARM	1MG	A091145	001	Jul 12, 2013
----	--	-------------	-----	---------	-----	--------------

FOSINOPRIL SODIUM

TABLET; ORAL

TABLET; ORAL

FOSINOPRIL SODIUM

@ WATSON LABS	10MG	A076987	001	Dec 23, 2004	Mar DISC
@	20MG	A076987	002	Dec 23, 2004	Mar DISC
@	40MG	A076987	003	Dec 23, 2004	Mar DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>D> AB	MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006	Aug DISC
>A>	@	10MG;12.5MG	A077705	001	Aug 14, 2006	Aug DISC
>D> AB		20MG;12.5MG	A077705	002	Aug 14, 2006	Aug DISC
>A>	@	20MG;12.5MG	A077705	002	Aug 14, 2006	Aug DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	AMNEAL PHARMS	EQ 50MG PNEYTOIN NA/ML	A078476	001	Mar 18, 2008	May CAHN
	@ APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007	Apr DISC
	@ TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ INTL MEDICATION	10MG/ML	N018025	001		Jan DISC
-------------------	---------	---------	-----	--	----------

TABLET; ORAL

FUROSEMIDE

@ DAVA PHARMS INC	20MG	N018415	001	Jul 27, 1982	Feb DISC
@	40MG	N018415	002	Jul 27, 1982	Feb DISC
@	80MG	N018415	003	Nov 26, 1984	Feb DISC

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	TARO	100MG	A077261	001	Aug 02, 2013	Jul NEWA
AB		300MG	A077261	002	Aug 02, 2013	Jul NEWA
AB		400MG	A077261	003	Aug 02, 2013	Jul NEWA

SOLUTION; ORAL

GABAPENTIN

AA	TARO	250MG/5ML	A076672	001	Jul 03, 2013	Jun NEWA
----	------	-----------	---------	-----	--------------	----------

TABLET; ORAL

GABAPENTIN

AB	ALLIED PHARMA INC	600MG	A203244	002	Jul 12, 2013	Jul NEWA
AB		800MG	A203244	001	Jul 12, 2013	Jul NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

XENOPORT INC	300MG	N022399	002	Dec 13, 2011	May CAHN
+	600MG	N022399	001	Apr 06, 2011	May CAHN

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+	GUERBET	3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Mar NEWA
+		5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Mar NEWA
+		7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Mar NEWA
+		37.69GM/100ML (376.9MG/ML)	N204781	001	Mar 20, 2013	Mar NEWA

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

BAYER HLTHCARE	2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013	Feb NEWA
----------------	------------------------------	---------	-----	--------------	----------

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

@ CHAPTER 7 TRUSTEE	25MG/ML	N019961	002	Jan 17, 1991	Jul CAHN
@ GENTA	25MG/ML	N019961	002	Jan 17, 1991	Jul DISC

GANCICLOVIR

IMPLANT; IMPLANTATION

IMPLANT;IMPLANTATION

VITRASERT

@ BAUSCH AND LOMB

4.5MG

N020569 001 Mar 04, 1996 May DISC

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR

>A> AP

PHARMAFORCE

EQ 500MG BASE/VIAL

A202624 001 Sep 18, 2013 Aug NEWA

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

>A>

+ ORGANON USA INC

EQ 250MCG BASE/0.5ML

N021057 001 Jul 29, 1999 Aug CTNA

GANIRELIX ACETATE INJECTION

>D>

+ ORGANON USA INC

EQ 250MCG BASE/0.5ML

N021057 001 Jul 29, 1999 Aug CTNA

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

@ APOTEX INC

0.3%

A079084 001 Aug 19, 2011 Apr DISC

>A> AT

LUPIN LTD

0.5%

A202653 001 Aug 28, 2013 Aug NEWA

ZYMAXID

>D>

+ ALLERGAN

0.5%

N022548 001 May 18, 2010 Aug CFTG

>A> AT

+

0.5%

N022548 001 May 18, 2010 Aug CFTG

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP

CIPLA LTD

EQ 1GM BASE/VIAL

A078759 002 Jul 25, 2011 Jul CAHN

AP

EQ 200MG BASE/VIAL

A078759 001 Jul 25, 2011 Jul CAHN

AP

DR REDDYS LABS LTD

EQ 2GM BASE/VIAL

A202997 001 May 07, 2013 Apr NEWA

AP

JIANGSU HANSON PHARM

EQ 1GM BASE/VIAL

A202485 002 May 07, 2013 Apr NEWA

AP

EQ 200MG BASE/VIAL

A202485 001 May 07, 2013 Apr NEWA

>A> AP

LUITPOLD

EQ 1GM BASE/VIAL

A202031 002 May 07, 2013 Aug CAHN

>A> AP

EQ 200MG BASE/VIAL

A202031 001 May 07, 2013 Aug CAHN

>D> AP

PHARMAFORCE

EQ 1GM BASE/VIAL

A202031 002 May 07, 2013 Aug CAHN

AP

EQ 1GM BASE/VIAL

A202031 002 May 07, 2013 Apr NEWA

>D> AP

EQ 200MG BASE/VIAL

A202031 001 May 07, 2013 Aug CAHN

AP

EQ 200MG BASE/VIAL

A202031 001 May 07, 2013 Apr NEWA

AP

SAGENT PHARMS

EQ 1GM BASE/VIAL

A091597 002 May 07, 2013 Apr NEWA

AP

EQ 200MG BASE/VIAL

A091597 001 May 07, 2013 Apr NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB

CARACO

600MG

A079239 001 Dec 29, 2008 Jun CAHN

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE

>D> AP

+ FRESENIUS KABI USA

EQ 10MG BASE/ML

A062356 001 Mar 04, 1982 Aug DISC

>A>

@

EQ 10MG BASE/ML

A062356 001 Mar 04, 1982 Aug DISC

>A> AP

EQ 10MG BASE/ML

A062366 002 Feb 06, 1986 Aug NEWA

>D> AP

+

EQ 40MG BASE/ML

A062356 002 Mar 04, 1982 Aug DISC

>A>

@

EQ 40MG BASE/ML

A062356 002 Mar 04, 1982 Aug DISC

>D> AP

EQ 40MG BASE/ML

A062366 001 Aug 04, 1983 Aug CRLD

>A> AP

+

EQ 40MG BASE/ML

A062366 001 Aug 04, 1983 Aug CRLD

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

AT

PERRIGO CO TENNESSEE

EQ 0.3% BASE

A065024 001 Jul 30, 2004 Jun CAHN

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

AT

PERRIGO CO TENNESSEE

EQ 0.3% BASE

A065121 001 Jan 30, 2004 Jun CAHN

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

@ TEVA PHARMS USA

20MG/VIAL

N020622 001 Dec 20, 1996 Apr CAHN

INJECTABLE;SUBCUTANEOUS

COPAXONE

+ TEVA PHARMS USA

20MG/ML

N020622 002 Feb 12, 2002 Apr CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

	@ COREPHARMA	1MG	A077274	001	Oct 06, 2005	Feb	DISC
	@	2MG	A077274	002	Oct 06, 2005	Feb	DISC
	@	4MG	A077274	003	Oct 06, 2005	Feb	DISC
AB	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Jul	NEWA
AB		2MG	A078952	002	Aug 01, 2013	Jul	NEWA
AB		4MG	A078952	003	Aug 01, 2013	Jul	NEWA
AB	INDOCO REMEDIES	1MG	A202112	001	Apr 17, 2013	Apr	NEWA
AB		2MG	A202112	002	Apr 17, 2013	Apr	NEWA
AB		4MG	A202112	003	Apr 17, 2013	Apr	NEWA
AB	MICRO LABS LTD INDIA	1MG	A091220	001	Jun 29, 2012	Jul	CAHN
AB		2MG	A091220	002	Jun 29, 2012	Jul	CAHN
		3MG	A091220	003	Jun 29, 2012	Jul	CAHN
AB		4MG	A091220	004	Jun 29, 2012	Jul	CAHN
		6MG	A091220	005	Jun 29, 2012	Jul	CAHN
AB		8MG	A091220	006	Jun 29, 2012	Jul	CAHN
>D> AB	MYLAN	1MG	A077486	001	Feb 10, 2006	Aug	DISC
>A>	@	1MG	A077486	001	Feb 10, 2006	Aug	DISC
>D> AB		2MG	A077486	002	Feb 10, 2006	Aug	DISC
>A>	@	2MG	A077486	002	Feb 10, 2006	Aug	DISC
>D> AB		4MG	A077486	003	Feb 10, 2006	Aug	DISC
>A>	@	4MG	A077486	003	Feb 10, 2006	Aug	DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	Apr	CAHN
AB		10MG	A074550	002	Sep 11, 1997	Apr	CAHN
	@ BARR LABS INC	5MG	A074619	001	Apr 04, 1997	May	CAHN
	@	10MG	A074619	002	Apr 04, 1997	May	CAHN

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	HYPERION THERAP INC	1.1GM/ML	N203284	001	Feb 01, 2013	Feb	NEWA
---	---------------------	----------	---------	-----	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

AP	+	HIKMA MAPLE	0.2MG/ML	N017558	001		Apr	CAHN
----	---	-------------	----------	---------	-----	--	-----	------

TABLET; ORAL

GLYCOPYRROLATE

AA	AUROLIFE PHARMA LLC	1MG	A202675	001	Apr 15, 2013	Apr	NEWA
	@ COREPHARMA	1MG	A040568	001	Dec 22, 2004	Mar	DISC
	@	2MG	A040568	002	Dec 22, 2004	Mar	DISC
	@ WEST WARD	1MG	A040836	001	Mar 05, 2009	Jul	DISC
	@	2MG	A040836	002	Mar 05, 2009	Jul	DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

	@	APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Apr	DISC
	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr	DISC
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr	DISC
	@	EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Feb	DISC
AP	+	TEVA PHARMS USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May	CAHN
AP	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	May	CAHN
AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May	CAHN
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
	@	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	May	CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Apr	CAHN
		TABLET; ORAL						
		GRISEOFULVIN						

TABLET;ORAL
GRISOFLUVIN

AB	SANDOZ	250MG	A091592	001	Aug 07, 2013	Jul NEWA
		500MG	A091592	002	Aug 07, 2013	Jul NEWA

GUANFACINE HYDROCHLORIDE

TABLET;ORAL
GUANFACINE HYDROCHLORIDE

	@ EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Jun DISC
	@	EQ 2MG BASE	A074673	002	Feb 28, 1997	Jun DISC

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

	@ FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Apr DISC
	@ G AND W LABS INC	0.05%	A077109	001	Jun 14, 2005	Jun CAHN
	@ TARO	0.05%	A076994	001	Dec 16, 2004	Mar DISC

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

>A>	@ AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Aug CAHN
>A>	@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Aug CAHN
>D>	@ APOTEX INC	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Aug CAHN
	@	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Apr DISC
>D>	@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Aug CAHN
	@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Apr DISC
AO	TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jun CAHN
AO		EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jun CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

	@ APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr DISC
	@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr DISC
AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Jun CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

>D>	AP	+	BAXTER HLTHCARE	1,000 UNITS/ML	N017037	001		Aug CAHN
>D>	AP	+		5,000 UNITS/ML	N017037	002		Aug CAHN
>D>		@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Aug CAHN
>D>	AP	+		10,000 UNITS/ML	N017037	003		Aug CAHN
>A>	AP	+	HIKMA MAPLE	1,000 UNITS/ML	N017037	001		Aug CAHN
>A>	AP	+		5,000 UNITS/ML	N017037	002		Aug CAHN
>A>		@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Aug CAHN
>A>	AP	+		10,000 UNITS/ML	N017037	003		Aug CAHN

HYALURONIDASE

INJECTABLE;INJECTION

VITRASE

	+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004	May CAHN
	@		6,200 UNITS/VIAL	N021640	001	May 05, 2004	May CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013	Mar NEWA
----	-------------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr CAHN
AA		25MG	A091679	002	Mar 04, 2013	Apr CAHN
AA		50MG	A091679	003	Mar 04, 2013	Apr CAHN
AA		100MG	A091679	004	Mar 04, 2013	Apr CAHN
AA	ACTAVIS PHARMA	10MG	A091679	001	Mar 04, 2013	Feb NEWA
AA		25MG	A091679	002	Mar 04, 2013	Feb NEWA
AA		50MG	A091679	003	Mar 04, 2013	Feb NEWA
AA		100MG	A091679	004	Mar 04, 2013	Feb NEWA
AA	ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012	Apr CTEC
AA		25MG	A200737	002	Dec 07, 2012	Apr CTEC
AA		50MG	A200737	003	Dec 07, 2012	Apr CTEC

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		100MG	A200737	004	Dec 07, 2012	Apr CTEC
AA	HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008	Apr CAHN
AA		25MG	A040901	002	Sep 12, 2008	Apr CAHN
AA		50MG	A040901	003	Sep 12, 2008	Apr CAHN
AA		100MG	A040901	004	Sep 12, 2008	Apr CAHN
AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr NEWA
AA		50MG	A200770	002	May 03, 2013	Apr NEWA
AA		100MG	A200770	003	May 03, 2013	Apr NEWA
	@ ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Jun DISC
	@	25MG	A040858	002	Feb 26, 2010	Jun DISC
	@	50MG	A040858	003	Feb 26, 2010	Jun DISC
	@	100MG	A040858	004	Feb 26, 2010	Jun DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar DISC
---	-------------	------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013	Feb NEWA
AB		12.5MG;300MG	A203630	002	Feb 22, 2013	Feb NEWA
AB	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013	Feb NEWA
AB		12.5MG;300MG	A201524	002	Feb 27, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	IPCA LABS LTD	12.5MG;50MG	A201682	001	Mar 01, 2013	Feb NEWA
AB		12.5MG;100MG	A201682	002	Mar 01, 2013	Feb NEWA
AB		25MG;100MG	A201682	003	Mar 01, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	+ WYETH PHARMS INC	25MG;40MG	N018031	001		Jul CAHN
	INDERIDE-80/25					
	@ WYETH PHARMS INC	25MG;80MG	N018031	002		Jul CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Mar NEWA
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Mar NEWA
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Mar NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE

AB	+ MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984	May CAHN
	MAXZIDE-25					
AB	MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988	May CAHN
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
	@ WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988	Jan DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A201662	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A201662	005	Mar 21, 2013	Mar NEWA
AB	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A203026	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A203026	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A203026	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A203026	005	Mar 21, 2013	Mar NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013	Mar NEWA

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		12.5MG;160MG	A202519	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A202519	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A202519	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A202519	005	Mar 21, 2013	Mar NEWA
AB	LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A078946	004	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A078946	001	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A078946	005	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A078946	002	Mar 21, 2013	Mar NEWA
AB	MACLEODS PHARMS LTD	12.5MG;80MG	A203145	001	Apr 19, 2013	Apr NEWA
AB		12.5MG;160MG	A203145	002	Apr 19, 2013	Apr NEWA
AB		12.5MG;320MG	A203145	003	Apr 19, 2013	Apr NEWA
AB		25MG;160MG	A203145	004	Apr 19, 2013	Apr NEWA
AB		25MG;320MG	A203145	005	Apr 19, 2013	Apr NEWA
AB	WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	Mar NEWA
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	Mar NEWA
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	Mar NEWA
AB		25MG;160MG	A091519	004	Mar 21, 2013	Mar NEWA
AB		25MG;320MG	A091519	005	Mar 21, 2013	Mar NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	May NEWA
AB		5MG;200MG	A091633	002	May 28, 2013	May NEWA
AB		7.5MG;200MG	A091633	003	May 28, 2013	May NEWA
AB		10MG;200MG	A091633	004	May 28, 2013	May NEWA
	REPREXAIN					
AB	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	May CFTG
AB		10MG;200MG	A076642	004	Oct 19, 2007	May CFTG

HYDROCORTISONE

LOTION;TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985 Feb DISC

OINTMENT;TOPICAL

HYDROCORTISONE

@ TARO

2.5%

A040310 001 Dec 29, 2000 Mar DISC

HYDROCORTISONE ACETATE

PASTE;TOPICAL

ORABASE HCA

@ COLGATE

0.5%

A083205 001 Mar DISC

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL

CARMOL HC

>D>

>D> AT

FOUGERA PHARMS

1%;10%

A080505 001 Aug DISC

>A>

@

1%;10%

A080505 001 Aug DISC

U-CORT

>D> AT

TARO

1%;10%

A089472 001 Jun 13, 1988 Aug CTEC

>A>

1%;10%

A089472 001 Jun 13, 1988 Aug CTEC

HYDROCORTISONE VALERATE

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

@ FOUGERA PHARMS

0.2%

A075085 001 Jul 31, 2001 Feb DISC

+

TARO

0.2%

A075043 001 Aug 25, 1998 Feb CRLD

WESTCORT

@ RANBAXY

0.2%

N018726 001 Aug 08, 1983 Feb DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EXALGO

MALLINCKRODT INC

16MG

N021217 003 Mar 01, 2010 Jan CRLD

+

32MG

N021217 004 Aug 24, 2012 Jan CRLD

HYDROXYUREA

CAPSULE;ORAL

HYDROXYUREA

CAPSULE;ORAL							
HYDROXYUREA							
	@ BARR LABS INC	250MG	A075020	002	Jun 26, 2000	Jun CAHN	
	@	500MG	A075020	001	Jul 30, 1998	Jun CAHN	
<u>HYDROXYZINE HYDROCHLORIDE</u>							
SYRUP;ORAL							
HYDROXYZINE HYDROCHLORIDE							
AA	SILARX PHARMS INC	10MG/5ML	A201674	001	Aug 21, 2013	Jul NEWA	
TABLET;ORAL							
HYDROXYZINE HYDROCHLORIDE							
AB	CARACO	10MG	A040899	001	Jun 10, 2008	Jun CAHN	
AB		25MG	A040899	002	Jun 10, 2008	Jun CAHN	
AB		50MG	A040899	003	Jun 10, 2008	Jun CAHN	
AB	HETERO LABS LTD III	10MG	A040805	001	May 29, 2008	Apr CAHN	
AB		25MG	A040805	002	May 29, 2008	Apr CAHN	
AB		50MG	A040805	003	May 29, 2008	Apr CAHN	
<u>HYDROXYZINE PAMOATE</u>							
CAPSULE;ORAL							
HYDROXYZINE PAMOATE							
AB	EMCURE PHARMS USA	25MG	A201507	001	Jun 03, 2013	May NEWA	
AB		50MG	A201507	002	Jun 03, 2013	May NEWA	
<u>IBUPROFEN</u>							
SOLUTION;INTRAVENOUS							
CALDOLOR							
	@ CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009	May DISC	
<u>IBUPROFEN LYSINE</u>							
INJECTABLE;INTRAVENOUS							
NEOPROFEN							
+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	May CAHN	
<u>ICOSAPENT ETHYL</u>							
CAPSULE;ORAL							
VASCEPA							
+	AMARIN PHARMS	1GM	N202057	001	Jul 26, 2012	Jun NEWA	
<u>IDARUBICIN HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
IDARUBICIN HYDROCHLORIDE PFS							
AP	TEVA PHARMS USA	1MG/ML	A065036	001	May 01, 2002	Apr CAHN	
<u>IFOSEFAMIDE</u>							
INJECTABLE;INJECTION							
IFOSEFAMIDE							
AP	+ TEVA PHARMS USA	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	May CAHN	
AP	+	3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	May CAHN	
<u>IFOSEFAMIDE; MESNA</u>							
INJECTABLE;INTRAVENOUS							
IFOSEFAMIDE/MESNA KIT							
+	TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002	May CAHN	
+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002	May CAHN	
<u>IMIPRAMINE HYDROCHLORIDE</u>							
TABLET;ORAL							
IMIPRAMINE HYDROCHLORIDE							
	@ PROSAM LABS	10MG	A040753	001	Feb 28, 2008	Mar DISC	
	@	25MG	A040752	001	Feb 28, 2008	Mar DISC	
	@	50MG	A040751	001	Feb 28, 2008	Mar DISC	
<u>IMIPRAMINE PAMOATE</u>							
CAPSULE;ORAL							
IMIPRAMINE PAMOATE							
AB	MYLAN PHARMS INC	EQ 75MG HCL	A202338	001	Jun 28, 2013	Jun NEWA	
AB		EQ 100MG HCL	A202338	002	Jun 28, 2013	Jun NEWA	
AB		EQ 125MG HCL	A202338	003	Jun 28, 2013	Jun NEWA	
AB		EQ 150MG HCL	A202338	004	Jun 28, 2013	Jun NEWA	

INDINAVIR SULFATECAPSULE;ORAL
CRIXIVAN

@ MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000	Jun DISC
---------------------	---------------	---------	-----	--------------	----------

INDOMETHACINCAPSULE;ORAL
INDOCIN

@ ICEUTICA OPERATIONS	25MG	N016059	001		Mar CAHN
@	50MG	N016059	002		Mar CAHN

INDOMETHACIN

AB	CARACO	25MG	A091401	001	Mar 28, 2013	Jun CAHN
AB		50MG	A091401	002	Mar 28, 2013	Jun CAHN
AB	HETERO LABS LTD III	25MG	A091240	001	Apr 12, 2011	Apr CAHN
AB		50MG	A091240	002	Apr 12, 2011	Apr CAHN
AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Mar NEWA
AB		50MG	A091401	002	Mar 28, 2013	Mar NEWA

INDOMETHACIN SODIUMINJECTABLE;INJECTION
INDOCIN

AP	+ RECORDATI RARE	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	May CAHN
----	------------------	------------------	---------	-----	--------------	----------

INSULIN GLARGINE RECOMBINANT

INJECTABLE;INJECTION

>A>	LANTUS SOLOSTAR					
>A>	+ SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081	002	Apr 27, 2007	Aug NEWA

IPRATROPIUM BROMIDESOLUTION;INHALATION
IPRATROPIUM BROMIDE

@ APOTEX INC	0.02%	A075441	001	Mar 28, 2001	Apr DISC
@ TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000	Mar DISC

SPRAY, METERED;NASAL
IPRATROPIUM BROMIDE

@ APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Apr DISC
@	0.042MG/SPRAY	A076155	001	Apr 18, 2003	Apr DISC

IRON SUCROSEINJECTABLE;INTRAVENOUS
VENOFER

LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Mar NEWA
----------	---------------------------------------	---------	-----	--------------	----------

ISONIAZIDTABLET;ORAL
ISONIAZID

>D> AA	MIKART	100MG	A040090	001	Jun 26, 1997	Aug DISC
>A>	@	100MG	A040090	001	Jun 26, 1997	Aug DISC
>D> AA		300MG	A040090	002	Jun 26, 1997	Aug DISC
>A>	@	300MG	A040090	002	Jun 26, 1997	Aug DISC
	@ WATSON LABS	300MG	A080521	001		Jun DISC

ISONIAZID; RIFAMPINCAPSULE;ORAL
RIFAMATE

+ SANOFI AVENTIS US	150MG;300MG	A061884	001		Apr CTEC
RIFAMPIN AND ISONIAZID					
@ WEST WARD PHARM CORP	150MG;300MG	A065221	001	Jul 29, 2005	Apr DISC

ISOPROTERENOL HYDROCHLORIDEINJECTABLE;INJECTION
ISOPROTERENOL HYDROCHLORIDE

@ INTL MEDICATION	0.2MG/ML	A083724	001		Mar DISC
-------------------	----------	---------	-----	--	----------

ISUPREL

+ HOSPIRA	0.2MG/ML	N010515	001		Mar CTEC
-----------	----------	---------	-----	--	----------

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE;ORAL
DILATRATE-SR

+ ACTIENT PHARMS	40MG	N019790	001	Sep 02, 1988	May CAHN
------------------	------	---------	-----	--------------	----------

TABLET; ORAL

ISORDIL

AB		VALEANT BERMUDA	5MG	N012093	007	Jul 29, 1988	Apr CAHN
AB			10MG	N012093	002	Jul 29, 1988	Apr CAHN
AB			20MG	N012093	006	Jul 29, 1988	Apr CAHN
AB	+		30MG	N012093	005	Jul 29, 1988	Apr CAHN
	+		40MG	N012093	001	Jul 29, 1988	Apr CAHN
AB		VALEANT PHARM NORTH	5MG	N012093	007	Jul 29, 1988	Mar CAHN
AB			10MG	N012093	002	Jul 29, 1988	Mar CAHN
AB			20MG	N012093	006	Jul 29, 1988	Mar CAHN
AB	+		30MG	N012093	005	Jul 29, 1988	Mar CAHN
	+		40MG	N012093	001	Jul 29, 1988	Mar CAHN

ISOSORBIDE DINITRATE

AB		PAR PHARM	5MG	A086923	001	Mar 12, 1987	Apr CMFD
	@		5MG	A086923	001	Mar 12, 1987	Feb DISC
	@	WATSON LABS	5MG	A086034	001	Jan 06, 1988	Apr DISC
	@		10MG	A086032	001	Jan 07, 1988	Apr DISC

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

		@	WATSON LABS	2.5MG	A086033	001	Feb 26, 1988	Jun	DISC
		@		5MG	A086031	001	Sep 29, 1987	Jun	DISC
>D>	AB		WEST WARD	2.5MG	A086054	001	Oct 29, 1987	Aug	DISC
>A>		@		2.5MG	A086054	001	Oct 29, 1987	Aug	DISC
>D>	AB	+	WEST WARD PHARM CORP	5MG	A086055	001	Nov 02, 1987	Aug	DISC
>A>		@		5MG	A086055	001	Nov 02, 1987	Aug	DISC
	AB	+		5MG	A086055	001	Nov 02, 1987	Jun	CRLD

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

BX		RANBAXY	10MG	N021951	001	May 25, 2012	Feb CAHN
BX			20MG	N021951	002	May 25, 2012	Feb CAHN
BX			30MG	N021951	003	May 25, 2012	Feb CAHN
>D>	BX		40MG	N021951	004	May 25, 2012	Aug CRLD
>A>	BX	+	40MG	N021951	004	May 25, 2012	Aug CRLD
	BX		40MG	N021951	004	May 25, 2012	Feb CAHN

AMNESTEEM

AB		MYLAN PHARMS INC	20MG	A075945	002	Nov 08, 2002	Apr CRLD
		CLARAVIS					
AB		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	May CAHN
AB			30MG	A076135	003	May 11, 2006	Apr CRLD
AB	+		40MG	A076135	001	Apr 11, 2003	Apr CRLD

ZENATANE

AB		DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar NEWA
AB			20MG	A202099	002	Mar 25, 2013	Mar NEWA
AB			40MG	A202099	003	Mar 25, 2013	Mar NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

		@ GLAXOSMITHKLINE LLC	5MG	N020336	001	Jun 01, 1994	Jun DISC
		@	10MG	N020336	002	Jun 01, 1994	Jun DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

		@ APOTEX INC	15MG/ML	A075631	002	Jun 29, 2001	Apr DISC
		@	30MG/ML	A075626	001	Jul 24, 2001	Apr DISC
		@	30MG/ML	A075631	001	Jun 29, 2001	Apr DISC
		@	30MG/ML	A077201	001	Oct 14, 2005	Apr DISC
		@ LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008	Jun DISC
		@	30MG/ML	A078145	002	Jan 14, 2008	Jun DISC

SOLUTION/DROPS; OPHTHALMIC

ACULAR PRESERVATIVE FREE

		@ ALLERGAN	0.5%	N020811	001	Nov 03, 1997	May DISC
--	--	------------	------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP		AKORN INC	5MG/ML	A075431	001	Nov 29, 1999	Jul CAHN
AP			5MG/ML	A075524	001	Nov 29, 1999	Jul CAHN
		@ APOTEX INC	5MG/ML	A076051	001	Jul 05, 2002	Apr DISC

TABLET;ORAL

LABETALOL HYDROCHLORIDE						
AB	+	SANDOZ	200MG	A075113	002	Aug 04, 1998 Jan CRLD
TRANDATE						
	@	PROMETHEUS LABS	100MG	N018716	001	May 24, 1985 Jan DISC
	@		200MG	N018716	002	Aug 01, 1984 Jan DISC

LACTULOSE

SOLUTION;ORAL

LACTULOSE						
	@	APOTEX INC	10GM/15ML	A075911	001	Feb 21, 2002 Apr DISC
SOLUTION;ORAL, RECTAL						
LACTULOSE						
	@	APOTEX INC	10GM/15ML	A076645	001	Jul 28, 2003 Apr DISC

LAMOTRIGINE

TABLET;ORAL

LAMICTAL						
AB	+	GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994 Mar CAHN
	@		50MG	N020241	006	Dec 27, 1994 Mar CAHN
AB			100MG	N020241	001	Dec 27, 1994 Mar CAHN
AB			150MG	N020241	002	Dec 27, 1994 Mar CAHN
AB			200MG	N020241	003	Dec 27, 1994 Mar CAHN
	@		250MG	N020241	004	Dec 27, 1994 Mar CAHN
LAMOTRIGINE						
AB		ALKEM LABS LTD	25MG	A200694	001	Jun 14, 2013 Jun NEWA
AB			100MG	A200694	002	Jun 14, 2013 Jun NEWA
AB			150MG	A200694	003	Jun 14, 2013 Jun NEWA
AB			200MG	A200694	004	Jun 14, 2013 Jun NEWA
>A>	AB	CIPLA LTD	25MG	A077783	001	Nov 01, 2010 Aug CAHN
>A>	AB		100MG	A077783	002	Nov 01, 2010 Aug CAHN
>A>	AB		150MG	A077783	003	Nov 01, 2010 Aug CAHN
>A>	AB		200MG	A077783	004	Nov 01, 2010 Aug CAHN
>D>	AB	WATSON LABS	25MG	A077783	001	Nov 01, 2010 Aug CAHN
>D>	AB		100MG	A077783	002	Nov 01, 2010 Aug CAHN
>D>	AB		150MG	A077783	003	Nov 01, 2010 Aug CAHN
>D>	AB		200MG	A077783	004	Nov 01, 2010 Aug CAHN

TABLET, CHEWABLE;ORAL

LAMICTAL CD						
AB		GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000 Mar CAHN
AB			5MG	N020764	001	Aug 24, 1998 Mar CAHN
AB	+		25MG	N020764	002	Aug 24, 1998 Mar CAHN
	@		100MG	N020764	003	Aug 24, 1998 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR						
AB		GLAXOSMITHKLINE LLC	25MG	N022115	001	May 29, 2009 Mar CAHN
AB	+		50MG	N022115	002	May 29, 2009 Mar CAHN
AB			100MG	N022115	003	May 29, 2009 Mar CAHN
AB			200MG	N022115	004	May 29, 2009 Mar CAHN
AB			250MG	N022115	006	Jun 21, 2011 Mar CAHN
AB			300MG	N022115	005	Apr 14, 2010 Mar CAHN
LAMOTRIGINE						
AB		DR REDDYS LABS LTD	25MG	A202383	001	Jun 19, 2013 Jun NEWA
AB			50MG	A202383	002	Jun 19, 2013 Jun NEWA
AB			100MG	A202383	003	Jun 19, 2013 Jun NEWA
AB			200MG	A202383	004	Jun 19, 2013 Jun NEWA
AB			300MG	A202383	005	Jun 19, 2013 Jun NEWA
AB		PAR PHARM	25MG	A201791	001	Jan 18, 2013 Jan NEWA
AB			50MG	A201791	002	Jan 18, 2013 Jan NEWA
AB			100MG	A201791	003	Jan 18, 2013 Jan NEWA
AB			200MG	A201791	004	Jan 18, 2013 Jan NEWA
AB			250MG	A201791	005	Jan 18, 2013 Jan NEWA
AB			300MG	A201791	006	Jan 18, 2013 Jan NEWA
AB		WILSHIRE PHARMS INC	25MG	A202887	001	Jun 17, 2013 Jun NEWA
AB			50MG	A202887	002	Jun 17, 2013 Jun NEWA
AB			100MG	A202887	003	Jun 17, 2013 Jun NEWA
AB			200MG	A202887	004	Jun 17, 2013 Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT						
AB		GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08, 2009 Jul CFTG
			25MG	N022251	001	May 08, 2009 Mar CAHN
AB	+		50MG	N022251	002	May 08, 2009 Jul CFTG

TABLET, ORALLY DISINTEGRATING;ORAL
LAMICTAL ODT

	+	50MG	N022251	002	May 08, 2009	Mar CAHN
AB		100MG	N022251	003	May 08, 2009	Jul CFTG
		100MG	N022251	003	May 08, 2009	Mar CAHN
AB		200MG	N022251	004	May 08, 2009	Jul CFTG
		200MG	N022251	004	May 08, 2009	Mar CAHN
LAMOTRIGINE						
AB	WATSON LABS INC	25MG	A200828	001	Jul 15, 2013	Jul NEWA
AB		50MG	A200828	002	Jul 15, 2013	Jul NEWA
AB		100MG	A200828	003	Jul 15, 2013	Jul NEWA
AB		200MG	A200828	004	Jul 15, 2013	Jul NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

>A>	AB	SUN PHARMA GLOBAL	15MG	A202637	001	Sep 13, 2013	Aug NEWA
>A>	AB		30MG	A091509	001	Sep 13, 2013	Aug NEWA
	AB	ZYDUS HLTHCARE	15MG	A202366	001	Aug 19, 2013	Jul NEWA
	AB		30MG	A202366	002	Aug 19, 2013	Jul NEWA
LANSOPRAZOLE							
>A>	AB	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Aug NEWA
>A>	AB		30MG	A091212	002	Sep 16, 2013	Aug NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

	@	APOTEX INC	0.005%	A077697	001	Mar 22, 2011	Apr DISC
AT		DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11, 2013	Jan NEWA

LENALIDOMIDE

CAPSULE;ORAL
REVLIMID

	CELGENE	20MG	N021880	006	Jun 05, 2013	Jun NEWA
--	---------	------	---------	-----	--------------	----------

LEPIRUDIN RECOMBINANT

INJECTABLE;INJECTION
REFLUDAN

	@	BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998	Jun DISC
--	---	----------------	-----------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL
LETROZOLE

AB		JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	Apr NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993	Mar CAHN
AP		EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997	Mar CAHN
	LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	@ LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001	Jun DISC

LEUPROLIDE ACETATE

INJECTABLE;INJECTION
LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471	001	Oct 25, 2000	Mar CAHN
	LUPRON					
	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul CAHN
	LUPRON DEPOT					
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr CAHN
+		7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul CAHN
+		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul CAHN
+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jul CAHN
		45MG/VIAL	N020517	003	Jun 17, 2011	Jul CAHN
	LUPRON DEPOT-PED					
	@ ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	Jul CAHN
	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	Jul CAHN
+		7.5MG/VIAL	N020263	002	Apr 16, 1993	Jul CAHN
+		11.25MG/VIAL	N020263	005	Jan 21, 1994	Jul CAHN
+		11.25MG/VIAL	N020263	007	Aug 15, 2011	Jul CAHN

INJECTABLE; INJECTION
LUPRON DEPOT-PED

+	15MG/VIAL	N020263	006	Jan 21, 1994	Jul CAHN
+	30MG/VIAL	N020263	008	Aug 15, 2011	Jul CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar NEWA
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar NEWA
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar NEWA
AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr NEWA
AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr NEWA
AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun NEWA
----	---------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

	@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr DISC
AA	HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Feb NEWA
AA	HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr CAHN
AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr NEWA

TABLET; ORAL

LEVETIRACETAM

AB	HETERO LABS LTD III	1GM	A090515	004	Oct 08, 2010	Apr CAHN
AB		250MG	A090515	001	Oct 08, 2010	Apr CAHN
AB		500MG	A090515	002	Oct 08, 2010	Apr CAHN
AB		750MG	A090515	003	Oct 08, 2010	Apr CAHN
AB	PRINSTON INC	1GM	A078106	004	Feb 10, 2009	Apr CAHN
AB		250MG	A078106	001	Feb 10, 2009	Apr CAHN
AB		500MG	A078106	002	Feb 10, 2009	Apr CAHN
AB		750MG	A078106	003	Feb 10, 2009	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar DISC
	@	750MG	A091668	002	Nov 01, 2012	Mar DISC
>A> AB	SUN PHARMA GLOBAL	500MG	A203059	001	Sep 09, 2013	Aug NEWA
>A> AB		750MG	A203059	002	Sep 09, 2013	Aug NEWA
AB	VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan NEWA
AB		750MG	A202533	002	Jul 20, 2012	Jan NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr DISC
	@	0.5%	A075475	001	Aug 03, 2000	Apr DISC

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May CAHN
----	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA	TARO PHARM INDS	2.5MG/5ML	A202673	001	Jul 26, 2013	Jul NEWA
----	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A> AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Aug NEWA
AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan NEWA
AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	May NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan NEWA

INJECTABLE; INJECTION							
LEVOFLOXACIN							
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan	NEWA
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	CLARIS LIFESCIENCES	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Jul	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Jul	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Jul	NEWA
AP	FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013	Jun	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013	Jun	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013	Jun	NEWA
SOLUTION/DROPS; OPHTHALMIC							
LEVOFLOXACIN							
	@ APOTEX INC	0.5%	A078282	001	Dec 20, 2010	Apr	DISC
<u>LEVOMILNACIPRAN HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
FETZIMA							
	FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jul	NEWA
		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jul	NEWA
		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jul	NEWA
+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jul	NEWA
<u>LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN							
	@ NOVOCOL	0.05MG/ML; 2%	A084697	001		Jun	DISC
	SCANDONEST L						
+	DEPROCO	0.05MG/ML; 2%	A088388	001	Oct 10, 1984	Jun	CRLD
<u>LEVONORGESTREL</u>							
INTRAUTERINE DEVICE; INTRAUTERINE							
SKYLA							
+	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jan	NEWA
TABLET; ORAL							
LEVONORGESTREL							
AB	LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Jan	NEWA
AB	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013	Feb	NEWA
<u>LEVOTHYROXINE SODIUM **</u>							
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium							
TABLET; ORAL							
LEVOTHYROXINE SODIUM							
	@ MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005	Jul	DISC
	@	0.05MG	A076752	002	Jun 16, 2005	Jul	DISC
	@	0.075MG	A076752	003	Jun 16, 2005	Jul	DISC
	@	0.088MG	A076752	004	Jun 16, 2005	Jul	DISC
	@	0.1MG	A076752	005	Jun 16, 2005	Jul	DISC
	@	0.112MG	A076752	006	Jun 16, 2005	Jul	DISC
	@	0.125MG	A076752	007	Jun 16, 2005	Jul	DISC
	@	0.15MG	A076752	008	Jun 16, 2005	Jul	DISC
	@	0.175MG	A076752	009	Jun 16, 2005	Jul	DISC
	@	0.2MG	A076752	010	Jun 16, 2005	Jul	DISC
	@	0.3MG	A076752	011	Jun 16, 2005	Jul	DISC
LEVOXYL							
AB1,	KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.05MG	N021301	002	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.075MG	N021301	003	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.088MG	N021301	004	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.1MG	N021301	005	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.112MG	N021301	006	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.125MG	N021301	007	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.137MG	N021301	008	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.15MG	N021301	009	May 25, 2001	Mar	CAHN
AB3							
AB1,		0.175MG	N021301	010	May 25, 2001	Mar	CAHN
AB3							

TABLET; ORAL							
LEVOXYL							
AB1, +		0.2MG	N021301	011	May 25, 2001	Mar	CAHN
AB3							
@		0.3MG	N021301	012	May 25, 2001	Mar	CAHN
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
LIDOCAINE HYDROCHLORIDE							
@	LUITPOLD	2%	A083198	001		Mar	DISC
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	AUROBINDO PHARMA LTD	1%	A203040	001	Mar 14, 2013	Mar	NEWA
AP		1%	A203082	001	Mar 14, 2013	Mar	NEWA
AP		2%	A203040	002	Mar 14, 2013	Mar	NEWA
AP		2%	A203082	002	Mar 14, 2013	Mar	NEWA
JELLY; TOPICAL							
ANESTACON							
@	POLYMEDICA	2%	A080429	001		May	DISC
LIDOCAINE HYDROCHLORIDE							
@	TEVA PHARMS USA	2%	A081318	001	Apr 29, 1993	Jun	DISC
<u>LIDOCAINE; TETRACAINE</u>							
PATCH; TOPICAL							
SYNERA							
>A>	+ GALEN SPECIALTY	70MG; 70MG	N021623	001	Jun 23, 2005	Aug	CAHN
>D>	+ ZARS PHARM	70MG; 70MG	N021623	001	Jun 23, 2005	Aug	CAHN
<u>LIOTHYRONINE SODIUM</u>							
TABLET; ORAL							
CYTOMEL							
AB	KING PHARMS R AND D	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB		EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+	EQ 0.05MG BASE	N010379	003		Mar	CAHN
<u>LISINAPRIL</u>							
TABLET; ORAL							
LISINAPRIL							
AB	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	Jul	NEWA
AB		5MG	A202554	002	Jul 30, 2013	Jul	NEWA
AB		10MG	A202554	003	Jul 30, 2013	Jul	NEWA
AB		20MG	A202554	004	Jul 30, 2013	Jul	NEWA
AB		30MG	A202554	005	Jul 30, 2013	Jul	NEWA
AB		40MG	A202554	006	Jul 30, 2013	Jul	NEWA
>D> AB	SANDOZ	2.5MG	A075903	001	Jul 01, 2002	Aug	DISC
>A>	@	2.5MG	A075903	001	Jul 01, 2002	Aug	DISC
	@	2.5MG	A075999	001	Jul 01, 2002	Jan	CAHN
>D> AB		5MG	A075903	002	Jul 01, 2002	Aug	DISC
>A>	@	5MG	A075903	002	Jul 01, 2002	Aug	DISC
	@	5MG	A075999	002	Jul 01, 2002	Jan	CAHN
>D> AB		10MG	A075903	003	Jul 01, 2002	Aug	DISC
>A>	@	10MG	A075903	003	Jul 01, 2002	Aug	DISC
	@	10MG	A075999	003	Jul 01, 2002	Jan	CAHN
>D> AB		20MG	A075903	004	Jul 01, 2002	Aug	DISC
>A>	@	20MG	A075903	004	Jul 01, 2002	Aug	DISC
	@	20MG	A075999	004	Jul 01, 2002	Jan	CAHN
>D> AB		30MG	A075903	005	Jul 01, 2002	Aug	DISC
>A>	@	30MG	A075903	005	Jul 01, 2002	Aug	DISC
	@	30MG	A075999	005	Jul 01, 2002	Jan	CAHN
>D> AB		40MG	A075903	006	Jul 01, 2002	Aug	DISC
>A>	@	40MG	A075903	006	Jul 01, 2002	Aug	DISC
	@	40MG	A075999	006	Jul 01, 2002	Jan	CAHN
<u>LITHIUM CARBONATE</u>							
CAPSULE; ORAL							
LITHIUM CARBONATE							
@	APOTEX INC	300MG	A076795	001	Nov 22, 2004	Feb	DISC
AB	HETERO LABS LTD III	150MG	A090702	001	Sep 25, 2009	Apr	CAHN
AB		300MG	A090702	002	Sep 25, 2009	Apr	CAHN
AB		600MG	A090702	003	Sep 25, 2009	Apr	CAHN
TABLET; ORAL							
LITHIUM CARBONATE							
>D> AB	WEST WARD	300MG	A078715	001	Dec 28, 2010	Aug	DISC

TABLET; ORAL							
LITHIUM CARBONATE							
>A>	@	300MG	A078715	001	Dec 28, 2010	Aug	DISC
<u>LOMUSTINE</u>							
CAPSULE; ORAL							
CEENU							
	CORDEN PHARMA	10MG	N017588	001		Apr	CAHN
		40MG	N017588	002		Apr	CAHN
	+	100MG	N017588	003		Apr	CAHN
<u>LORAZEPAM</u>							
CONCENTRATE; ORAL							
LORAZEPAM							
AA	LUPIN LTD	2MG/ML	A091407	001	Feb 19, 2013	Feb	NEWA
INJECTABLE; INJECTION							
LORAZEPAM							
AP	AKORN	2MG/ML	A075025	001	Jul 23, 1998	Jul	CAHN
TABLET; ORAL							
LORAZEPAM							
	@ SANDOZ	0.5MG	A071193	001	Apr 15, 1988	Apr	DISC
	@	1MG	A071194	001	Apr 15, 1988	Apr	DISC
	@	2MG	A071195	001	Apr 15, 1988	Apr	DISC
<u>LOSARTAN POTASSIUM</u>							
TABLET; ORAL							
LOSARTAN POTASSIUM							
AB	ACTAVIS GRP PTC	25MG	A090382	001	Oct 06, 2010	Mar	CAHN
AB		50MG	A090382	002	Oct 06, 2010	Mar	CAHN
AB		100MG	A090382	003	Oct 06, 2010	Mar	CAHN
>A> AB	IPCA LABS LTD	25MG	A200290	001	Aug 30, 2013	Aug	NEWA
>A> AB		50MG	A200290	002	Aug 30, 2013	Aug	NEWA
>A> AB		100MG	A200290	003	Aug 30, 2013	Aug	NEWA
<u>LOVASTATIN</u>							
TABLET; ORAL							
LOVASTATIN							
AB	+ CARLSBAD	40MG	A075991	003	Jun 05, 2002	Feb	CRLD
	MEVACOR						
	@ MERCK	20MG	N019643	003	Aug 31, 1987	Feb	DISC
	@	40MG	N019643	004	Dec 14, 1988	Feb	DISC
<u>LOXAPINE</u>							
POWDER; INHALATION							
ADASUVE							
	+ TEVA PHARMS USA INC	10MG	N022549	001	Dec 21, 2012	Jul	CAHN
<u>LOXAPINE SUCCINATE</u>							
CAPSULE; ORAL							
LOXAPINE SUCCINATE							
AB	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May	CMFD
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May	CMFD
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May	CMFD
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May	CMFD
<u>LURASIDONE HYDROCHLORIDE</u>							
TABLET; ORAL							
LATUDA							
	SUNOVION PHARMS INC	60MG	N200603	005	Jul 12, 2013	Jul	NEWA
<u>MAFENIDE ACETATE</u>							
CREAM; TOPICAL							
SULFAMYLOX							
	+ MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001		May	CAHN
FOR SOLUTION; TOPICAL							
MAFENIDE ACETATE							
AB	PAR FORM	5%	A201511	001	Feb 12, 2013	Jan	NEWA
SULFAMYLOX							
AB	+ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	May	CAHN
AB	+ MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jan	CFTG

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATESOLUTION; ORAL
SUCLEAR

+	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Jan NEWA
---	----------------	--	---------	-----	--------------	----------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 20%

@ B BRAUN	20GM/100ML	N014738	001		Jan DISC
-----------	------------	---------	-----	--	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	Mar NEWA
---------------	-------	---------	-----	--------------	----------

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

>A>							
>A>							
>A>	+	CEPTARIS THERAP	0.02%	N202317	001	Aug 23, 2013	Aug NEWA

INJECTABLE; INJECTION

MUSTARGEN

+	RECORDATI RARE	10MG/VIAL	N006695	001		May CAHN
---	----------------	-----------	---------	-----	--	----------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

	@ TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004	May CAHN
AB		150MG/ML	A076553	001	Jul 28, 2004	May CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	CYPRESS PHARM	250MG	A090359	001	Feb 05, 2013	Jan NEWA
----	---------------	-------	---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

@ WEST WARD PHARM CORP	250MG	A077699	001	Apr 21, 2010	Jun DISC
------------------------	-------	---------	-----	--------------	----------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

@ APOTEX INC	40MG/ML	A077404	001	Feb 16, 2006	Apr DISC
--------------	---------	---------	-----	--------------	----------

MELOXICAM

TABLET; ORAL

MELOXICAM

>A>	AB	CIPLA LTD	7.5MG	A077929	001	Jul 19, 2006	Aug CAHN
>A>	AB		15MG	A077929	002	Jul 19, 2006	Aug CAHN
		@ COREPHARMA	7.5MG	A077930	001	Jul 19, 2006	Feb DISC
		@	15MG	A077930	002	Jul 19, 2006	Feb DISC
		@ CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006	Apr DISC
	AB		7.5MG	A078039	001	Dec 14, 2006	Mar CAHN
		@	15MG	A078039	002	Dec 14, 2006	Apr DISC
	AB		15MG	A078039	002	Dec 14, 2006	Mar CAHN
>D>	AB	MYLAN	7.5MG	A077934	001	Jul 20, 2006	Aug DISC
>A>		@	7.5MG	A077934	001	Jul 20, 2006	Aug DISC
>D>	AB		15MG	A077934	002	Jul 20, 2006	Aug DISC
>A>		@	15MG	A077934	002	Jul 20, 2006	Aug DISC
>D>	AB	WATSON LABS	7.5MG	A077929	001	Jul 19, 2006	Aug CAHN
>D>	AB		15MG	A077929	002	Jul 19, 2006	Aug CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ TARO	200MG	A200998	001	May 23, 2011	Jan DISC
@	400MG	A200998	002	May 23, 2011	Jan DISC

MESALAMINECAPSULE, DELAYED RELEASE;ORAL
DELZICOL+ WARNER CHILCOTT LLC 400MG
SUPPOSITORY;RECTAL

N204412 001 Feb 01, 2013 Feb NEWA

CANASA

+ APTALIS PHARMA US 1GM

N021252 002 Nov 05, 2004 Feb CRLD

MESNAINJECTABLE;INTRAVENOUS
MESNA

AP TEVA PHARMS USA 100MG/ML

A075764 001 Apr 27, 2001 May CAHN

METAPROTERENOL SULFATESOLUTION;INHALATION
METAPROTERENOL SULFATE

@ APOTEX INC 0.4%

A075402 001 Feb 28, 2001 Apr DISC

@ 0.6%

A075403 001 Feb 28, 2001 Apr DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

@ APOTEX INC 10MG/5ML

A075235 001 Jan 27, 2000 Apr DISC

@ NOVEX 10MG/5ML

A075235 001 Jan 27, 2000 Feb DISC

+ SILARX 10MG/5ML

A073632 001 Jul 22, 1992 Feb CTEC

TABLET;ORAL

METAPROTERENOL SULFATE

PAR PHARM 10MG

A072024 001 Jun 28, 1988 Mar CTEC

+ 20MG

A072025 001 Jun 28, 1988 Mar CTEC

@ WATSON LABS 10MG

A073013 001 Jan 31, 1991 Mar DISC

@ 20MG

A072795 001 Jan 31, 1991 Mar DISC

METAXALONE

TABLET;ORAL

METAXALONE

AB AMNEAL PHARMS 800MG

A203399 001 Jun 21, 2013 Jun NEWA

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>A> AB CHARTWELL LIFE SCI 1GM

A075972 003 Jan 24, 2002 Aug CAHN

>A> AB 500MG

A075972 001 Jan 24, 2002 Aug CAHN

>A> 625MG

A075972 005 Jan 24, 2002 Aug CAHN

>A> 750MG

A075972 004 Jan 24, 2002 Aug CAHN

>A> AB 850MG

A075972 002 Jan 24, 2002 Aug CAHN

>D> AB IVAX SUB TEVA PHARMS 1GM

A075972 003 Jan 24, 2002 Aug CAHN

>D> AB 500MG

A075972 001 Jan 24, 2002 Aug CAHN

>D> 625MG

A075972 005 Jan 24, 2002 Aug CAHN

>D> 750MG

A075972 004 Jan 24, 2002 Aug CAHN

>D> AB 850MG

A075972 002 Jan 24, 2002 Aug CAHN

AB SANDOZ 1GM

A075965 003 Jan 25, 2002 May CMFD

@ 1GM

A075965 003 Jan 25, 2002 Mar DISC

AB 500MG

A075965 001 Jan 25, 2002 May CMFD

@ 500MG

A075965 001 Jan 25, 2002 Mar DISC

AB 850MG

A075965 002 Jan 25, 2002 May CMFD

@ 850MG

A075965 002 Jan 25, 2002 Mar DISC

>A> AB SCIEGEN PHARMS INC 500MG

A203769 001 Sep 11, 2013 Aug NEWA

>A> AB 850MG

A203769 002 Sep 11, 2013 Aug NEWA

>A> AB 1GM

A203769 003 Sep 11, 2013 Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

FORTAMET

AB2 + ANDRX LABS LLC 1GM

N021574 002 Apr 27, 2004 Jul CTEC

GLUMETZA

AB3 + SANTARUS 1GM

N021748 002 Jun 03, 2005 Jul CTEC

AB3 500MG

N021748 001 Jun 03, 2005 Jul CTEC

METFORMIN HYDROCHLORIDE

AB2 LUPIN LTD 1GM

A090692 002 Jun 29, 2011 Jul CTEC

AB3 1GM

A091664 002 Jul 19, 2013 Jul NEWA

AB3 500MG

A091664 001 Jul 19, 2013 Jul NEWA

AB2 MYLAN PHARMS INC 1GM

A200690 002 Aug 01, 2012 Jul CTEC

@ TORRENT PHARMS LTD 750MG

A079226 001 Feb 18, 2010 Jun DISC

@ WATSON LABS INC 500MG

A076818 001 Dec 14, 2004 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823	001	Feb 13, 2013	Jan NEWA
AB		850MG;EQ 15MG BASE	A200823	002	Feb 13, 2013	Jan NEWA
AB	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Apr NEWA
AB		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Apr NEWA
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan NEWA
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan NEWA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	MALLINCKRODT INC	40MG	A077142	001	Jul 12, 2005	Mar CDFR
AA	+ ROXANE	40MG	N017058	001		Mar CDFR
AA	SANDOZ	40MG	A075082	001	Mar 25, 1998	Mar CDFR
METHADOSE						
AA	MALLINCKRODT	40MG	A074184	001	Apr 29, 1993	Mar CDFR

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AA	+ RECORDATI RARE	5MG	N005378	002		May CAHN
----	------------------	-----	---------	-----	--	----------

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

@ WATSON LABS 100MG/ML
ROBAXIN

A086459 001 Jul DISC

+ BAXTER HLTHCARE CORP 100MG/ML

N011790 001 Jul CTEC

TABLET; ORAL

METHOCARBAMOL

AA	AUSTARPHARMA LLC	500MG	A200958	001	Oct 21, 2011	May CMFD
	@	500MG	A200958	001	Oct 21, 2011	Jan DISC
AA		750MG	A200958	002	Oct 21, 2011	May CMFD
AA	HETERO LABS LTD III	500MG	A090200	001	Nov 06, 2009	Apr CAHN
AA		750MG	A090200	002	Nov 06, 2009	Apr CAHN
AA	PRINSTON INC	500MG	A086989	001		Feb CMFD
AA		750MG	A086988	001		Feb CAHN
	@ SOLCO HLTHCARE	500MG	A086989	001		Jan DISC

METHOXSALEN

CAPSULE; ORAL

OXSORALEN-ULTRA

+ DOW PHARM 10MG

N019600 001 Oct 30, 1986 Apr CAHN

METHYLOTHIAZIDE

TABLET; ORAL

METHYLOTHIAZIDE

+ MYLAN PHARMS INC 5MG
@ WATSON LABS 5MG

A087672 001 Aug 17, 1982 Jan CTEC
A088724 001 Sep 06, 1984 Jan DISC

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

@ GALDERMA LABS LP EQ 16.8% BASE

N021415 001 Jul 27, 2004 Jun DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@ ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985	Apr CAHN
AB		250MG	A070084	001	Oct 15, 1985	Apr CAHN
AB		500MG	A070085	001	Oct 15, 1985	Apr CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1	WATSON LABS INC	20MG	A078458	001	Dec 01, 2011	Apr CAHN
AB1		30MG	A078458	002	Dec 01, 2011	Apr CAHN
AB1		40MG	A078458	003	Dec 01, 2011	Apr CAHN

TABLET; ORAL

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	AKORN INC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jul CAHN
	@ APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr DISC
	@ CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan DISC
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan DISC
	@ INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005	Jun DISC
	@	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005	Jun DISC
	@ INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May DISC
	@	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

	@ APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr DISC
--	--------------	----------------	---------	-----	--------------	----------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@ APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr DISC
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	@ APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr NEWA
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr NEWA
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr NEWA

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

	@ RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	May DISC
	@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May DISC
	@	EQ 90MG BASE	N201922	003	Jul 11, 2012	May DISC
	@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May DISC
	@	EQ 135MG BASE	N201922	005	Jul 11, 2012	May DISC

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

	@ MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006	Apr DISC
+		EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr CRLD
+		EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr CRLD
	@	EQ 135MG BASE	N050808	003	May 08, 2006	Apr DISC

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jan NEWA
---	--------------	---------------------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jun DISC
	@	30MG	A077959	002	Feb 14, 2011	Jun DISC
	@	45MG	A077959	003	Feb 14, 2011	Jun DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar CAIN
AP	TEVA PHARMS USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356	001	Apr 11, 2006	May CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356	002	Apr 11, 2006	May CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356	003	Apr 11, 2006	May CAHN

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Apr NEWA
----	-------------------	------	---------	-----	--------------	----------

OINTMENT; TOPICAL

MOMETASONE FUROATE

OINTMENT; TOPICAL							
MOMETASONE FUROATE							
@ TARO	0.1%		A076624	001	Dec 03, 2004	May	DISC
<u>MORPHINE SULFATE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
KADIAN							
AB1	+	WATSON LABS INC	10MG	N020616	008	Apr 20, 2007	May CTEC
	+		10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Apr CAHN
			40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Apr CAHN
			70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Apr CAHN
			130MG	N020616	011	Jul 09, 2012	Apr CAHN
			150MG	N020616	012	Jul 09, 2012	Apr CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	May CTEC
	+		200MG	N020616	007	Feb 27, 2007	Apr CAHN
MORPHINE SULFATE							
AB1		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Apr CTEC
AB1			30MG	A200812	002	Nov 10, 2011	Apr CTEC
AB1			50MG	A200812	003	Nov 10, 2011	Apr CTEC
AB1			60MG	A200812	004	Nov 10, 2011	Apr CTEC
AB1			80MG	A200812	005	Nov 10, 2011	Apr CTEC
AB1			100MG	A200812	006	Nov 10, 2011	Apr CTEC
AB1		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	May NEWA
AB1			20MG	A202104	002	Jun 03, 2013	May NEWA
AB1			30MG	A202104	003	Jun 03, 2013	May NEWA
AB1			50MG	A202104	004	Jun 03, 2013	May NEWA
AB1			60MG	A202104	005	Jun 03, 2013	May NEWA
AB1			80MG	A202104	006	Jun 03, 2013	May NEWA
AB1			100MG	A202104	007	Jun 03, 2013	May NEWA
SOLUTION; ORAL							
MORPHINE SULFATE							
		LANNETT HOLDINGS INC	100MG/5ML	N201517	001	Jun 23, 2011	Jul CPOT
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
EMBEDA							
+		ALPHARMA KING	60MG; 2.4MG	N022321	004	Aug 13, 2009	Jul CRLD
			100MG; 4MG	N022321	006	Aug 13, 2009	Jul CRLD
<u>MUPIROCIN CALCIUM</u>							
CREAM; TOPICAL							
BACTROBAN							
AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan CFTG
MUPIROCIN							
AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	Jan NEWA
<u>MYCOPHENOLATE MOFETIL</u>							
CAPSULE; ORAL							
MYCOPHENOLATE MOFETIL							
AB		ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009	Apr CAHN
AB		ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013	Jun NEWA
<u>NABUMETONE</u>							
TABLET; ORAL							
NABUMETONE							
	@	DR REDDYS LABS LTD	500MG	A078420	001	Sep 24, 2008	Apr DISC
	@		750MG	A078420	002	Sep 24, 2008	Apr DISC
	@	PROSAM LABS	500MG	A079093	001	Feb 27, 2009	Mar DISC
	@		750MG	A079093	002	Feb 27, 2009	Mar DISC
<u>NAFTIFINE HYDROCHLORIDE</u>							
GEL; TOPICAL							
NAFTIN							
+		MERZ PHARMS	2%	N204286	001	Jun 27, 2013	Jun NEWA

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

>A>	AB	GAVIS PHARMS	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Aug CTNA
>A>	AB	RANBAXY	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Aug CTNA
>A>	AB	+ WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736	001	Jan 21, 1997	Aug CTNA
PENTAZOCINE AND NALOXONE HYDROCHLORIDE							
>D>	AB	GAVIS PHARMS	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Aug CTNA
PENTAZOCINE AND NALOXONE HYDROCHLORIDES							
>D>	AB	RANBAXY	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Aug CTNA
>D>	AB	+ WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736	001	Jan 21, 1997	Aug CTNA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

		@ SANDOZ	50MG	A075434	001	Mar 08, 2000	Apr DISC
		REVIA					
AB	+	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984	Jul CAHN

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

AT		AKORN INC	0.1%	A083590	001		Jul CAHN
----	--	-----------	------	---------	-----	--	----------

NAPROXEN

TABLET; ORAL

NAPROXEN

AB		WEST WARD PHARM CORP	250MG	A076494	001	Jan 14, 2004	Apr CAHN
AB			375MG	A076494	002	Jan 14, 2004	Apr CAHN
AB			500MG	A076494	003	Jan 14, 2004	Apr CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

AB		GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763	002	Feb 10, 1998	Mar CAHN
AB	+		EQ 2.5MG BASE	N020763	001	Feb 10, 1998	Mar CAHN

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

@ AGOURON

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997 Jun DISC

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

@ X GEN PHARMS

100%

A061579 001 Mar DISC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

@ ALLERGAN

EQ 0.35% BASE;10,000 UNITS/ML;0.5%

N050081 002 May DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

+ ECLAT PHARMS LLC

5MG/10ML (0.5MG/ML)

N204078 001 May 31, 2013 May NEWA

+

10MG/10ML (1MG/ML)

N204078 002 May 31, 2013 May NEWA

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

>A> + ALCON RES LTD 0.3%

N203491 001 Oct 16, 2012 Aug CTNA

NEPAFENAC

>D> + ALCON RES LTD 0.3%

N203491 001 Oct 16, 2012 Aug CTNA

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

>D> @ BARR 1GM

A076250 001 Apr 14, 2005 Aug CMFD

>A> AB 1GM

A076250 001 Apr 14, 2005 Aug CMFD

TABLET, EXTENDED RELEASE;ORAL
 NIACIN

>D>	@	500MG	A076378	001	Apr 26, 2005	Aug CMFD
>A>	AB	500MG	A076378	001	Apr 26, 2005	Aug CMFD
>D>	@	750MG	A076378	002	Apr 26, 2005	Aug CMFD
>A>	AB	750MG	A076378	002	Apr 26, 2005	Aug CMFD

NIFEDIPINE

CAPSULE;ORAL
 NIFEDIPINE

AB	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Apr CTEC
	@ CATALENT	10MG	A073250	001	Oct 08, 1991	Apr DISC
AB	EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013	Apr NEWA
AB		20MG	A202644	002	Apr 25, 2013	Apr NEWA

NILUTAMIDE

TABLET;ORAL
 NILANDRON

@	COVIS PHARMA SARL	50MG	N020169	001	Sep 19, 1996	Apr CAHN
+		150MG	N020169	002	Apr 30, 1999	Apr CAHN

NIMODIPINE

CAPSULE;ORAL
 NIMODIPINE

AB	+ BANNER PHARMACAPS	30MG	A076740	001	Jan 17, 2008	Jul CRLD
AB	SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007	Jul CRLD

SOLUTION;ORAL
 NYMALIZE

+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	May NEWA
---	------------------	-----------	---------	-----	--------------	----------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL
 NISOLDIPINE

MYLAN	20MG	A079051	001	Jul 25, 2008	Jul CRLD
-------	------	---------	-----	--------------	----------

NITISINONE

CAPSULE;ORAL
 ORFADIN

SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	May CAHN
	5MG	N021232	002	Jan 18, 2002	May CAHN
+	10MG	N021232	003	Jan 18, 2002	May CAHN

NITROFURANTOIN

SUSPENSION;ORAL
 NITROFURANTOIN

AB	CARACO	25MG/5ML	A201355	001	Aug 14, 2013	Jul NEWA
----	--------	----------	---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
 MACRODANTIN

AB	ALVOGEN INC	25MG	N016620	003		Mar CTEC
AB		25MG	N016620	003		Feb CAHN
AB		50MG	N016620	001		Feb CAHN
AB	+	100MG	N016620	002		Feb CAHN
	NITROFURANTOIN					
	@ WATSON LABS	25MG	A073696	001	Dec 31, 1992	Mar DISC
	@	50MG	A073696	002	Dec 31, 1992	Mar DISC
	@	100MG	A073696	003	Dec 31, 1992	Mar DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
 MACROBID

AB	+ ALVOGEN INC	75MG;25MG	N020064	001	Dec 24, 1991	Mar CAHN
----	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
 NITRO-DUR

AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145	001	Apr 04, 1995	Mar CAHN
AB1	+		0.2MG/HR	N020145	002	Apr 04, 1995	Mar CAHN
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Mar CAHN
AB1	+		0.4MG/HR	N020145	004	Apr 04, 1995	Mar CAHN
AB1	+		0.6MG/HR	N020145	005	Apr 04, 1995	Mar CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITRO-DUR

+		0.8MG/HR	N020145	006	Apr 04, 1995	Mar CAHN
INJECTABLE;INJECTION						
NITROGLYCERIN						
@	HOSPIRA	5MG/ML	N018531	001		Jul DISC
+	LUITPOLD	5MG/ML	A072034	001	May 24, 1988	Jul CTEC

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

@	APOTEX INC	150MG	A076383	001	Jan 23, 2003	Feb DISC
@		300MG	A076383	002	Jan 23, 2003	Feb DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP	TEVA PHARMS USA	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	May CAHN
----	-----------------	----------------	---------	-----	--------------	----------

NORETHINDRONE

TABLET;ORAL

NORETHINDRONE

>D>	AB1	HAUPT PHARMA	0.35MG	A202260	001	Aug 01, 2013	Aug CDFR
	AB1		0.35MG	A202260	001	Aug 01, 2013	Jul NEWA

TABLET;ORAL-28

JENCYCLA

AB2	LUPIN LTD	0.35MG	A091323	001	Mar 28, 2013	Apr CTEC
AB		0.35MG	A091323	001	Mar 28, 2013	Mar NEWA

NORETHINDRONE

AB2	FAMY CARE LTD	0.35MG	A200980	001	Jun 12, 2013	May NEWA	
AB1		0.35MG	A201483	001	Jun 24, 2013	Jun NEWA	
>A>	AB1	HAUPT PHARMA	0.35MG	A202260	001	Aug 01, 2013	Aug CDFR
>A>	AB2	NOVAST LABS	0.35MG	A200961	001	Sep 13, 2013	Aug NEWA
>A>	AB1	NOVAST LABS LTD	0.35MG	A202014	001	Sep 13, 2013	Aug NEWA

NYSTATIN

SUSPENSION;ORAL

NILSTAT

@	GLENMARK GENERICS	100,000 UNITS/ML	N050299	001		Feb DISC
---	-------------------	------------------	---------	-----	--	----------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May CAHN
AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May CAHN
AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May CAHN
AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May CAHN
AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr NEWA
@	APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr DISC

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr NEWA
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr NEWA
ZEGERID						
AB	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CFTG
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CFTG

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

@	APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr DISC
AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Jul CPOT
AP		2MG/ML	A078288	001	Feb 22, 2013	Feb NEWA
@	LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar DISC
@	PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb DISC

INJECTABLE; INJECTION									
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER									
	@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan	DISC		
	@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan	DISC		
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE									
	@ APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr	DISC		
AP	BD RX	EQ 2MG BASE/ML	A202253	001	Jul 19, 2013	Jul	NEWA		
AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Jul	CPOT		
AP		2MG/ML	A078287	001	Feb 22, 2013	Feb	NEWA		
	@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar	DISC		
<u>OSPEMIFENE</u>									
TABLET; ORAL									
OSPHERA									
	+ SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb	NEWA		
<u>OXACILLIN SODIUM</u>									
INJECTABLE; INJECTION									
OXACILLIN SODIUM									
AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan	NEWA		
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan	NEWA		
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan	NEWA		
<u>OXAPROZIN</u>									
TABLET; ORAL									
OXAPROZIN									
	@ CARACO	600MG	A075844	001	Jan 03, 2002	Jan	DISC		
<u>OXAZEPAM</u>									
CAPSULE; ORAL									
OXAZEPAM									
AB	+ ACTAVIS ELIZABETH	30MG	A072253	001	Apr 14, 1988	Jul	CRLD		
AB	IVAX SUB TEVA PHARMS	30MG	A070945	001	Aug 03, 1987	Jul	CRLD		
<u>OXCARBAZEPINE</u>									
TABLET; ORAL									
OXCARBAZEPINE									
	@ TEVA PHARMS USA	150MG	A078005	001	Dec 11, 2007	Mar	DISC		
	@	300MG	A078005	002	Dec 11, 2007	Mar	DISC		
	@	600MG	A078005	003	Dec 11, 2007	Mar	DISC		
<u>OXYBUTYNIN</u>									
GEL, METERED; TRANSDERMAL									
GELNIQUE 3%									
	+ WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Jun	CTNA		
<u>OXYBUTYNIN CHLORIDE</u>									
SYRUP; ORAL									
OXYBUTYNIN CHLORIDE									
	@ APOTEX INC	5MG/5ML	A074997	001	Oct 15, 1997	Apr	DISC		
	@ MIKART	5MG/5ML	A075039	001	Jan 29, 1999	Jun	DISC		
TABLET; ORAL									
OXYBUTYNIN CHLORIDE									
AB	TEVA PHARMS USA	5MG	A071655	001	Nov 14, 1988	Mar	CAHN		
<u>OXYCODONE HYDROCHLORIDE</u>									
SOLUTION; ORAL									
OXYCODONE HYDROCHLORIDE									
AA	ROXANE	5MG/5ML	A204037	001	Jul 15, 2013	Jul	NEWA		
AA		100MG/5ML	A203208	001	Jul 12, 2013	Jul	NEWA		
AA	+ VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jul	CTEC		
TABLET; ORAL									
OXYCODONE HYDROCHLORIDE									
AB	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Jun	CMFD		
	@	5MG	A077290	001	Dec 08, 2005	Mar	DISC		
AB		10MG	A077290	002	Dec 08, 2005	Jun	CMFD		
	@	10MG	A077290	002	Dec 08, 2005	Mar	DISC		
AB		15MG	A077290	003	Dec 08, 2005	Jun	CMFD		
	@	15MG	A077290	003	Dec 08, 2005	Mar	DISC		
AB		20MG	A077290	004	Dec 08, 2005	Jun	CMFD		
	@	20MG	A077290	004	Dec 08, 2005	Mar	DISC		
AB		30MG	A077290	005	Dec 08, 2005	Jun	CMFD		

TABLET;ORAL						
OXYCODONE HYDROCHLORIDE						
@	30MG		A077290	005	Dec 08, 2005	Mar DISC
<u>OXYMORPHONE HYDROCHLORIDE</u>						
TABLET;ORAL						
OXYMORPHONE HYDROCHLORIDE						
AB	AVANTHI INC	5MG	A203601	001	Jan 30, 2013	Jan NEWA
AB		10MG	A203601	002	Jan 30, 2013	Jan NEWA
AB	MALLINCKRODT INC	5MG	A202321	001	Apr 25, 2013	Apr NEWA
AB		10MG	A202321	002	Apr 25, 2013	Apr NEWA
TABLET, EXTENDED RELEASE;ORAL						
OXYMORPHONE HYDROCHLORIDE						
AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Jul NEWA
AB		7.5MG	A079046	001	Dec 13, 2010	Apr CAHN
AB		10MG	A079046	004	Jul 11, 2013	Jul NEWA
AB		15MG	A079046	002	Dec 13, 2010	Apr CAHN
AB		20MG	A079046	005	Jul 11, 2013	Jul NEWA
AB		30MG	A079046	006	Jul 11, 2013	Jul NEWA
AB		40MG	A079046	007	Jul 11, 2013	Jul NEWA
AB	IMPAX LABS	5MG	A079087	001	Jun 14, 2010	Jul CTEC
AB		10MG	A079087	003	Jun 14, 2010	Jul CTEC
AB		20MG	A079087	005	Jun 14, 2010	Jul CTEC
AB		30MG	A079087	006	Jul 22, 2010	Jul CTEC
AB		40MG	A079087	007	Jun 14, 2010	Jul CTEC
AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Jul NEWA
AB		7.5MG	A200822	003	Jul 15, 2013	Jul NEWA
AB		10MG	A200822	004	Jul 15, 2013	Jul NEWA
AB		15MG	A200822	005	Jul 15, 2013	Jul NEWA
AB		20MG	A200822	006	Jul 15, 2013	Jul NEWA
AB		30MG	A200822	007	Jul 15, 2013	Jul NEWA
AB		40MG	A200822	001	Jul 15, 2013	Jul NEWA
<u>OXYTOCIN</u>						
INJECTABLE;INJECTION						
OXYTOCIN						
AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219	001	Feb 13, 2013	Jan NEWA
	@ TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	May CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	May CAHN
<u>PACLITAXEL</u>						
INJECTABLE;INJECTION						
PACLITAXEL						
	@ ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004	Apr DISC
	@ TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002	May CAHN
TAXOL						
AP	HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Apr CMFD
	@	6MG/ML	N020262	001	Dec 29, 1992	Jan CAHN
<u>PAMIDRONATE DISODIUM</u>						
INJECTABLE;INJECTION						
PAMIDRONATE DISODIUM						
AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar CAHN
AP		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar CAHN
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)</u>						
CAPSULE, DELAYED RELEASE;ORAL						
CREON						
	ABBVIE	180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005	Mar 14, 2013	Mar NEWA
<u>PANCURONIUM BROMIDE</u>						
INJECTABLE;INJECTION						
PANCURONIUM BROMIDE						
AP	+ TEVA PHARMS USA	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
AP	+	2MG/ML	A072760	001	Jul 31, 1990	Mar CAHN
<u>PAROXETINE HYDROCHLORIDE</u>						
SUSPENSION;ORAL						
PAROXETINE HYDROCHLORIDE						
	@ APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006	Apr DISC

PAROXETINE MESYLATECAPSULE;ORAL
BRISDELLE

+	NOVEN THERAP	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun NEWA
---	--------------	---------------	---------	-----	--------------	----------

PEGINESATIDE ACETATESOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS

@	TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	May DISC
+		EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Apr CAHN
@		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	May DISC
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Apr CAHN
OMONTYS PRESERVATIVE FREE						
@	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	May DISC
+		EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Apr CAHN
@		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	May DISC
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Apr CAHN
@		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	May DISC
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Apr CAHN
@		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	May DISC
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Apr CAHN
@		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	May DISC
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Apr CAHN
@		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	May DISC
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Apr CAHN

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Mar NEWA
+		10%	N203510	002	Mar 21, 2013	Mar NEWA

PHENYTOIN SODIUMINJECTABLE;INJECTION
PHENYTOIN SODIUM

@	HOSPIRA	50MG/ML	A089744	001	Dec 18, 1987	Mar DISC
---	---------	---------	---------	-----	--------------	----------

PHYTONADIONETABLET;ORAL
MEPHYTON

+	VALEANT PHARMS	5MG	N010104	003		Jun CAHN
---	----------------	-----	---------	-----	--	----------

PINDOLOLTABLET;ORAL
PINDOLOL

	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Jun CTEC
+		10MG	A074019	002	Sep 03, 1992	Jun CTEC
@	WATSON LABS	5MG	A074437	001	Feb 27, 1995	Jun DISC
@		10MG	A074437	002	Feb 27, 1995	Jun DISC

PIOGLITAZONE HYDROCHLORIDETABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A200044	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A200044	003	Feb 13, 2013	Jan NEWA
AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A200268	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A200268	003	Feb 13, 2013	Jan NEWA
AB	DR REDDYS LABS LTD	EQ 15MG BASE	A078383	001	Mar 12, 2013	Mar NEWA
AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Mar NEWA
AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Mar NEWA

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 15MG BASE	A202467	001	Feb 06, 2013	Jan NEWA
AB		EQ 30MG BASE	A202467	002	Feb 06, 2013	Jan NEWA
AB		EQ 45MG BASE	A202467	003	Feb 06, 2013	Jan NEWA
AB	SANDOZ	EQ 15MG BASE	A078670	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078670	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078670	003	Feb 13, 2013	Jan NEWA
AB	SYNTHON PHARMS	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A078472	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A078472	003	Feb 13, 2013	Jan NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A091298	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A091298	003	Feb 13, 2013	Jan NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456	001	Feb 13, 2013	Jan NEWA
AB		EQ 30MG BASE	A202456	002	Feb 13, 2013	Jan NEWA
AB		EQ 45MG BASE	A202456	003	Feb 13, 2013	Jan NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

MEDA PHARMS 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; N018983 010 Jan 31, 1989 Jul CTEC
5.53GM/BOT;21.5GM/BOT

@ 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. N018983 007 Jun 12, 1987 Jul DISC
84GM/BOT;22.72GM/BOT

COLYTE WITH FLAVOR PACKS

MEDA PHARMS 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. N018983 012 Oct 08, 1998 Jul CTEC
84GM/BOT;22.72GM/BOT

COLYTE-FLAVORED

@ MEDA PHARMS 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; N018983 008 Nov 14, 1991 Jul DISC
5.53GM/BOT;21.5GM/BOT

@ 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. N018983 009 Nov 14, 1991 Jul DISC
84GM/BOT;22.72GM/BOT

POLYMYXIN B SULFATE

POWDER;FOR RX COMPOUNDING

POLY-RX

@ X GEN PHARMS 100,000,000 UNITS/BOT A061578 001 Mar DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT AKORN INC 10,000 UNITS/ML;EQ 1MG BASE/ML A065006 001 Dec 17, 1998 Jul CAHN

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

CELGENE 1MG N204026 001 Feb 08, 2013 Feb NEWA

2MG N204026 002 Feb 08, 2013 Feb NEWA

3MG N204026 003 Feb 08, 2013 Feb NEWA

+ 4MG N204026 004 Feb 08, 2013 Feb NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB AMNEAL PHARMS 10MEQ A202128 001 Feb 22, 2013 Feb NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB ACTAVIS GRP PTC 0.125MG A091254 001 Nov 30, 2010 Mar CAHN

AB 0.25MG A091254 002 Nov 30, 2010 Mar CAHN

AB 0.5MG A091254 003 Nov 30, 2010 Mar CAHN

AB 0.75MG A091254 004 Nov 30, 2010 Mar CAHN

AB 1MG A091254 005 Nov 30, 2010 Mar CAHN

AB 1.5MG A091254 006 Nov 30, 2010 Mar CAHN

AB SUN PHARM INDS INC 0.125MG A091683 001 Mar 27, 2013 Mar NEWA

AB 0.25MG A091683 002 Mar 27, 2013 Mar NEWA

AB 0.5MG A091683 003 Mar 27, 2013 Mar NEWA

AB 0.75MG A091683 004 Mar 27, 2013 Mar NEWA

AB 1MG A091683 005 Mar 27, 2013 Mar NEWA

AB 1.5MG A091683 006 Mar 27, 2013 Mar NEWA

PRAMLINTIDE ACETATEINJECTABLE;SUBCUTANEOUS
SYMLIN

	AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Jan CAHN
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jan CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jan CAHN
+	AMYLIN PHARMS LLC	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Jun CRLD
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Jun DISC

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>A>	AB	CIPLA LTD	10MG	A077904	001	Oct 23, 2006	Aug CAHN
>A>	AB		20MG	A077904	002	Oct 23, 2006	Aug CAHN
>A>	AB		40MG	A077904	003	Oct 23, 2006	Aug CAHN
>D>	AB	WATSON LABS	10MG	A077904	001	Oct 23, 2006	Aug CAHN
>D>	AB		20MG	A077904	002	Oct 23, 2006	Aug CAHN
>D>	AB		40MG	A077904	003	Oct 23, 2006	Aug CAHN

PRAZICQUANTEL

TABLET;ORAL

BILTRICIDE

+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@	APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005	Apr DISC
@		15MG/5ML	A040571	001	Aug 25, 2005	Apr DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

ORAPRED

AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	May CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
	@	NESHER PHARMS	EQ 15MG BASE/5ML	A076988	001	May 24, 2005	May DISC
	@	PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar DISC
	@	WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar DISC
		TABLET, ORALLY DISINTEGRATING;ORAL					
		ORAPRED ODT					
AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	May CAHN
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	May CAHN
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	May CAHN
AB		SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar CFTG
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar CFTG
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar CFTG
		PREDNISOLONE SODIUM PHOSPHATE					
AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar NEWA
AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar NEWA
AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar NEWA

PREDNISONE

TABLET;ORAL

PREDNISONE

AB		HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	May CAHN
AB			2.5MG	A040538	001	Jan 08, 2004	May CAHN
AB			5MG	A080292	001		May CAHN
AB			10MG	A088832	001	Dec 04, 1985	May CAHN
AB			20MG	A083677	001		May CAHN
AB			50MG	A088465	001	Jun 01, 1984	May CAHN

PRIMIDONE

TABLET;ORAL

PRIMIDONE

@	DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008	Apr DISC
@		250MG	A040862	002	Oct 03, 2008	Apr DISC
@	WEST WARD	50MG	A040667	001	Jul 27, 2006	Jul DISC

PROBENECIDTABLET; ORAL
PROBENECID

@ IVAX SUB TEVA PHARMS 500MG

A083740 001 May 09, 1984 May DISC

PROGESTERONECAPSULE; ORAL
PROGESTERONEAB BANNER PHARMACAPS 100MG
AB 200MGA200900 001 Aug 16, 2013 Jul NEWA
A200900 002 Aug 16, 2013 Jul NEWAPROMETRIUM
AB ABBVIE INC 100MG
AB + 200MG
@ 300MGN019781 001 May 14, 1998 May CAHN
N019781 002 Oct 15, 1999 May CAHN
N019781 003 Oct 15, 1999 May CAHNPROMETHAZINE HYDROCHLORIDEINJECTABLE; INJECTION
PROMETHAZINE HYDROCHLORIDEAP + TEVA PHARMS USA 25MG/ML
AP + 50MG/MLA040454 001 Aug 22, 2002 Mar CAHN
A040454 002 Aug 22, 2002 Mar CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE
AA CARACO 6.25MG/5ML

A040891 001 Mar 13, 2009 May CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE
AB CARACO 12.5MG
AB 25MG
AB 50MGA040863 001 Dec 30, 2008 May CAHN
A040863 002 Dec 30, 2008 May CAHN
A040863 003 Dec 30, 2008 May CAHNPROPARACAINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PROPARACAINE HYDROCHLORIDE

AT AKORN INC 0.5%

A040277 001 Mar 16, 2000 Jul CAHN

PROPOFOLINJECTABLE; INJECTION
PROPOFOL

AB TEVA PHARMS USA 10MG/ML

A075102 001 Jan 04, 1999 Mar CAHN

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDEAB GLATT AIR 60MG
AB 80MG
AB 120MG
AB 160MGA078065 001 Jan 26, 2007 Feb CAHN
A078065 002 Jan 26, 2007 Feb CAHN
A078065 003 Jan 26, 2007 Feb CAHN
A078065 004 Jan 26, 2007 Feb CAHN

TABLET; ORAL

INDERAL

@ WYETH PHARMS INC 10MG
@ 20MG
AB 40MG
AB 60MG
AB + 80MG
@ 90MGN016418 001 Jul CAHN
N016418 003 Jul CAHN
N016418 002 Jul CAHN
N016418 009 Oct 18, 1982 Jul CAHN
N016418 004 Jul CAHN
N016418 010 Oct 18, 1982 Jul CAHNPROTRIPTYLINE HYDROCHLORIDETABLET; ORAL
VIVACTIL@ TEVA WOMENS 5MG
@ 10MGN016012 001 Mar CAHN
N016012 002 Mar CAHNPYRIMETHAMINETABLET; ORAL
DARAPRIM

+ AMEDRA PHARMS 25MG

N008578 001 Apr CAHN

QUAZEPAMTABLET; ORAL
DORAL@ SCIECURE PHARMA INC 7.5MG
+ 15MGN018708 003 Feb 26, 1987 Jun CAHN
N018708 001 Dec 27, 1985 Jun CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202152	001	Mar 27, 2012	Apr CAHN
AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Apr CAHN
AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Apr CAHN
AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Apr CAHN
AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Apr CAHN
AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Apr CAHN
AB	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	May CAHN
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	May CAHN
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	May CAHN
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	May CAHN
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	May CAHN
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	May CAHN
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	May CAHN
AB	ACTAVIS PHARMA	EQ 25MG BASE	A201762	001	Feb 27, 2013	Feb NEWA
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	Feb NEWA
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	Feb NEWA
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	Feb NEWA
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	Feb NEWA
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	Feb NEWA
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	Feb NEWA
AB	ALKEM LABS LTD	EQ 25MG BASE	A201504	001	Feb 12, 2013	Jan NEWA
AB		EQ 50MG BASE	A201504	002	Feb 12, 2013	Jan NEWA
AB		EQ 100MG BASE	A201504	003	Feb 12, 2013	Jan NEWA
AB		EQ 150MG BASE	A201504	004	Feb 12, 2013	Jan NEWA
AB		EQ 200MG BASE	A201504	005	Feb 12, 2013	Jan NEWA
AB		EQ 300MG BASE	A201504	006	Feb 12, 2013	Jan NEWA
AB		EQ 400MG BASE	A201504	007	Feb 12, 2013	Jan NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@ APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006	Mar DISC
	@	EQ 10MG BASE	A076240	002	Jan 26, 2006	Mar DISC
	@	EQ 20MG BASE	A076240	003	Jan 26, 2006	Mar DISC
	@	EQ 40MG BASE	A076240	004	Jan 26, 2006	Mar DISC
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725	001	Apr 29, 2013	Apr NEWA
AB		EQ 10MG BASE	A202725	002	Apr 29, 2013	Apr NEWA
AB		EQ 20MG BASE	A202725	003	Apr 29, 2013	Apr NEWA
AB		EQ 40MG BASE	A202725	004	Apr 29, 2013	Apr NEWA
>D> AB	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Aug DISC
>A>	@	EQ 5MG BASE	A076036	001	Jan 28, 2005	Aug DISC
>D> AB		EQ 10MG BASE	A076036	002	Jan 28, 2005	Aug DISC
>A>	@	EQ 10MG BASE	A076036	002	Jan 28, 2005	Aug DISC
>D> AB		EQ 20MG BASE	A076036	003	Jan 28, 2005	Aug DISC
>A>	@	EQ 20MG BASE	A076036	003	Jan 28, 2005	Aug DISC
>D> AB		EQ 40MG BASE	A076036	004	Jan 28, 2005	Aug DISC
>A>	@	EQ 40MG BASE	A076036	004	Jan 28, 2005	Aug DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

	EISAI INC	5MG	N204736	001	Mar 26, 2013	Mar NEWA
+		10MG	N204736	002	Mar 26, 2013	Mar NEWA

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+	BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971	001	May 15, 2013	May NEWA
---	----------------	-----------------------	---------	-----	--------------	----------

RAMELTEON

TABLET; ORAL

RAMELTEON

AB	TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013	Jul NEWA
	ROZEREM					
AB	+ TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul CFTG

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ CIPLA	1.25MG	A077004	001	Aug 07, 2008	Jul	DISC
@	2.5MG	A077004	002	Aug 07, 2008	Jul	DISC
@	5MG	A077004	003	Aug 07, 2008	Jul	DISC
@	10MG	A077004	004	Aug 07, 2008	Jul	DISC

RANITIDINE HYDROCHLORIDE

GRANULE, EFFERVESCENT;ORAL

ZANTAC 150

@ GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994	Jun	CAHN
-----------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	25MG/ML	A091534	001	Feb 22, 2013	Feb	NEWA
	ZANTAC IN PLASTIC CONTAINER						

@ COVIS PHARMA SARL	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jun	DISC
---------------------	----------------	---------	-----	--------------	-----	------

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA	@ APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007	Apr	DISC
AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Apr	CAHN
AA	CARACO	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Apr	CAHN

ZANTAC

AA	+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988	Jun	CAHN
----	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@ WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997	Jan	DISC
	@	EQ 300MG BASE	A074864	002	Oct 20, 1997	Jan	DISC
	@ WATSON LABS INC	EQ 150MG BASE	A077426	001	Dec 19, 2005	Mar	DISC
	@	EQ 300MG BASE	A077426	002	Dec 19, 2005	Mar	DISC

ZANTAC 150

AB	GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Jun	CAHN
	ZANTAC 300						

AB	+ GLAXO GRP LTD	EQ 300MG BASE	N018703	002	Dec 09, 1985	Jun	CAHN
----	-----------------	---------------	---------	-----	--------------	-----	------

TABLET, EFFERVESCENT;ORAL

ZANTAC 150

@ GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994	Jun	CAHN
-----------------	---------------	---------	-----	--------------	-----	------

ZANTAC 25

+ GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Jun	CAHN
-----------------	--------------	---------	-----	--------------	-----	------

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

AB	+ GILEAD	1GM	N021526	001	Feb 12, 2007	Jul	CFTG
AB		500MG	N021526	002	Jan 27, 2006	Jul	CFTG

RANOLAZINE

AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Jul	NEWA
AB		1GM	A201046	002	Jul 29, 2013	Jul	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT

AB	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006	Jun	CFTG
AB	+	EQ 1MG BASE	N021641	002	May 16, 2006	Jun	CFTG

RASAGILINE MESYLATE

>A>	AB	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Aug	NEWA
>A>	AB		EQ 1MG BASE	A201950	002	Sep 12, 2013	Aug	NEWA
	AB	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Jun	NEWA
	AB		EQ 1MG BASE	A201823	002	Jul 01, 2013	Jun	NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

AB	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997	Jul	CTEC
AB		1MG	N020741	002	Dec 22, 1997	Jul	CFTG
AB	+	2MG	N020741	003	Dec 22, 1997	Jul	CFTG

REPAGLINIDE

	AB	CARACO	1MG	A077571	002	Jul 11, 2013	Jul	NEWA
	AB		2MG	A077571	003	Jul 11, 2013	Jul	NEWA
>A>	AB	MYLAN PHARMS INC	0.5MG	A090252	001	Aug 23, 2013	Aug	NEWA
	AB	PADDOCK LLC	0.5MG	A201189	001	Jul 17, 2013	Jul	NEWA

RESERPINETABLET; ORAL
SERPALAN@ LANNETT
@0.1MG
0.25MGN010124 001
N010124 002May DISC
May DISCRIFAMPINCAPSULE; ORAL
RIFAMPINAB LUPIN PHARMS
AB150MG
300MGA090034 001 Aug 21, 2013 Jul NEWA
A090034 002 Aug 21, 2013 Jul NEWARILUZOLETABLET; ORAL
RILUTEKAB + COVIS PHARMA SARL
RILUZOLE

50MG

N020599 001 Dec 12, 1995 Apr CAHN

AB APOTEX CORP 50MG
AB GLENMARK GENERICS 50MG
AB MYLAN PHARMS INC 50MG
AB SUN PHARM INDS LTD 50MGA091300 001 Jun 18, 2013 Jun NEWA
A091394 001 Jun 18, 2013 Jun NEWA
A203042 001 Jul 01, 2013 Jun NEWA
A091417 001 Jun 18, 2013 Jun NEWARIMANTADINE HYDROCHLORIDETABLET; ORAL
RIMANTADINE HYDROCHLORIDE

@ COREPHARMA

100MG

A075916 001 Nov 02, 2001 Feb DISC

RISPERIDONESOLUTION; ORAL
RISPERIDONEAA BIO PHARM INC 1MG/ML
TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

A078909 001 Jul 29, 2009 May CAHN

AB MYLAN PHARMS INC 0.25MG
AB PAR PHARM 0.25MG
AB SUN PHARM INDS LTD 0.5MG
AB 1MG
AB 2MG
AB 3MG
AB 4MGA091537 006 Feb 12, 2013 Feb NEWA
A077494 001 Apr 30, 2009 Feb CTEC
A078464 001 Apr 08, 2013 Mar NEWA
A078464 002 Apr 08, 2013 Mar NEWA
A078464 003 Apr 08, 2013 Mar NEWA
A078464 004 Apr 08, 2013 Mar NEWA
A078464 005 Apr 08, 2013 Mar NEWARIVASTIGMINE TARTRATECAPSULE; ORAL
RIVASTIGMINE TARTRATEAB APOTEX INC EQ 1.5MG BASE
AB EQ 3MG BASE
AB EQ 4.5MG BASE
AB EQ 6MG BASEA091072 001 May 16, 2013 Apr NEWA
A091072 002 May 16, 2013 Apr NEWA
A091072 003 May 16, 2013 Apr NEWA
A091072 004 May 16, 2013 Apr NEWARIZATRIPTAN BENZOATETABLET; ORAL
RIZATRIPTAN BENZOATEAB CIPLA LTD EQ 5MG BASE
AB EQ 10MG BASE
AB INVAGEN PHARMS EQ 5MG BASE
AB EQ 10MG BASEA077526 001 Mar 26, 2013 Mar NEWA
A077526 002 Mar 26, 2013 Mar NEWA
A204339 001 Jul 01, 2013 Jun NEWA
A204339 002 Jul 01, 2013 Jun NEWATABLET, ORALLY DISINTEGRATING; ORAL
RIZATRIPTAN BENZOATEAB APOTEX INC EQ 5MG BASE
AB EQ 10MG BASE
AB AUROBINDO PHARMA LTD EQ 5MG BASE
AB EQ 10MG BASE
AB GLENMARK GENERICS EQ 5MG BASE
AB EQ 10MG BASE
AB NATCO PHARMA LTD EQ 5MG BASE
AB EQ 10MG BASE
AB SANDOZ EQ 5MG BASE
AB EQ 10MG BASEA202477 001 Jul 01, 2013 Jun NEWA
A202477 002 Jul 01, 2013 Jun NEWA
A203062 001 Jul 01, 2013 Jun NEWA
A203062 002 Jul 01, 2013 Jun NEWA
A201914 001 Jul 01, 2013 Jun NEWA
A201914 002 Jul 01, 2013 Jun NEWA
A203478 001 Jul 01, 2013 Jun NEWA
A203478 002 Jul 01, 2013 Jun NEWA
A078739 001 Jul 01, 2013 Jun NEWA
A078739 002 Jul 01, 2013 Jun NEWAROCURONIUM BROMIDE

INJECTABLE; INJECTION

INJECTABLE; INJECTION

ZEMURON							
AP	+	ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan CAHN
AB	@		10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan CAHN
AP	+		100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP							
AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar CAHN
AB			EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar CAHN
AB			EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar CAHN
AB			EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar CAHN
AB			EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar CAHN
AB			EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar CAHN
AB			EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar CAHN

ROPINIROLE HYDROCHLORIDE

	@	COREPHARMA	EQ 0.25MG BASE	A078230	001	May 20, 2008	Jul DISC
	@		EQ 0.5MG BASE	A078230	002	May 20, 2008	Jul DISC
	@		EQ 1MG BASE	A078230	003	May 20, 2008	Jul DISC
	@		EQ 2MG BASE	A078230	004	May 20, 2008	Jul DISC
	@		EQ 3MG BASE	A078230	005	May 20, 2008	Jul DISC
	@		EQ 4MG BASE	A078230	006	May 20, 2008	Jul DISC
	@		EQ 5MG BASE	A078230	007	May 20, 2008	Jul DISC

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL							
AB	+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar CAHN
	@		EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar CAHN
AB			EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar CAHN
AB			EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar CAHN
AB			EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar CAHN
AB			EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar CAHN

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr CAHN
AB			EQ 4MG BASE	A090869	002	May 17, 2012	Apr CAHN
AB			EQ 6MG BASE	A090869	003	May 17, 2012	Apr CAHN
AB			EQ 8MG BASE	A090869	004	May 17, 2012	Apr CAHN
AB			EQ 12MG BASE	A090869	005	May 17, 2012	Apr CAHN
AB		ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	Apr NEWA
AB			EQ 4MG BASE	A202786	002	Apr 22, 2013	Apr NEWA
AB			EQ 6MG BASE	A202786	003	Apr 22, 2013	Apr NEWA
AB			EQ 8MG BASE	A202786	004	Apr 22, 2013	Apr NEWA
AB			EQ 12MG BASE	A202786	005	Apr 22, 2013	Apr NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA							
AB		SB PHARMC0	EQ 2MG BASE	N021071	002	May 25, 1999	Jan CFTG
AB			EQ 4MG BASE	N021071	003	May 25, 1999	Jan CFTG
AB	+		EQ 8MG BASE	N021071	004	May 25, 1999	Jan CFTG
ROSIGLITAZONE MALEATE							
AB		TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jan NEWA
AB			EQ 4MG BASE	A076747	002	Jan 25, 2013	Jan NEWA
AB			EQ 8MG BASE	A076747	003	Jan 25, 2013	Jan NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO							
	+	UCB INC	2MG/24HR	N021829	001	May 09, 2007	May CRLD
			8MG/24HR	N021829	006	Apr 02, 2012	May CRLD

SAQUINAVIR MESYLATE

TABLET; ORAL

INVIRASE							
	+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004	Feb CAHN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE							
	@	DAVA PHARMS INC	5MG	A074641	001	Aug 02, 1996	Jan DISC

SERTACONAZOLE NITRATECREAM; TOPICAL
ERTACZO

+ VALEANT LUXEMBOURG 2% N021385 001 Dec 10, 2003 Jun CAHN

SERTRALINE HYDROCHLORIDETABLET; ORAL
SERTRALINE HYDROCHLORIDE

>A>	@ CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007	Aug CAHN
>A>	@	EQ 50MG BASE	A077162	002	Feb 06, 2007	Aug CAHN
>A>	@	EQ 100MG BASE	A077162	003	Feb 06, 2007	Aug CAHN
	@ DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr DISC
	@	EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr DISC
	@	EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr DISC
>D>	@ WATSON LABS	EQ 25MG BASE	A077162	001	Feb 06, 2007	Aug CAHN
>D>	@	EQ 50MG BASE	A077162	002	Feb 06, 2007	Aug CAHN
>D>	@	EQ 100MG BASE	A077162	003	Feb 06, 2007	Aug CAHN

SILDENAFIL CITRATETABLET; ORAL
SILDENAFIL CITRATE

AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr CAHN
AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149	001	Feb 25, 2013	Feb NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013	Feb NEWA

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Mar NEWA
		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Mar NEWA
		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Mar NEWA
		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Mar NEWA
		90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Mar NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Mar CPOT
--	-------------	-----------------	---------	-----	--------------	----------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	450MG/100ML	N017864	001			Jan DISC
-------------------	-------------	---------	-----	--	--	----------

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

+ MCPRF	10-91.5MCI/ML	A203605	001	Jun 28, 2013	Jun NEWA
---------	---------------	---------	-----	--------------	----------

SODIUM PHENYL BUTYRATEPOWDER; ORAL
BUPHENYL

AB	+ MEDICIS	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CFTG
	SODIUM PHENYL BUTYRATE					
AB	SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819	001	Mar 22, 2013	Mar NEWA

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATETABLET; ORAL
VISICOL

@ SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Jul DISC
----------------	-----------------	---------	-----	--------------	----------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATETABLET; ORAL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

>D>	NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Aug DISC	
>D>	@	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Aug DISC	
	OSMOPREP						
>D>	AB	+ SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Aug CTEC
>A>		+	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Aug CTEC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE; INJECTION
SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Jun CRLD
-----------	-------------------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

	POWDER;ORAL, RECTAL						
	KAYEXALATE						
AA	+ COVIS PHARMA SARL	453.6GM/BOT	N011287	001			Apr CAHN
	SUSPENSION;ORAL, RECTAL						
	SODIUM POLYSTYRENE SULFONATE						
	@ ROXANE	15GM/60ML	A089049	001	Nov 17, 1986		Mar DISC

STAVUDINE

	CAPSULE;ORAL						
	STAVUDINE						
AB	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008		Apr CAHN
AB		20MG	A078957	002	Dec 29, 2008		Apr CAHN
AB		30MG	A078957	003	Dec 29, 2008		Apr CAHN
AB		40MG	A078957	004	Dec 29, 2008		Apr CAHN

STREPTOZOCIN

	INJECTABLE;INJECTION						
	ZANOSAR						
	+ TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982		Apr CAHN

SUCCIMER

	CAPSULE;ORAL						
	CHEMET						
	+ RECORDATI RARE	100MG	N019998	002	Jan 30, 1991		May CAHN

SULFACETAMIDE SODIUM

	LOTION;TOPICAL						
	KLARON						
AB	+ VALEANT BERMUDA	10%	N019931	001	Dec 23, 1996		Feb CAHN
	OINTMENT;OPHTHALMIC						
	SULFACETAMIDE SODIUM						
AT	PERRIGO CO TENNESSEE	10%	A080029	001			Jun CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

	INJECTABLE;INJECTION						
	SULFAMETHOXAZOLE AND TRIMETHOPRIM						
	+ TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991		Mar CAHN
	TABLET;ORAL						
	SULFAMETHOPRIM						
	@ NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985		Mar DISC
	SULFAMETHOPRIM-DS						
	@ NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985		Mar DISC
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH						
	@ SANDOZ	800MG;160MG	N018598	004	May 19, 1982		Jun DISC

SULINDAC

	TABLET;ORAL						
	SULINDAC						
AB	HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991		Apr CMFD
AB		200MG	A073262	001	Sep 06, 1991		Apr CMFD

SUMATRIPTAN SUCCINATE

	INJECTABLE;SUBCUTANEOUS						
	SUMATRIPTAN SUCCINATE						
AP	AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013		Apr NEWA
>A> AP	HIKMA FARMACEUTICA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A200183	001	Sep 16, 2013		Aug NEWA
AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010		Feb CAHN
AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009		Mar CAHN
	SYSTEM;IONTOPHORESIS						
	ZECUITY						
	+ NUPATHE	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013		Jan NEWA
	TABLET;ORAL						
	SUMATRIPTAN SUCCINATE						
AB	HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013		May NEWA
AB		EQ 50MG BASE	A078298	002	May 21, 2013		May NEWA
AB		EQ 100MG BASE	A078298	003	May 21, 2013		May NEWA

TABLET;ORAL

SUMATRIPTAN SUCCINATE

>D>	AB	MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009	Aug DISC
>A>		@	EQ 25MG BASE	A077163	001	Nov 02, 2009	Aug DISC
>D>	AB		EQ 50MG BASE	A077163	002	Nov 02, 2009	Aug DISC
>A>		@	EQ 50MG BASE	A077163	002	Nov 02, 2009	Aug DISC
>D>	AB		EQ 100MG BASE	A077163	003	Nov 02, 2009	Aug DISC
>A>		@	EQ 100MG BASE	A077163	003	Nov 02, 2009	Aug DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

		ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jul NEWA
			EQ 1MG BASE	N204096	002	Jul 19, 2013	Jul NEWA
		+	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jul NEWA
		OINTMENT;TOPICAL					
		PROTOPIC					
		+	ASTELLAS	0.03%	N050777	001	Dec 08, 2000
							Jun CRLD

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	0.4MG	A202433	001	Apr 30, 2013	Apr NEWA
----	--	----------------------	-------	---------	-----	--------------	----------

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION

LYMPHOSEEK KIT

		+	NAVIDEA BIOPHARMS	N/A	N202207	001	Mar 13, 2013	Mar NEWA
--	--	---	-------------------	-----	---------	-----	--------------	----------

TENIPOSIDE

INJECTABLE;INJECTION

VUMON

		+	CORDEN PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Apr CAHN
		+	HQ SPECILT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Jul CAHN

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB		CIPLA LTD	EQ 250MG BASE	A077137	001	Jul 02, 2007	Jul CAHN
>D>	AB	MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Aug DISC
>A>		@	EQ 250MG BASE	A077136	001	Jul 02, 2007	Aug DISC

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

		@	TEVA PHARMS USA	1MG/ML	A076853	001	Jul 20, 2004	Mar CAHN
--	--	---	-----------------	--------	---------	-----	--------------	----------

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

		PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan NEWA
			50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan NEWA

GEL, METERED;TRANSDERMAL

TESTOSTERONE

		PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jan NEWA
--	--	----------------	-------------------------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

AO		SUN PHARM INDS LTD	100MG/ML	A201720	001	Jun 03, 2013	May NEWA
AO			200MG/ML	A201720	002	Jun 03, 2013	May NEWA

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTRYL

		@	ENDO PHARMS	200MG/ML	N009165	001	Jan CAHN
AO		+		200MG/ML	N009165	003	Jan CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE;INTRAVENOUS

THALLOUS CHLORIDE TL 201

INJECTABLE;INTRAVENOUS
THALLOUS CHLORIDE TL 201

>D>	AP	MALLINCKRODT	2mCi/ML	A077698	001	Nov 09, 2006	Aug DISC
>A>		@	2mCi/ML	A077698	001	Nov 09, 2006	Aug DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB	+	TEVA PHARMS	450MG	A081236	001	Nov 09, 1992	Mar CAHN
----	---	-------------	-------	---------	-----	--------------	----------

THIABENDAZOLE

SUSPENSION;ORAL
MINTEZOL

@	MERCK SHARP DOHME	500MG/5ML	N016097	001		May CAHN
---	-------------------	-----------	---------	-----	--	----------

TABLET, CHEWABLE;ORAL
MINTEZOL

@	MERCK SHARP DOHME	500MG	N016096	001		May CAHN
---	-------------------	-------	---------	-----	--	----------

THIOGUANINE

TABLET;ORAL
THIOGUANINE

+	ASPEN GLOBAL INC	40MG	N012429	001		Mar CAHN
---	------------------	------	---------	-----	--	----------

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

>D>	AB	MYLAN	250MG	A075161	001	Sep 13, 1999	Aug DISC
>A>		@	250MG	A075161	001	Sep 13, 1999	Aug DISC

TIGECYCLINE

INJECTABLE;IV (INFUSION)
TYGACIL

>A>	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Aug CAHN
>D>	+	WYETH PHARMS INC	50MG/VIAL	N021821	001	Jun 15, 2005	Aug CAHN

TILUDRONATE DISODIUM

TABLET;ORAL
SKELID

@	SANOFI AVENTIS US	EQ 200MG BASE	N020707	001	Mar 07, 1997	Jun DISC
---	-------------------	---------------	---------	-----	--------------	----------

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOPTIC-XE

AB	+	VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Jan CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Jan CAHN

SOLUTION/DROPS;OPHTHALMIC
ISTALOL

BT	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	May CAHN
		TIMOLOL MALEATE					
	@	AKORN	EQ 0.25% BASE	A074515	001	Mar 25, 1997	Jun DISC
	@	APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Apr DISC
	@		EQ 0.5% BASE	A075412	001	Sep 08, 2000	Apr DISC

TIOPRONIN

TABLET;ORAL
THIOLA

>A>	+	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988	Aug CTNA
-----	---	----------------	-------	---------	-----	--------------	----------

>D>	+	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988	Aug CTNA
-----	---	----------------	-------	---------	-----	--------------	----------

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 2MG BASE	A091502	001	Nov 09, 2012	May CAHN
AB			EQ 4MG BASE	A091502	002	Nov 09, 2012	May CAHN
AB			EQ 6MG BASE	A091502	003	Nov 09, 2012	May CAHN

TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 2MG BASE	A076282	001	Dec 16, 2003	Feb DISC
@		EQ 4MG BASE	A076282	002	Dec 16, 2003	Feb DISC

TOBRAMYCIN

POWDER; INHALATION

TOBI PODHALER

+ NOVARTIS 28MG

N201688 001 Mar 22, 2013 Mar NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

@ APOTEX INC 0.3%

A065087 001 Feb 25, 2002 Apr DISC

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

MYLAN PHARMS INC 250MG

A070259 001 Jan 02, 1986 Mar CTEC

+ 500MG

A070259 003 Mar 17, 1986 Mar CTEC

@ WATSON LABS 250MG

A070514 001 Jan 09, 1986 Mar DISC

@ 500MG

A070515 001 Jan 09, 1986 Mar DISC

TOPIRAMATE

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> TROKENDI XR

>A> SUPERNUS PHARMS 25MG

N201635 001 Aug 16, 2013 Aug NEWA

>A> 50MG

N201635 002 Aug 16, 2013 Aug NEWA

>A> 100MG

N201635 003 Aug 16, 2013 Aug NEWA

>A> + 200MG

N201635 004 Aug 16, 2013 Aug NEWA

TABLET; ORAL

TOPAMAX

AB JANSSEN PHARMS 25MG

N020505 004 Dec 24, 1996 Apr CRLD

AB + 100MG

N020505 001 Dec 24, 1996 Apr CRLD

TOPIRAMATE

AB ACTIVIS TOTOWA LLC 25MG

A078637 001 Feb 27, 2013 Feb NEWA

AB 50MG

A078637 002 Feb 27, 2013 Feb NEWA

AB 100MG

A078637 003 Feb 27, 2013 Feb NEWA

AB 200MG

A078637 004 Feb 27, 2013 Feb NEWA

>A> AB LUPIN 25MG

A078410 001 Sep 11, 2013 Aug NEWA

>A> AB 50MG

A078410 002 Sep 11, 2013 Aug NEWA

>A> AB 100MG

A078410 003 Sep 11, 2013 Aug NEWA

>A> AB 200MG

A078410 004 Sep 11, 2013 Aug NEWA

AB UNICHEM LABS LTD 200MG

A090162 004 Feb 19, 2013 Feb NEWA

@ UPSHER SMITH 25MG

A078499 001 Jan 07, 2010 Jun DISC

@ 50MG

A078499 002 Jan 07, 2010 Jun DISC

@ 100MG

A078499 003 Jan 07, 2010 Jun DISC

@ 200MG

A078499 004 Jan 07, 2010 Jun DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP ACCORD HLTHCARE EQ 4MG BASE/VIAL

A202351 001 Jun 26, 2013 Jun NEWA

>A> AP SUN PHARM INDS LTD EQ 4MG BASE/VIAL

A202203 001 Aug 29, 2013 Aug NEWA

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ PROSTRAKAN INC EQ 60MG BASE

N020497 001 May 29, 1997 May CAHN

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB HETERO LABS LTD III 5MG

A079234 001 Jan 27, 2009 Apr CAHN

AB 10MG

A079234 002 Jan 27, 2009 Apr CAHN

AB 20MG

A079234 003 Jan 27, 2009 Apr CAHN

AB 100MG

A079234 004 Jan 27, 2009 Apr CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB ACCORD HLTHCARE INC 50MG

A202390 001 May 16, 2013 Apr NEWA

AB CSPC OUYI PHARM CO 50MG

A091498 001 Mar 29, 2013 Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

@ PURDUE PHARMA 100MG

N021745 001 Dec 30, 2008 Jan DISC

@ 200MG

N021745 002 Dec 30, 2008 Jan DISC

@ 300MG

N021745 003 Dec 30, 2008 Jan DISC

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012	Apr CAHN
AB2		200MG	A091609	002	Jun 27, 2012	Apr CAHN
AB2		300MG	A091609	003	Jun 27, 2012	Apr CAHN
AB1	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009	Feb CRLD
AB2	+ SUN PHARMA GLOBAL	100MG	A091607	001	Dec 30, 2011	Feb CRLD
>D>	TABLET, ORALLY DISINTEGRATING;ORAL					
>D>	RYBIX ODT					
>D>	+ SHIONOGI INC	50MG	N021693	001	May 05, 2005	Aug DISC
>A>	@	50MG	N021693	001	May 05, 2005	Aug DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL
MEKINIST

	GLAXOSMITHKLINE LLC	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	May NEWA
		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	May NEWA
+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	May NEWA

TRANDOLAPRIL

TABLET;ORAL
TRANDOLAPRIL

@	CIPLA	1MG	A077307	002	Jun 12, 2007	Jul DISC
@		2MG	A077307	001	Jun 12, 2007	Jul DISC
@		4MG	A077307	003	Jun 12, 2007	Jul DISC
@	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008	Apr DISC
@		2MG	A078493	002	Aug 25, 2008	Apr DISC
@		4MG	A078493	003	Aug 25, 2008	Apr DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

AP	CUSTOPHARM INC	100MG/ML	A201580	001	Jun 14, 2013	Jun NEWA
----	----------------	----------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb NEWA
-----------	--------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL
TRAZODONE HYDROCHLORIDE

AB	TEVA PHARMS USA	50MG	A071523	001	Dec 11, 1987	Mar CAHN
AB		100MG	A071524	001	Dec 11, 1987	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
OLEPTRO

@	ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	May DISC
@		300MG	N022411	002	Feb 02, 2010	May DISC
+	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Jun CMFD
		300MG	N022411	002	Feb 02, 2010	Jun CMFD

TREPROSTINIL

INJECTABLE;IV (INFUSION)-SC
REMODULIN

UNITED THERAP	1MG/ML	N021272	001	May 21, 2002	May CAIN
	2.5MG/ML	N021272	002	May 21, 2002	May CAIN
	5MG/ML	N021272	003	May 21, 2002	May CAIN
+	10MG/ML	N021272	004	May 21, 2002	Jun CAIN

SOLUTION;INHALATION
TYVASO

+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009	May CAIN
---	---------------	------------------	---------	-----	--------------	----------

TRETINOIN

CREAM;TOPICAL
RETIN-A

AB	+	VALEANT BERMUDA	0.025%	N019049	001	Sep 16, 1988	Jun CAHN
AB1	+		0.05%	N017522	001		Jun CAHN
AB	+		0.1%	N017340	001		Jun CAHN

GEL;TOPICAL
ATRALIN

+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Apr CAHN
---	-----------	-------	---------	-----	--------------	----------

RETIN-A MICRO

GEL; TOPICAL							
RETIN-A MICRO							
AB	+ VALEANT INTL	0.04%	N020475	002	May 10, 2002	Jul	CTEC
AB	+ TRETINOIN	0.1%	N020475	001	Feb 07, 1997	Jul	CTEC
SPEAR PHARMS INC		0.04%	A202567	001	Jul 17, 2013	Jul	NEWA
AB		0.1%	A202026	001	Jul 17, 2013	Jul	NEWA
<u>TRIAMCINOLONE ACETONIDE</u>							
CREAM; TOPICAL							
KENALOG							
	@ APOTHECON	0.025%	N011601	003		Apr	DISC
	@ TRIACET	0.1%	N011601	006		Apr	DISC
	@ TEVA	0.025%	A084908	001		Apr	DISC
	@ TRIAMCINOLONE ACETONIDE	0.5%	A084908	003		Apr	DISC
AT	+ FOUGERA PHARMS	0.025%	A085692	001		Apr	CRLD
AT	+ @ G AND W LABS	0.1%	A085692	003		Apr	CRLD
	@ TARO	0.025%	A089797	001	May 31, 1991	May	DISC
	@	0.025%	A086277	001		Apr	DISC
	@	0.1%	A086276	001		Apr	DISC
	@	0.5%	A086275	001		Apr	DISC
INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL							
TRIVARIS							
	@ ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008	May	DISC
LOTION; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	VERSAPHARM INC	0.025%	A202374	001	May 08, 2013	Apr	NEWA
AT		0.1%	A202374	002	May 08, 2013	Apr	NEWA
AT	+ WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Apr	CAHN
OINTMENT; TOPICAL							
KENALOG							
	@ APOTHECON	0.025%	N011600	003		Apr	DISC
	@ TRIAMCINOLONE ACETONIDE	0.1%	N011600	001		Apr	DISC
	@ TARO	0.025%	A040040	001	Sep 30, 1994	May	DISC
	@	0.025%	A040374	001	Jun 05, 2001	May	DISC
	@	0.1%	A087902	001	Dec 27, 1982	May	DISC
	@	0.5%	A040386	001	Jun 05, 2001	May	DISC
<u>TRIHEXYPHENIDYL HYDROCHLORIDE</u>							
TABLET; ORAL							
TRIHEXYPHENIDYL HYDROCHLORIDE							
	@ WEST WARD	2MG	A040337	002	Feb 16, 2000	Jul	DISC
	@	5MG	A040337	001	Feb 16, 2000	Jul	DISC
<u>TRIMETHOPRIM</u>							
TABLET; ORAL							
TRIMETHOPRIM							
AB	+ TEVA	100MG	N018679	001	Jul 30, 1982	Jul	CRLD
	@	200MG	A071259	001	Jun 18, 1987	Jun	DISC
<u>TROSPIMUM CHLORIDE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
TROSPIMUM CHLORIDE							
AB	PADDOCK LLC	60MG	A201291	001	May 24, 2013	May	NEWA
<u>URSODIOL</u>							
TABLET; ORAL							
URSODIOL							
AB	PAR PHARM	250MG	A202540	001	Feb 14, 2013	Feb	NEWA
AB		500MG	A202540	002	Feb 14, 2013	Feb	NEWA
	@ TEVA PHARMS USA	250MG	A079184	001	May 13, 2009	Apr	DISC
	@	500MG	A079184	002	May 13, 2009	Apr	DISC
<u>VALACYCLOVIR HYDROCHLORIDE</u>							
TABLET; ORAL							
VALACYCLOVIR HYDROCHLORIDE							
AB	ACTAVIS GRP PTC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Mar	CAHN
AB		EQ 500MG BASE	A090370	001	Mar 16, 2011	Mar	CAHN

VALPROIC ACID

CAPSULE;ORAL						
VALPROIC ACID						
AB	SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	Feb NEWA
CAPSULE, DELAYED RELEASE;ORAL						
STAVZOR						
	@ BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008	Jun DISC
	@	250MG	N022152	002	Jul 29, 2008	Jun DISC
	@	500MG	N022152	003	Jul 29, 2008	Jun DISC

VECURONIUM BROMIDE

INJECTABLE;INJECTION						
VECURONIUM BROMIDE						
AP	TEVA PHARMS USA	10MG/VIAL	A074688	001	Aug 25, 1999	Apr CAHN
AP		20MG/VIAL	A074688	002	Aug 25, 1999	Apr CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
VENLAFAXINE HYDROCHLORIDE						
AB	VALEANT BERMUDA	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Jul CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Jul CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Jul CAHN

VERAPAMIL HYDROCHLORIDE

INJECTABLE;INJECTION						
VERAPAMIL HYDROCHLORIDE						
	@ INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985	Mar DISC
TABLET;ORAL						
VERAPAMIL HYDROCHLORIDE						
>D>	@ HERITAGE PHARMS INC	80MG	A071880	001	Apr 05, 1988	Aug CMFD
>A> AB		80MG	A071880	001	Apr 05, 1988	Aug CMFD
>D>	@	120MG	A071881	001	Apr 05, 1988	Aug CMFD
>A> AB		120MG	A071881	001	Apr 05, 1988	Aug CMFD
TABLET, EXTENDED RELEASE;ORAL						
VERAPAMIL HYDROCHLORIDE						
AB	CARACO	120MG	A090529	001	Dec 30, 2011	May CAHN
AB		180MG	A090529	002	Dec 30, 2011	May CAHN
AB		240MG	A090529	003	Dec 30, 2011	May CAHN

VERTEPORFIN

INJECTABLE;INJECTION						
VISUDYNE						
	+ VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000	Jan CAHN

VINCRISTINE SULFATE

INJECTABLE;INJECTION						
VINCRISTINE SULFATE PFS						
AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Apr CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION						
VINORELBINE TARTRATE						
>A> AP	DR REDDYS LABS LTD	EQ 10MG BASE/ML	A202017	001	Sep 12, 2013	Aug NEWA
AP	TEVA PHARMS USA	EQ 10MG BASE/ML	A076028	001	Feb 03, 2003	Apr CAHN

VORICONAZOLE

FOR SUSPENSION;ORAL						
VFEND						
AB	+ PFIZER	200MG/5ML	N021630	001	Dec 19, 2003	May CFTG
VORICONAZOLE						
AB	MYLAN PHARMS INC	200MG/5ML	A202361	001	May 28, 2013	May NEWA

WARFARIN SODIUM

TABLET;ORAL						
WARFARIN SODIUM						
AB	AMNEAL PHARMS	1MG	A202202	001	Mar 04, 2013	Feb NEWA
AB		2MG	A202202	002	Mar 04, 2013	Feb NEWA
AB		2.5MG	A202202	003	Mar 04, 2013	Feb NEWA
AB		3MG	A202202	004	Mar 04, 2013	Feb NEWA
AB		4MG	A202202	005	Mar 04, 2013	Feb NEWA
AB		5MG	A202202	006	Mar 04, 2013	Feb NEWA

TABLET;ORAL
WARFARIN SODIUM

AB		6MG	A202202	007	Mar 04, 2013	Feb NEWA
AB		7.5MG	A202202	008	Mar 04, 2013	Feb NEWA
AB		10MG	A202202	009	Mar 04, 2013	Feb NEWA
AB	IPCA LABS LTD	1MG	A200104	001	Jun 27, 2013	Jun NEWA
AB		2MG	A200104	002	Jun 27, 2013	Jun NEWA
AB		2.5MG	A200104	003	Jun 27, 2013	Jun NEWA
AB		3MG	A200104	004	Jun 27, 2013	Jun NEWA
AB		4MG	A200104	005	Jun 27, 2013	Jun NEWA
AB		5MG	A200104	006	Jun 27, 2013	Jun NEWA
AB		6MG	A200104	007	Jun 27, 2013	Jun NEWA
AB		7.5MG	A200104	008	Jun 27, 2013	Jun NEWA
AB		10MG	A200104	009	Jun 27, 2013	Jun NEWA

ZALEPLON

CAPSULE;ORAL
SONATA

AB	PFIZER	5MG	N020859	001	Aug 13, 1999	Apr CAHN
AB	+	10MG	N020859	002	Aug 13, 1999	Apr CAHN

ZIDOVUDINE

TABLET;ORAL
RETROVIR

	@ VIIIV HLTHCARE	300MG	N020518	002	Oct 04, 1996	Apr DISC
	ZIDOVUDINE					
AB	HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	Feb CMFD
	@	300MG	A202058	001	Oct 07, 2011	Jan DISC
AB	+	HETERO LABS LTD III	A090092	001	Apr 25, 2008	Apr CRLD

ZOLEDRONIC ACID

INJECTABLE;INJECTION
ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar NEWA
AP	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar NEWA

INJECTABLE;IV (INFUSION)
RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CTEC	
>A>		ZOLEDRONIC ACID						
>A>	AP	ACS DOBFAR INFO SA	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Aug NEWA	
	AP	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Feb NEWA	
	AP	AGILA SPECLTS	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Feb NEWA	
	AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Feb NEWA	
	AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Jul CDFR	
	AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar NEWA	
	AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Jul CDFR	
	AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Jul NEWA	
	AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	May NEWA	
	AP	HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar NEWA	
	AP	PHARMACEUTICS	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Feb NEWA	
	AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Jul NEWA	
	AP	PHARMS	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Apr NEWA	
	+	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb NEWA	
	AP		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Feb NEWA	
		ZOMETA						
	AP	+	NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Feb CFTG
>D>		+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Aug CTEC	
>A>	AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Aug CTEC	

ZOLMITRIPTAN

TABLET;ORAL
ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Apr NEWA
AB		5MG	A202078	002	May 14, 2013	Apr NEWA
AB	GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013	Apr NEWA
AB		5MG	A201779	002	May 14, 2013	Apr NEWA
AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Apr NEWA
AB		5MG	A203186	002	May 14, 2013	Apr NEWA
		ZOMIG				
AB	IPR	2.5MG	N020768	001	Nov 25, 1997	Apr CFTG
AB	+	5MG	N020768	002	Nov 25, 1997	Apr CFTG

TABLET, ORALLY DISINTEGRATING;ORAL

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Apr	NEWA
AB		5MG	A202476	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013	Apr	NEWA
AB		5MG	A202560	002	May 14, 2013	Apr	NEWA
AB	ZYDUS PHARMS USA INC	2.5MG	A202890	001	May 15, 2013	Apr	NEWA
AB		5MG	A202890	002	May 15, 2013	Apr	NEWA

ZOMIG-ZMT

AB	ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Apr	CFTG
AB	+	5MG	N021231	002	Sep 17, 2001	Apr	CFTG

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

@	DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007	Apr	DISC
@		10MG	A077985	002	Apr 23, 2007	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Apr	CAHN
AB		12.5MG	A078179	001	Jun 06, 2011	Apr	CAHN
>A> AB	APOTEX INC	6.25MG	A200266	001	Sep 10, 2013	Aug	NEWA
>A> AB		12.5MG	A200266	002	Sep 10, 2013	Aug	NEWA
>A> AB	LUPIN LTD	6.25MG	A078970	001	Sep 11, 2013	Aug	NEWA
>A> AB		12.5MG	A078970	002	Sep 11, 2013	Aug	NEWA
AB	WATSON LABS INC FL	6.25MG	A090153	001	Mar 25, 2013	Mar	NEWA
AB		12.5MG	A090153	002	Mar 25, 2013	Mar	NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@	COREPHARMA	25MG	A077876	001	Feb 21, 2007	Feb	DISC
@		50MG	A077876	002	Feb 21, 2007	Feb	DISC
@		100MG	A077876	003	Feb 21, 2007	Feb	DISC
@	DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Mar	DISC
@		50MG	A077645	003	Sep 29, 2006	Mar	DISC
@		100MG	A077645	001	Dec 22, 2005	Mar	DISC

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
TYLENOL

+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Jul CTNA
+		650MG	N019872	002	Jan 11, 2001	Jul CTNA

ASPIRIN

CAPSULE;ORAL
ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan NEWA
---	------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May CAHN
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Aug NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	CIPLA LTD	5MG	A077318	001	Jul 25, 2013	Jul NEWA
		10MG	A077318	002	Jul 25, 2013	Jul NEWA

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr CRLD
---	--------	------	---------	-----	--------------	----------

CHILDREN'S ZYRTEC ALLERGY

@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr DISC
+		5MG	N021621	003	Nov 16, 2007	Feb CRLD
@		10MG	N021621	004	Nov 16, 2007	Feb DISC

CHILDREN'S ZYRTEC HIVES RELIEF

@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr DISC
+		5MG	N021621	005	Nov 16, 2007	Feb CRLD
@		10MG	N021621	006	Nov 16, 2007	Feb DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL
DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr CAHN
--	-------------------	-------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB;TOPICAL

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar CTNA
---	------------	-----------------	---------	-----	--------------	----------

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

CIMETIDINE

TABLET;ORAL

TAGAMET HB

>D>	@	GLAXOSMITHKLINE	100MG	N020238	001	Jun 19, 1995	Aug CAHN
>D>	+		200MG	N020238	002	Aug 21, 1996	Aug CAHN
>A>	@	MEDTECH PRODS	100MG	N020238	001	Jun 19, 1995	Aug CAHN
>A>	+		200MG	N020238	002	Aug 21, 1996	Aug CAHN

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Feb NEWA
--	-------------	-----------	---------	-----	--------------	----------

FAMOTIDINE

TABLET;ORAL

PEPCID AC

	MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Jul CTNA
--	-------------	------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL				
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013 Jan NEWA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013 Jan NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC				
KETOTIFEN FUMARATE				
@ APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006 Apr DISC

LEVONORGESTREL

TABLET;ORAL				
LEVONORGESTREL				
LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013 Jan NEWA
NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013 Feb NEWA

LORATADINE

SYRUP;ORAL				
LORATADINE				
@ APOTEX INC	1MG/ML	A075565	001	Oct 05, 2004 Apr DISC

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
LORATADINE AND PSEUDOEPHEDRINE SULFATE				
@ WATSON LABS INC FL	5MG;120MG	A076208	001	Jan 28, 2004 Feb DISC

MICONAZOLE NITRATE

CREAM;VAGINAL				
MICONAZOLE NITRATE				
APHENA PHARMA MD	2%	A074366	001	Feb 22, 1996 Jan CAHN

MINOXIDIL

SOLUTION;TOPICAL				
MINOXIDIL (FOR MEN)				
@ APOTEX INC	2%	A074924	001	Apr 29, 1998 Apr DISC
MINOXIDIL (FOR WOMEN)				
@ APOTEX INC	2%	A074924	002	Apr 29, 1998 Apr DISC
MINOXIDIL EXTRA STRENGTH (FOR MEN)				
@ APOTEX INC	5%	A075839	001	Oct 01, 2001 Apr DISC

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC				
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE				
AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013 Jan NEWA

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL				
ZEGERID OTC				
+ MSD CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013 Jun NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL				
OXYTROL FOR WOMEN				
+ MSD CONSUMER	3.9MG/24HR	N202211	001	Jan 25, 2013 Jan NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL				
POLYETHYLENE GLYCOL 3350				
PAR PHARM	17GM/SCOOPFUL	A079214	001	Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL				
RANITIDINE HYDROCHLORIDE				
@ WATSON LABS	EQ 75MG BASE	A075212	001	Jan 14, 2000 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2013

NO AUGUST 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2013 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8399445	Aug 24, 2025	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001					NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8435502	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8445543	Jul 12, 2027	U-1078		NPP	Feb 01, 2016
<u>ADEFOVIR DIPIVOXIL - ADEFOVIR DIPIVOXIL</u>						
A 202051 001					>A> PC	Mar 02, 2014
<u>AFATINIB DIMALEATE - GILOTREF</u>						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTREF</u>						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTREF</u>						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 001 >A>	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 002 >A>	8168616	Jul 03, 2026	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6589508	Apr 03, 2014	U-793			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					>A> M-129	Aug 30, 2016
					>A> NPP	Aug 30, 2016
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002					NC	Dec 20, 2014
					NCE	Feb 25, 2016
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	>A> 8497256	Jun 23, 2031	U-1229			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
<u>BOCEPREVIR - VICTRELIS</u>						
N 022258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 024708 001 >A>	7439241	Aug 25, 2025	U-1428		>A> NDF	Aug 23, 2016
	>A> 8053427	Jun 13, 2031	DP U-1428			
	>A> 8163725	Jun 13, 2031	DP			
	>A> 8231885	May 24, 2025	DP			
	>A> 8410102	May 24, 2025	U-1428			
	>A> 8426410	May 24, 2025	U-1428			
	>A> 8513247	Mar 25, 2031	DP U-1428			
	>A> 8513249	Mar 25, 2031	DP U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 024251 001 >A>	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 023168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-976			
	7888310	Jul 25, 2023	U-1379			
	8137992	Jul 25, 2023	U-1380			
	8137993	Jul 25, 2023	U-1379			
	8137994	Jul 25, 2023	U-1379			
	8431155	Apr 30, 2032	DP U-1379			
<u>BUDESONIDE - UCERIS</u>						
N 023634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8475832	Mar 26, 2030	DP U-1411			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421			
	>A> 8470361	Oct 14, 2029	DP U-1425			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421			
	>A> 8470361	Oct 14, 2029	DP U-1425			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	RE43580	Feb 02, 2021	DP U-227			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A 090704 003					PC	Jun 02, 2013
<u>CAPECITABINE - XELODA</u>						
N 020896 001	>A> 5472949	Dec 14, 2013	U-271			
	>A> 5472949*PED	Jun 14, 2014				
<u>CAPECITABINE - XELODA</u>						
N 020896 002	>A> 5472949	Dec 14, 2013	U-271			
	>A> 5472949*PED	Jun 14, 2014				
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Aug 25, 2027	U-1357			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	8187632	Jun 23, 2021	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	8187632	Jun 23, 2021	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N 203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 201402 001					PC	Jul 31, 2013
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8460641	Nov 05, 2028	DP U-1410			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					I-665	Jan 23, 2016
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Apr 23, 2028	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	>A> 8506987	Jan 09, 2023	U-1204			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Dec 13, 2019
					PED	Sep 22, 2016
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001 >A>	8129385	Oct 05, 2027	DS DP		>A> NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918		D-136	Apr 11, 2016
					NS	Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-248			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5646286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP U-954			
	8372872	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	8481078	Oct 01, 2024	DP U-1416			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 26, 2029	DP			
	>A> 8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	>A> 8486972	Apr 26, 2029	DP		>A> NP	Jan 04, 2015
	>A> 8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	>A> 8486972	Apr 26, 2029	DP		>A> NP	Jan 04, 2015
	>A> 8486973	Apr 26, 2029	U-55			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	>A> 7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	>A> 7754702	Feb 13, 2027	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	8501158	Mar 08, 2020	U-1422			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	>A> 8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	>A> 8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	>A> 8506929	Apr 30, 2027	DS DP U-1423			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001					>A> M-128	Aug 28, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003					NPP	Jul 26, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005					NPP	Jul 26, 2016
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8347879	Apr 01, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP			
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7361787	Mar 23, 2023	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
>A>	8511304	Nov 11, 2025	DP U-1424			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	>A> 7107986	Jun 08, 2018	DP			
	>A> 7107986*PED	Dec 08, 2018				
<u>FLUVOXAMINE MALEATE - FLUVOXAMINE MALEATE</u>						
A 091476 002					>A> PC	Sep 09, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001 >A>	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002 >A>	7566705	May 21, 2020	DP U-1068			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOFOSESET TRISODIUM - ABLAVAR</u>						
N 021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSESET TRISODIUM - ABLAVAR</u>						
N 021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	6653286	Jun 16, 2018	U-1354			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 002	8367605	May 24, 2014	DS			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	8415337	Mar 02, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
>A>	8518929	Apr 29, 2030	U-1287			
>A>	8524698	Apr 29, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001 >A>	6123916	Sep 26, 2017	U-1125			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002 >A>	8512297	Sep 15, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003 >A>	8512297	Sep 15, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8367102	Sep 21, 2021	U-1347			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8367102	Sep 21, 2021	U-1347			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001 >A>	8512717	Mar 07, 2028	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		NS	Jun 05, 2016
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 002					PC	Feb 16, 2013

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					RTO* RTO**	Apr 30, 2016 Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	7101569	Oct 02, 2023	U-759			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001 >A>	8501219	Nov 28, 2021	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001 >A>	8367657	Apr 10, 2023	DS DP U-1252			
	>A> 8367657	Apr 10, 2023	DS DP U-1253			
	>A> 8367657	Apr 10, 2023	DS DP U-1254			
	>A> 8367657	Apr 10, 2023	DS DP U-1255			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005					D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	>A> 7838564	Mar 07, 2026	DP		>A> NDF	Aug 23, 2016
	>A> 7872050	Jul 08, 2029	U-1427			
	>A> 8450375	Mar 07, 2026	DP			
	>A> 8501818	Mar 07, 2026	DP			
	>A> 8501819	Mar 07, 2026	U-1427			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8496965	Apr 20, 2018	DP			
<u>MESALAMINE - DELZICOL</u>						
N 204412 001	5541170	Jul 30, 2013	DP U-141			
	5541171	Jul 30, 2013	DP U-141			
	6649180	Apr 13, 2020	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 001	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 002	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	RE44186	Jul 31, 2023	DS DP U-1097			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7459428	Feb 02, 2019	U-1036			
	8414921	Jul 21, 2028	DP U-1036			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8420663	Sep 30, 2029	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8420663	Sep 30, 2029	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
A 090903 001					PC	Dec 28, 2013
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001 >A>	8147852	Mar 30, 2028	U-1426			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050703 001	5569672	Oct 29, 2013	U-1358			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050746 001	5569672	Oct 29, 2013	U-1358			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001					NP	Jun 27, 2016
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	5475034	Jun 06, 2014	U-100			
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	8455524	Apr 18, 2027	U-1029			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001 >A>	8501164	Jun 14, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002 >A>	8501164	Jun 14, 2029	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 001					ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001					NPP	Jul 26, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004					NPP	Jul 26, 2016
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	6489346	Jul 16, 2016	DS DP U-588	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-588	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	6489346	Jul 16, 2016	DS DP U-623	Y		
	6489346	Jul 16, 2016	DS DP U-624	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-623	Y		
	6699885	Jul 16, 2016	U-624	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016	U-1025			
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016	U-1025			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					NPP	Dec 21, 2015
<u>OSPENIFENE - OSPHENA</u>						
N 023505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 022211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 020280 001	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 020280 002	8409616	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 006					PC	Jul 07, 2013

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001					>A> I-676 >A> ODE	Sep 06, 2016 Sep 06, 2020
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001 >A>	8518981	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002 >A>	8518981	Jan 30, 2024	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005					M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	5874447	Jun 10, 2017	DS			
	7598271	Feb 12, 2023	DS		NP	Jun 28, 2016
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	8440170	Mar 14, 2029	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001 >A>	5856336	Dec 25, 2020	DS	U-998		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002 >A>	5856336	Dec 25, 2020	DS	U-998		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003 >A>	5856336	Dec 25, 2020	DS	U-998		
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	RE42152	Dec 10, 2018	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	8404703	Mar 02, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	8404703	Mar 02, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREGABALIN - LYRICA</u>						
N 022488 001					I-651	Jun 20, 2015
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	8470801	Jun 22, 2019	U-116			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001				I-667 ODE	Feb 25, 2016 Feb 25, 2020
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571	002				PC	Jan 20, 2014
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571	003				PC	Jan 20, 2014
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001 >A> 8518949	Mar 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554	001 >A> 8518949	Mar 27, 2026	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417	001	8399015 8399015*PED 8470347 8470347*PED	Aug 25, 2024 Feb 25, 2025 Sep 17, 2026 Mar 17, 2027	DP DP		
<u>RIVASTIGMINE - EXELON</u>						
N 022083	005				NPP	Jun 27, 2016
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173	001				PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173	002				PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	001 8431154	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	001 5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	003 5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	004 5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533	005 5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	001 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	002 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	003 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	004 8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192	005 8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181	001 8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628	001				M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785	001				M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	001 RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	002 RE44186	Jul 31, 2023	DS DP U-995			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990	001	7067555 7067555*PED	Oct 11, 2019 Apr 11, 2020	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8457988	Dec 17, 2022	U-1110			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	>A> 6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	>A> 6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	>A> 6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NCE	Mar 13, 2018
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	8431615	May 30, 2028	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022154 001					M-124	Jan 28, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001					M-128	Jul 24, 2016
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001 >A>	6794410	Apr 15, 2022	U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002 >A>	6794410	Apr 15, 2022	U-1285			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8372995	Oct 08, 2030	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001 >A>	6645963	Nov 02, 2018	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5258510	Nov 02, 2013	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5258510	Nov 02, 2013	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5258510	Nov 02, 2013	DS DP			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001 >A>	8298576	Mar 18, 2029	DP U-106			
	>A> 8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002 >A>	8298576	Mar 18, 2029	DP U-106			
	>A> 8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003 >A>	8298576	Mar 18, 2029	DP U-106			
	>A> 8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004 >A>	8298576	Mar 18, 2029	DP U-106			
	>A> 8298580	Nov 16, 2027	DP U-106			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		NCE ODE	May 29, 2018 May 29, 2020
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 202093 001					PC	Jul 02, 2013
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8487005	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	8388941	Sep 20, 2027	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	7999007	Mar 29, 2029	DP U-1413			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	7999007	Mar 29, 2029	DP U-1413			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	7999007	Mar 29, 2029	DP U-1413			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	7999007	Mar 29, 2029	DP U-1413			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS			
<u>TROSPIMUM CHLORIDE - TROSPIMUM CHLORIDE</u>						
A 091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389			
	>A> 8512745	Feb 14, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6770675	Nov 24, 2018	DP U-1322			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8470818	Aug 02, 2026	U-1418			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	8052987	Oct 27, 2023	U-1199			

Footnote: 1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5). 2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>